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Respiratory syncytial virus (RSV) is associated with 3.2 million severe lower respiratory 
illness (LRI) episodes and 118,200 deaths in children <5 years of age annually, with the 
greatest burden in infants less than 6 months of age. There is no licensed vaccine for 
RSV, although several candidates are in development. It is not well understood how the 
prevention of RSV LRI in infancy might impact LRI with other pathogens, or long-term 
sequelae including subsequent wheeze and asthma. Recently, a double-blinded 
randomized trial of a monoclonal antibody, motavizumab, showed efficacy for the 
prevention of RSV-associated medically attended LRI (MALRI) in healthy Native 
American infants. Infants were followed through three years of age, with nasopharyngeal 
secretions collected at every MALRI. We tested these samples for respiratory viruses and 
for Streptococcus pneumoniae in order to: 
1. Evaluate the role of RSV MALRI prevention in infancy on the prevalence and 
density of S. pneumoniae carriage in the nasopharynx  
2. Evaluate the impact of RSV MALRI prevention in infancy on MALRI with other 
respiratory viruses, and on subsequent medically attended wheeze  
3. Evaluate the risk of RSV MALRI in the second year of life 
RSV MALRI was associated with increased S. pneumoniae density in the nasopharynx, 
suggesting a role for its prevention in reducing the incidence of pneumococcal 
pneumonia in vaccinated children and in their communities through indirect protection. 
Motavizumab prevented RSV MALRI in the presence of co-infecting viruses, with 
increased efficacy in more severe cases. A family history of asthma, and MALRI in 
infancy with parainfluenza viruses, rhinovirus and coronaviruses were independently 
	
	 iii	
associated with subsequent medically attended wheeze at ages 1-3 years. Infants who 
broke through motavizumab prophylaxis to have inpatient RSV LRI had higher risk of 
medically attended wheezing at ages 1-3 years than children in the placebo group with 
inpatient RSV LRI, and may represent a subgroup at high risk for both outcomes. We 
found no increased risk of disease in the second RSV season following receipt of 
motavizumab in the first season, a finding that has not been demonstrated previously in 
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Chapter 1: Introduction 
 
Respiratory Syncytial Virus (RSV) 
 
Characteristics of the Virus 
	
 
RSV is a member of the Paramyxoviridae family, genus Pneumovirus. It is an enveloped, 
negative-sense single stranded RNA virus, with surface proteins that allow for infection 
of the human airway epithelial cells.  RSV was first isolated from chimpanzees in 1955, 
and subsequently from infants with lower respiratory tract infection in 1956 [1]. The 
name ‘respiratory syncytial virus’ was proposed because infected cells sometimes 
appeared as large syncytia surrounding multinucleated giant cells [1]. There are two 
major viral subtypes: RSV-A and RSV-B, each containing clusters of strains with related 
genotypes [2].  In humans, tropism for the ciliated epithelia of the small bronchioles and 
type I pneumocytes of the alveoli leads to infection of the respiratory tract, directly 
causing disease and predisposing the host to superinfections from other pathogens by 
damaging the epithelium and impeding ciliary clearance of bacteria, as well as via 
potential synergistic interactions between RSV and other respiratory pathogens [3].  
 
The RSV genome encodes for 11 proteins including nonstructural proteins (NS1, NS2, 
and M2-2), the (N) viral nucleocapsid protein, the phosphoprotein (P), matrix (M), RNA-
dependent polymerase (L), M2-1, and three surface glycoproteins (G [attachment], F 
[fusion], and SH [small hydrophobic]) [4]. The NS1 and NS2 proteins suppress a key 
host defense mechanism by blocking signaling of type I and II interferons, and NS2 may 
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also promote shedding of infected airway epithelial cells [5]. The surface glycoproteins 
are critical to infection and immune response: the G protein is responsible for viral 
attachment to the host cell, while the F protein allows fusion between the virion and the 
host cell and allows entry of the virus into the host [2]. The immune response to infection 
is mainly targeted to the G and F glycoproteins, the only viral components that induce 
neutralizing antibody [6]. The F glycoprotein appears to be the most important for 
generating active immunity, as it induces a high serum antibody response, activation of 
the pattern recognition receptors CD14 and toll like receptor (TLR)-4, and its genome is 
highly conserved between RSV groups [4, 6, 7].  The F protein has therefore been the 
target for most antivirals, prophylaxis strategies, and vaccine candidates [4]. It is a class I 
fusion glycoprotein that must be cleaved to be activated, and consists of two subunits (F1 
and F2) that are linked by disulfide bonds [6]. RSV F is present on the viral surface in 
both prefusion and postfusion conformations, and when the prefusion form is triggered, it 
leads to fusion of the viral and cell membranes and changes the conformation to the 
stable postfusion form [6]. Neutralizing epitopes have been identified on both 
conformations and monoclonal antibodies directed towards these epitopes prevent fusion 
of the virus to cell membranes. Site II and site IV epitopes are located on both 
conformations, and site Ø is located on the prefusion confirmation only. Antibodies 
directed towards the site Ø are highly neutralizing [6]. 
 




RSV is considered to be one of the most important causes of acute lower respiratory tract 
illness (LRI) in infants less than one year of age [8, 9]. Infection in children is almost 
always symptomatic, with illness ranging from mild upper respiratory illness (URI) to 
severe and sometimes fatal disease of the lower airways [10].  
 
By the time they reach their second birthday, nearly all children have had an RSV 
infection, but most experience only a mild URI that does not require medical attention 
[11, 12]. The incubation period between RSV exposure and symptom onset is typically 4-
6 days (range 2-8 days). Common URI symptoms include rhinorrhea, nasal congestion, 
low-grade intermittent fever and cough [8, 13, 14].  RSV is also the primary virus that 
invades the middle ear in children with acute otitis media [15]. The acute illness usually 
lasts 5-10 days with a cough that may persist for several weeks [8].  
 
Involvement of the lower airways occurs in 15-50% of infants and young children with 
an RSV-infection, typically 1-3 days after the onset of rhinorrhea [8, 10]. RSV-associated 
LRI (RSV-LRI) is often referred to as “severe RSV illness” and usually corresponds to a 
clinical diagnosis of bronchiolitis (inflammation and infection of the distal bronchiolar 
airways, the bronchioles) or pneumonia (inflammation and infection of the alveolar lung 
regions) [14]. Risk of RSV-associated hospitalization is highest in children less than 3 
months of age and typically occurs approximately 4 days after illness onset [16, 17].  In a 
study of children hospitalized with RSV in the U.S., 85% of those less than 12 months of 
age and 31% of those 24-59 months of age were diagnosed with bronchiolitis, with 
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pneumonia and asthma more commonly diagnosed in the older age group (51% and 60%, 
respectively) [18].  
 
It is presumed that the virus moves from the upper to the lower airways via mechanical 
aspiration of infectious material, or by directly spreading along the respiratory epithelium 
[14, 19]. Once in the lower airways, RSV colonizes and replicates within the bronchiolar 
epithelial cells, causing necrosis of the epithelium [20]. This is consequential for two 
significant reasons: one is that it depletes the epithelial defense mechanism; the other is 
that it causes epithelial cells to be sloughed off the wall of the airways and into the lumen 
of the bronchioles. Bronchospasm may occur as the smooth muscle of the bronchial walls 
constricts, and mechanical clearance of the sloughed material is reduced due to the 
damaged cilia [14]. The infection of the lower airways is accompanied by an 
inflammatory response involving the recruitment of neutrophils, macrophages, 
lymphocytes and plasma cells [17, 21]. The neutrophils, mucus and other non-cellular 
material combine with the sloughed epithelial cells to form dense plugs that can occlude 
the lumen of the bronchioles at the same time that the airway is constricting due to 
edema. This combination of events is particularly problematic in preterm and very young 
infants with small diameter airways [3]. Depending on the type of occlusion caused by 
the plug, airflow both in to and out of the alveolar area may be restricted (bypass valve 
mechanism), there may be complete obstruction of the airway (stop valve mechanism), 
air may be allowed out of but not into the alveolar area (ball valve mechanism) or air may 
be allowed into the alveolar area but not back out (check valve mechanism), with the 




Clinical symptoms that distinguish RSV-LRI from URI are the onset of moderate 
tachypnea, diffuse rhonchi, fine rales and wheezing [14]. In the early stages of lower 
airway involvement, chest x-rays are normal and the illness may resolve on its own 
within 1-2 weeks [14]. The precise factors that cause RSV bronchiolitis to spontaneously 
resolve or to develop into more severe disease are not yet well understood [14]. There is 
evidence that higher viral loads are associated with increased disease severity, but the 
extent to which viral load and clinical outcomes are correlated is not fully established 
[21-25]. A number of genetic polymorphisms that impair the immune response of the 
human host have been identified and are also associated with more severe disease [26]. 
Wheezing, caused by the increased rate of airflow through restricted bronchioles, is the 
most prominent clinical feature of RSV-LRI and most severely affects infants less than 
three months of age, due to their narrow airways [8, 16]. Along with cough, wheeze 
worsens as disease becomes more severe [14]. Poor feeding, irritability, and lethargy are 
also often observed in infants with RSV-LRI [16]. With gas trapping, severe tachypnea 
and chest hyperexpansion can occur [14]. When the trapped air is re-absorbed, partial or 
complete collapse of the lung may follow, leading to ventilation perfusion mismatch and 
hypoxia [14]. Direct infection of the alveolar epithelium or spillover of inflammation 
from the bronchioles to the alveoli results in RSV-pneumonia, reducing alveolar gas 
exchange and causing hypoxia [14]. On radiology, partial or complete collapse of the 
lung may be seen and, less commonly, there may be scattered interstitial infiltrates [8]. 
Radiological evidence of gas trapping and bronchial thickening may also be present [14]. 
Hypoxia can lead to apnea and respiratory failure in infants and death may result if 
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proper care, such as mechanical ventilation, is not received [9]. Pneumothorax and sepsis 
are also strongly associated with respiratory failure and death in RSV-infected infants 
[27]. Underlying co-morbidities associated with increased disease severity and risk of 
death include congenital heart disease, chronic lung disease, and the presence of an 
immunocompromised state [28]. The case fatality ratio (CFR) for infants hospitalized 
with RSV is highly dependent on access to care. In infants 6-11 months old in 
industrialized countries, it is extremely low – with point estimates around 0.1% - while in 
the lowest income settings point estimates as high as 9.3% in this age group; in younger 
infants (0-6 months), CFR point estimates range from 0.0% in industrialized countries to 
2.7% in low-middle income countries [29]. There is considerable uncertainty in CFR 
estimates from developing country settings, and RSV deaths may be underestimated as a 
result of not taking into account the indirect effect of RSV infection on risk of death from 
other pathogens, such as Streptococcus pneumoniae.  
 
Seasonal epidemics of RSV suggest that the development of immunity to the virus 
prevents continued transmission, but unlike many other viruses, RSV infection does not 
result in sustained natural immunity to subsequent infections or disease. Reinfection 
throughout childhood and into adulthood is common, although infection in adults is 
frequently asymptomatic [1, 8, 30]. The incomplete immunity that results from natural 
RSV infection is thought to be the result of ‘selective immunological amnesia’ induced 
by the virus, though the mechanisms for this are not fully understood [31]. In healthy 
adults, RSV infection almost always manifests as a common cold, but incidence of severe 
disease peaks again among the elderly where it is often exacerbated by the presence of 
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other conditions such as congestive heart failure and chronic obstructive pulmonary 
disease [8]. 
 
The Immune Response to RSV Infection  
	
There are many gaps in our understanding of infant immunology and the immune 
response to RSV, including the relative contributions of the virus and the host immune 
response to disease pathogenesis [32]. Some evidence points to a positive relationship 
between viral load (measured by plaque assay) and disease severity, but this correlation is 
not fully established [31, 33]. Other evidence suggests that an excessive and dysregulated 
immune response to RSV infection can be pathogenic and lead to disease-enhancing 
inflammation [31]. It may be that a sufficiently high viral load is required to establish 
LRI, but that the severity of illness depends on the subsequent immune response, which is 
driven by host factors including genetics, age, the respiratory microbiome, and 
underlying medical conditions [31]. 
 
Both humoral and cell-mediated responses are involved in the immune response to RSV. 
In general, secretory antibodies protect against infection of the upper respiratory tract, 
while serum antibodies (acquired as a result of natural infection, or received passively 
through placental transfer or injection of antibodies) protect against infection of the lower 
respiratory tract, and cell-mediated responses appear to terminate infection [6].  The 
initial immune response to RSV infection of the ciliated epithelial cells is mediated by 
pattern recognition receptors (PRR), which are important for recognizing invading 
pathogens and initiating both the innate and adaptive immune responses [17]. Toll-like 
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receptors (TLRs) are an important class of PRRs in the RSV response and promote up-
regulation of cytokines, chemokines and anti-viral factors [34]. Eosinophils and 
monocytes are then recruited into the lungs by chemokines. The F-protein of RSV 
activates TLR-4, likely through interaction with CD14+, a surface molecule expressed on 
monocytes [21]. TLR-4 causes the release of respiratory inflammatory cytokines 
interleukin (IL)-6, IL-8, and IL-1β [21]. Neutrophils, induced by IL-8, are the 
predominant inflammatory cell of the lungs during RSV infection. It is unclear whether 
significant neutrophilia is pathogenic or protective, as neutrophils release enzymes that 
damage infected as well as uninfected host tissue [32]. Severe bronchiolitis in infants is 
associated with an abundant influx of neutrophils that result in mucus overproduction and 
increased epithelial cell damage [17]. Plasmacytoid dendritic cells (pDC) also play a key 
role in the innate immune response to RSV by releasing type-1 interferons (INF) to 
promote viral clearance [17]. 
 
RSV infection in young infants is characterized by a poorly protective innate immune 
response with reduced signaling of TLRs, altered antigen presenting cell function, and 
enhanced production of pro-inflammatory cytokines [32]. In the presence of RSV, there 
is also reduced production of antiviral cytokines, such as interferons [32]. The increased 
susceptibility of young infants to RSV disease may be due to underdeveloped TLR-
mediated responses, reduced capacity of their pDC to transport and present antigen and to 
release type-1 INF, and ineffective natural killer cells, which are necessary for the 




In the adaptive immune response to RSV, conventional DCs serve as antigen presenting 
cells and T cells are essential for viral clearance and for virus-specific immune memory 
[31]. In infants, there is reduced activation of regulatory CD4+ T-cells, which can skew 
T-cell activation from a protective Th1 response to a pathogenic Th2/Th17 response that 
is associated with severe disease [32].  There is also impaired T helper cell activation, 
little or no B cell memory, and inhibition of antibody production by interferon gamma, 
resulting in low-titer, low-affinity antibody [17, 32].  
 
Although the adaptive immune response is limited in early infancy, it is well documented 
that IgG antibody, which is directed to RSV G and prefusion RSV F proteins, is received 
from the mother via placental transfer and colostrum and is present in nearly all infants at 
birth [35-37]. Maternal antibody titers are inversely associated with both incidence and 
severity of RSV illness in young infants but quickly decline to very low levels within the 
first three months of life, corresponding to the peak age of RSV-LRI risk [1]. While 
young infants can generate their own antibodies in response to RSV infection, the 
response is impaired in the presence of maternal antibody and generally of poor 
functional quality. Achieving effective antibody titers by vaccination in young infants is 
challenging both due to interference by maternal antibody as well as the weak response 
due to the immaturity of the infant immune system [32]. 
 
Several features that have not yet been fully elucidated allow RSV to evade the immune 
system [31]. These immunomodulatory mechanisms lead to poor immune memory and 
insufficiently protective RSV-specific serum antibody in both children and adults that 
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allows for re-infection throughout the lifetime [31]. Longitudinal studies of children over 
successive RSV seasons have shown that there is limited protection for approximately 6 
months following the primary infection [38], although they can be re-infected with the 
same viral strain within a single RSV season [39], and that the duration of viral shedding 
is reduced in subsequent infections [40].  
 
Other Viruses Associated with Viral Bronchiolitis 
	
Viral bronchiolitis is estimated to occur in 20-30% of children in the first year of life [41, 
42]. RSV and human rhinovirus (HRV) are the most commonly observed etiologies, 
although bronchiolitis can also be caused by human metapneumovirus, influenza, 
adenovirus and parainfluenza viruses [43, 44]. RSV is the most frequent etiologic agent, 
detected in 60-80% of children hospitalized with bronchiolitis [18, 45, 46].  In temperate 
climates, RSV and HRV have alternating seasonality, with RSV predominating in the 
winter months (November –April) and HRV peaking in the autumn and spring months 
[43, 47]. Despite their alternating epidemic peaks, however, RSV and HRV are 
frequently observed as co-infections because HRV circulates at a high prevalence even in 
its non-peak months [16, 48]. Compared to other viruses, RSV bronchiolitis is associated 
with more severe and prolonged disease and higher rates of hospitalization in young 
children [14]. One reason for this may be the increased cytopathology that RSV exhibits 
compared to other viruses associated with bronchiolitis [14]. Co-infection by other 
viruses at the time of RSV infection has not been found to increase severity of illness 




Diagnosis and Treatment of Acute Illness 
	
Because management and treatment of bronchiolitis is not pathogen-specific, the 
American Academy of Pediatrics (AAP) recommends diagnosis based on history and 
physical examination alone, and that laboratory and radiologic studies should not be 
routinely ordered for diagnostic purposes [28]. For this reason, RSV is often presumed to 
be the etiological agent of disease during the RSV season and is not confirmed by 
laboratory testing [14]. For surveillance and clinical trials, however, laboratory 
confirmation is needed. Available diagnostic tests include culture-based approaches, 
rapid antigen detection, and nucleic acid amplification tests (NAATs) [16]. Culture tests 
are sensitive but require a viable virus sample. Point-of-care rapid tests are also available 
and useful in individuals with higher viral loads (most often infants and children).  
NAATs are the current laboratory diagnostic of choice for research purposes, with high 
sensitivity allowing for the detection of virus even in the presence of low viral load.  
Furthermore, the quantitative capacities of real time PCR tests can provide estimates of 
viral load that correlate well with viral culture data [16]. NAAT analyses of frozen 
specimens have shown little difference when compared to fresh aliquots of the same 
specimen, allowing specimens to be shipped to centralized locations for specialized 
testing [16, 50]. One of the general disadvantages of NAATs is that their increased 
sensitivity can result in virus detection in asymptomatic individuals and therefore the 
presence of the pathogen does not always attribute disease causality. Detection of RSV in 
the absence of clinical symptoms is rare in infants, occurring in 9% of those regularly 




In addition to the assay used, specimen type contributes significantly to the sensitivity of 
the diagnostic method. Potential specimen types for RSV diagnosis include 
nasopharyngeal aspirates and washes, as well as nasopharyngeal, mid-turbinate, nasal or 
oropharyngeal swabs [51].  Specimens taken from the nasopharynx (including 
nasopharyngeal aspirates, washes and swabs) exhibit the highest sensitivity for detection 
of the virus. Nasal (as opposed to nasopharyngeal) swabs are more comfortable for the 
child and easier to collect, but have been demonstrated to have a lower sensitivity for 
RSV detection, even when NAATs are used [52, 53]. However, their logistic advantages 
may justify their use in some contexts, such as community-based surveillance settings.  
 
In industrialized country settings, approximately 1% of patients who seek medical care 
for RSV-infection will require hospitalization [54]. Even among such settings, 
management of bronchiolitis varies by country and within country varies by facility and 
health care provider [28]. The primary treatment is supportive in nature and includes 
continuous monitoring, intravenous hydration, and supplemental oxygen [54]. The 
routine use of bronchodilators and corticosteroid medications is not recommended as 
studies do not show a clear benefit on the overall course of the illness [28]. Ribavirin, a 
broad-spectrum antiviral, may be considered for use in children with co-morbidities that 
put them at highest risk of severe disease but is also not recommended for routine use 
[28]. Antibiotics may be administered if a bacterial co-infection is suspected. On average 
in the United States, young children hospitalized with RSV-illness are discharged 3.5 
days following admission after receiving supportive therapy such as supplemental oxygen 
and intravenous fluids [14]. In low and middle income countries (LMICs) where most 
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RSV-associated deaths occur, survival can be improved by increased access to medical 
care and better availability of pulse oximetry and supplemental oxygen [29]. 
 
Risk Factors for RSV-associated Severe Lower Respiratory Illness and Death 
	
Risk factors for severe RSV-LRI 
Most children who experience severe illness with RSV are otherwise healthy and have no 
identifiable risk factors other than young age [10]. The identification of socio-behavioral 
and biological risk factors associated with the progression of RSV infection to severe 
illness has therefore been an area of intense research interest.  
 
A meta-analysis of putative risk factors from 20 studies found prematurity (<37 weeks 
gestation), low birth weight (<2.5 kg), male sex, the presence of siblings, maternal 
smoking, family history of asthma/atopy, lack of breastfeeding, and living in crowded 
conditions (≥7 person/household) to be associated with increased risk of RSV-LRI in 
children less than five years of age [55]. No overall association was found for low 
parental education, passive smoking, daycare attendance, or indoor air pollution exposure 
though these have been identified as risk factors in individual studies.  There were 
insufficient numbers of high quality studies to conduct meta-analyses of multiple births, 
HIV infection in the mother or infant, malnutrition, altitude, previous illness or lack of 
indoor plumbing as risk factors for severe RSV-LRI [55]. Incomplete immunization, 
vitamin A deficiency, vitamin D deficiency, zinc deficiency, anemia, birth order and birth 
interval have been shown to be associated with all-cause ALRI but need further 
evaluation as risk factors for RSV-LRI [55]. A role for undernutrition as a risk factor for 
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severe RSV illness is supported by evidence that poor growth (measured as weight-for-
age) in infants is associated with increased risk of RSV hospitalization [56]. 
 
RSV hospitalizations occur most frequently in infants between 2-3 months of age, and 
there are several explanations for the elevated risk in this age group [57]. Young infants 
are at highest risk for severe RSV illness due to their immature immune systems, waning 
trans-placental maternal antibodies, and narrow airways that are more susceptible to 
physical obstruction (mean bronchiole diameter in 2-4 month old infants is 120 µm, 
compared to 250 µm in an adult) [14]. Additionally, young infants have not yet 
developed lung structure that allows for collateral ventilation, whereby air from healthy 
alveolar regions can bypass the normal airways through channels and passages to 
ventilate areas of obstructed airflow [20]. Male infants are at a slightly increased risk for 
severe RSV-LRI compared to female infants due to shorter and narrower airways that put 
them at an elevated risk for bronchial obstruction [58]. In temperate climates, birth during 
the first half of the RSV season is associated with a higher risk of severe disease, 
potentially due to lower circulating maternal antibodies at the beginning of the RSV 
season as well as a longer exposure window for infants born early in the season [58, 59]. 
 
Preterm birth has been shown to be an independent risk factor for RSV-hospitalization in 
U.S. population-based surveillance studies [18].  Preterm infants have lower maternal 
anti-RSV IgG antibodies at birth, as well as increased risk of lower airway obstruction 
and reduced capacity for gas exchange in the lung compared to term infants [1, 60]. The 
definition of preterm birth varies by study and setting, generally ranging from <33 to <38 
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weeks gestation, with increased prematurity (<33 weeks gestation at birth compared to 
<37 weeks) associated with increased risk of severe RSV-LRI [55].  
 
In addition to prematurity, children with co-morbidities such as chronic lung disease, 
cyanotic or complicated congenital heart disease and immunosuppression are at higher 
risk of developing RSV than the general population due to their increased sensitivity to 
subtle changes in oxygenation, ventilation or pulmonary pressure [21, 61, 62]. 
Approximately 30% of infants with chronic lung disease of prematurity (CLD) and 
hemodynamically significant congenital heart disease (CHD) will be hospitalized for an 
RSV-related illness within the first two years of life, and will experience longer 
hospitalization stays, a greater need for intensive care, and a higher risk of mortality 
during their RSV-illness compared to otherwise healthy infants [1]. Congenital 
abnormalities of the airways, cystic fibrosis, and severe neuromuscular disorders are 
other co-morbidities that can increase the risk of severe RSV-illness [1]. Additionally, 
hospital-based studies in South Africa have reported significant associations between 
HIV-infection and incidence of RSV-LRI [63-65]. Deficiencies in T cell response due to 
HIV-infection are thought to explain the greater risk of severe disease in this subgroup 
[32]. 
 
Household crowding and day care attendance are consistent environmental risk factors 
for severe RSV-LRI in infants across several studies, with crowding showing the stronger 
association with disease status [60, 66]. Crowding is presumed to increase risk of RSV 
transmission and infection due to increased exposure to droplets of infectious secretions 
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and fomites [67, 68]. A systematic review of 13 studies found crowding to be associated 
with laboratory-confirmed RSV illness in both high risk and mixed risk/general 
population groups, regardless of differences in crowding definitions, study design, or 
geographic locations [60]. Although different measures of crowding have been used 
across studies, it is presumed that the most important components of crowding for 
increased risk of RSV hospitalization are the number of other people living in the home, 
the proportion of time spent in the crowded residence, and the sharing of bedrooms, 
although it is challenging to differentiate exposures that happen within the home from 
those that occur elsewhere [60]. Furthermore, the impact of crowding on risk for severe 
disease, given infection, may be modified by other environmental factors believed to 
increase risk of severe respiratory disease such as home construction, the presence of 
indoor air pollution or tobacco smoke within the home, and climate or altitude (discussed 
further in Transmission, Circulation and Seasonality section below) [60].  
 
Studies of twins estimate that approximately 20% of overall susceptibility to developing 
RSV-LRI is attributed to genetic factors [69, 70]. Several single nucleotide 
polymorphisms (SNPs) of innate immune genes are associated with severe RSV illness, 
although further research is required to determine whether these mutations themselves are 
causally associated with severe disease or whether they are associated with other 
causative variants [26, 32, 69, 71]. Genetic risk factors can also be complicated by 
environmental interactions. For example, substitutions have been identified in the TLR-4 
genome that cause hyporesponsiveness to bacterial endotoxin (LPS) [33, 72, 73]. In a 
prospective study of infants with RSV-bronchiolitis, it was observed that prior 
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environmental exposure to LPS activated the TLR-4 response in infants and conditioned 
the immune response to infection. Infants with the combination of the hyporesponsive 
TLR-4 phenotype and low exposure to LPS (which corresponded to higher 
socioeconomic status) had significantly increased risk of severe RSV-LRI after adjusting 
for all other risk factors [33]. This suggests that prior TLR-4 / environment interactions 
are important drivers of the immune response to infection and that full term infants with 
the hyporesponsive phenotype and low LPS exposure may represent a distinct risk group 
for severe RSV bronchiolitis [33].  
 
Characterization of the respiratory microbiome composition as a risk factor for severe 
RSV-illness is an emerging area of research. RSV-infected infants with nasopharyngeal 
microbiota profiles dominated by Haemophilus influenzae and Streptococcus species 
have been shown to mount distinct immune responses such as increased TLR-signaling 
and heightened neutrophil recruitment compared to infants with microbiomes dominated 
by Staphylococcus aureus, and were more likely to experience severe disease [74]. These 
findings, along with other studies, support the hypothesis that microbial ‘cosignaling’ 
could be involved in the inflammatory response to RSV-infection [74]. 
 
Risk Factors for RSV-associated mortality  
Most studies of RSV-associated mortality have been conducted in middle to upper-
income settings, where risk for death is significantly elevated in children with co-
morbidities such as preterm birth (weighted mean CFR 1.1%), bronchopulmonary 
dysplasia (weighted mean CFR 3.1%), and congenital heart disease (weighted mean CFR 
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5.3%) [75]. A retrospective analysis of globally representative RSV-associated deaths 
(the RSV-GOLD study) was recently undertaken to better understand risk factors for 
RSV mortality in LMICs [76]. The analysis showed that children who die from RSV-
associated deaths in LMICs tend to have different clinical profiles compared to upper 
income countries. In lower income countries, children who experience RSV-associated 
mortality tend to be younger (5 months of age at death, on average, compared to 7 
months of age in upper income countries). Co-morbidities (most commonly congenital 
heart disease, but also HIV-infection, and active tuberculosis) and chromosomal or 
genetic disorders are present in approximately 28% of children who die in LMICs 
compared to 70% of children in upper income settings [76]. In all settings, the age at 
death tended to be higher for children with comorbidities compared to the age of death in 
otherwise healthy children, including otherwise healthy-preterm children [76]. Some 
hypothesized reasons for these differences are that deaths of young but otherwise healthy 
infants in low / lower-middle income countries are reflective of low access to care, and 
that children born in such settings with severe prematurity or significant comorbidities at 
birth are more likely to have died in the neonatal period with a different cause of death 
[76]. In a prospective cohort study in a low-resource area of Argentina, medical 
complications including sepsis and clinically significant pneumothorax were strongly 
associated with RSV-respiratory failure and would presumably lead to death in the 
context of inaccessible or inadequate medical care [27].  
 
Importantly, in low resource settings, a substantial fraction of deaths occur in the 
community, outside of the hospital setting [77]. Data on RSV-deaths occurring in the 
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community are limited, in part because post-mortem sample collection is extremely 
challenging. Because children who have access to care may differ in significant ways 
from those who do not, it is possible that the clinical picture of children who die in 
communities is distinct from those who die at facilities. Generating accurate mortality 
burden estimates in the community is an area of increased research focus [78]. 
 
Transmission, Circulation, and Seasonality 
	
RSV transmission occurs by (1) large particle droplet aerosols spread by sneezing, 
coughing, and breathing, and (2) by infectious secretions contaminating environmental 
surfaces, which are then self-inoculated [8]. RSV can persist for several hours as a 
fomite, making it a major hazard for nosocomial respiratory illness on pediatric wards 
[79]. In addition to respiratory secretions, RSV RNA has also been detected in stool, 
sweat, and saliva, though it is unknown whether those virions are infectious or constitute 
a potential mode of transmission [80]. The mean duration of viral shedding, defined as 
RSV PCR-positive nasopharyngeal samples, is 13.5 days in symptomatic individuals 
[81]. Young age, severity of illness and the co-occurrence of other viruses during the 
RSV infection is associated with increased duration of shedding, which in turn increases 
the probability of transmission [81]. The basic reproductive number (R0) for RSV, 
defined as the average number of individuals infected by a typically infectious person in a 
susceptible population, has been calculated to be 2.18 (95% CI 1.49, 3.24) [82]. In 
transmission modeling studies in Kenya, household transmission has been found to be 
responsible for 39% of infant RSV infections, with school-aged children playing a 




RSV has a complex circulation pattern, with the predominant strain changing from year 
to year and varying within communities [2, 83]. In general, RSV subgroup A is 
understood to be more virulent and is more often the predominant circulating strain 
compared to subtype B [2, 84-86]. Unlike rhinovirus and influenza, the same RSV strain 
can re-infect an individual multiple times [2, 87].  
 
RSV seasonality varies substantially by geography and is marked by seasonal epidemics. 
Survival of the virus in temperate climates is highest when humidity is <30%, which is 
often the case during the winter months [8].  The low humidity and temperatures during 
this season may increase the survival of RSV in the environment, such as on surfaces 
[88]. Increased crowding and lower micronutrient levels (such as vitamin D) in hosts 
likely augment survival and transmission of the virus during this time [88]. In such 
settings, most RSV infection occurs in yearly outbreaks lasting 3-4 months, often in late 
fall, winter, and early spring (between November and April in the northern hemisphere 
and March to October in the Southern Hemisphere) [8, 89]. The timing of outbreaks 
varies by year and within the same year can vary by region and community [8]. In the 
U.S., surveillance has established that the onset of the RSV season occurs between 
November and January in most communities, although it has been noted to occur earlier 
in the year in the southern and eastern U.S. (particularly Florida), and later in the northern 
and western parts of the country, likely due to differences in climate between these 




In subtropical regions, RSV peak months typically manifest during the cooler seasons 
and in tropical/equatorial regions, can occur throughout the year with episodic peaks of 
higher incidence [91]. Unlike in temperate climates, RSV in tropical regions is usually, 
but not always, associated with the rainy season [92]. The high humidity during that time 
may facilitate indirect virus transmission by increasing the amount of time it is encased in 
droplets on surfaces – once dry, the higher humidity and temperatures tend to decrease 
virus survival [88]. Similar to winter in temperate regions, transmission during tropical 
rainy season may be facilitated by increased crowding, reduced sunshine and poorer 
nutritional status [92]. Seasonal patterns of malnutrition that do not always coincide with 
the rainy season have been shown to drive RSV seasonality in The Gambia [92]. 
Seasonal changes in nutritional status may drive RSV transmission patterns in other 
locations as well, and could explain RSV seasons that occur outside of the rainy season in 
other tropical settings, such as Nigeria and Kenya [88].   
 
 
Case Definitions and Endpoints for Surveillance and Clinical Trials 
	
Improvements in surveillance are needed to better define the burden of RSV-illness and 
strengthen the evidence base that informs vaccine development and policy. It is 
particularly important to generate disease burden estimates within finer infant age strata, 
among pregnant women, and in LMIC community settings [93, 94]. With adapted case 
definitions and surveillance methods, an ongoing effort that could be leveraged for the 
purpose of RSV surveillance is the Global Influenza Surveillance and Response System 
(GISRS), a WHO-coordinated network of 143 national influenza centers across 113 
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member states from all six WHO regions that collects specimens from individuals with 
respiratory illness [95]. A pilot study is being established to assess the feasibility of using 
these influenza centers for the purpose of RSV surveillance and will include both hospital 
and community-based surveillance to establish appropriate case-definitions for RSV-
illness in both of these settings [95]. Unlike influenza, children with RSV-LRI are often 
afebrile at the time of clinic presentation, and surveillance efforts will need to take this 
distinction into account since the influenza surveillance case definitions include the 
requirement of fever [96]. Additionally, RSV can present as apnea alone, particularly in 
very young infants, and this is not captured in the influenza surveillance case definitions 
[97]. The RSV Global Epidemiology Network (RSV GEN), a collaboration of more than 
70 investigator groups, primarily in LMICs, is also working to improve RSV surveillance 
efforts and data from the investigators forming this collaboration are the basis for updated 
global RSV disease burden estimates [29]. 
 
Medically attended acute lower respiratory infection (MALRI) has been used as a clinical 
endpoint for RSV immunoprophylaxis studies in industrialized country settings and 
includes physician visits, urgent care, emergency visits and hospitalization [16]. Expert 
consensus recommends that in middle and high-income countries, clinical endpoints to 
measure incidence of severe RSV-LRI should focus on RSV-associated inpatient and 
outpatient health-care utilization, length of intensive care stay, and reduction in 
subsequent wheezing and asthma, with RSV infection confirmed if the virus is detected 
in respiratory specimens within 72 hours of the LRI diagnosis [98]. Because these 
endpoints are based on physician diagnosis rather than case-defining clinical criteria, they 
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may be too subjective and dependent on cultural care-seeking norms to compare between 
different settings [16]. An alternative approach may be to develop illness-based endpoints 
such as RSV-LRI and RSV-hypoxemia with distinct case definitions based on 
standardized signs and symptoms, rather than facility-based endpoints [99]. It will be 
important to ensure that individual measures of clinical signs such as respiratory rate, 
pulse oximetry and wheezing are collected in a standardized way so that outcome 
comparisons can be made across studies, even in the context of varying case definitions 
[100]. 
 
Global Burden of RSV 
	
RSV disease burden in children has been defined in many high-income settings, but our 
understanding of the burden of RSV morbidity and mortality in LMICs is less clear 
[101]. This data gap is important to address as widespread use of Haemophilus influenzae 
type B (Hib) vaccine and pneumococcal conjugate vaccine (PCV) have reduced the 
burden of disease from these two pathogens and as a result the proportion of the 
remaining LRI cases and deaths due to RSV has increased [101]. The true global burden 
of RSV is challenging to fully quantify not only due to limited surveillance data from 
developing countries, but also because of difficulty in capturing RSV illness that is not 
medically attended, and a lack of data regarding laboratory-confirmed RSV-associated 
deaths [102]. While RSV is not as frequently lethal as bacterial-associated LRI (i.e. the 
case fatality ratio for RSV is lower than for bacterial disease), its high prevalence makes 
it quantitatively an important cause of death globally, and accurate estimates of severe 
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RSV-LRI and RSV-associated deaths are critical for the development of vaccination 
strategies and policies [27].  
 
The first global burden of disease estimates for RSV were generated for the year 2005 by 
a systematic review and meta-analysis of published and unpublished data [77]. While 
these estimates contributed significantly to the field, they were limited by scarce data that 
were not stratified by narrow age bands, as well as non-uniform case-definitions [29, 
101]. Disease burden estimates were updated for 2015 using data from 291 additional 
studies [29]. With these updated data, it was estimated that RSV is associated with 28% 
of all child LRI and 13-22% of all child LRI deaths globally [29]. The case definitions for 
RSV-LRI were as follows: RSV-associated LRI was defined as cough or difficulty 
breathing with increased respiratory rate for age (consistent with the WHO integrated 
management of childhood illnesses case definition) and laboratory confirmed RSV; 
severe RSV-LRI was defined cough or difficulty in breathing with chest wall indrawing 
and laboratory confirmed RSV (in children less than 2 months of age, an increased 
respiratory rate >60 breaths/min with RSV confirmation would also meet the case 
definition of severe RSV LRI, regardless of whether lower chest wall indrawing was 
present). The addition of a danger sign (cyanosis, difficulty in breastfeeding or drinking, 
vomiting everything, convulsions, lethargy or unconsciousness, or head-nodding) defined 
a child as having very severe LRI [29]. Of note, some studies included in the meta-
analysis used more restrictive case-definitions, and the sensitivity and specificity of 
laboratory diagnostics between studies also varied [29].  Approximately 33.1 (uncertainty 
range [UR] 21.6 – 50.3) million RSV-LRI cases were estimated to occur globally in 
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2015, with more than 90% occurring in LMICs, and approximately half of the burden 
borne by five countries (India, China, Pakistan, Indonesia and Nigeria). One fifth of cases 
were estimated to be severe, defined by the presence of lower chest wall indrawing. 
 
Hospital-associated RSV-LRI was estimated separately, using a case definition of 
physician confirmed LRI diagnosis with RSV detected from a respiratory sample and a 
recommendation for hospitalization. Comparing RSV-hospitalization rates alone across 
countries does not fully reflect the difference in RSV disease burden, because of 
differences in access to care and care-seeking behaviors contribute substantially to the 
likelihood of admission. In 2015, there were 3.2 million RSV hospitalizations (UR 2.7 – 
3.8 million), with 45% of hospitalizations in children < 6 months, 85% associated with 
lower chest wall in-drawing, and 20% estimated to be hypoxemic [29]. Hospital case 
fatality ratios (hCFR) were estimated and were highest among neonates (5.3 deaths/100 
cases (95% CI 2.8-9.8 deaths/100 cases) in developing countries), and in low-income 
countries (9.3 deaths/100 cases [95% CI 3.0 – 28.7 deaths/100 cases] for infants 6-11 
months old in these settings) [29]. Overall in-hospital mortality was estimated to be 
59,600 deaths (UR 48,000 – 74,500) [29]. Infants less than 6 months of age made up just 
under half of the burden, with 1.4 million (UR 1.2-1.7 million) estimated hospitalizations 
and 27,300 (20,700 – 36,200) in-hospital deaths [29]. Using data from three LMIC field 
sites, out-of hospital fatalities were modeled and added to the in-hospital deaths, resulting 
in a total estimate of 118,200 (UR 94,600 – 149,400) RSV-associated deaths [29]. 
Overall, there is a trend over time for decreasing hCFR for RSV-LRI across all regions 
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and age groups, though 99% of RSV-related mortality still occurs in developing countries 
[29]. 
 
Challenges associated with global RSV disease burden estimation efforts include paucity 
of data, especially in important regions of the world, few eligible studies, and missing 
data from existing studies. The greatest uncertainty lies in estimations of RSV-associated 
deaths, particularly in the first month of life [101]. Due to limited care seeking and the 
possibility that study hospitals are better resourced than non-study hospitals, it is possible 
that RSV-associated mortality is underestimated, especially since it may predispose 
children to bacterial pneumonia [46].  Better estimates of RSV deaths in the community 
are also critically important. The Child Health Mortality Prevention Surveillance 
(CHAMPS) study, a 20-year project in six high-mortality settings, will attempt to pair 
surveillance of community child mortality with post-mortem sample collection to address 
this data gap [78]. Even in facilities, it is not always possible to collect laboratory 
samples before death and CFR has been observed to be higher in those who do not have 
samples collected. While almost all RSV-associated deaths in high-income countries 
occur in the first year of life, in developing countries RSV related deaths also occur 
among children who are in their second year of life [46].  
 
RSV Burden in the United States 
	
Population-based surveillance of medically attended RSV-illness in children <5 years of 
age in the United States has found RSV to be associated with 18% of all respiratory 
illness, 20% of hospitalizations, 18% of emergency department visits, and 15% of 
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pediatric office visits during the RSV season (November – April) [18]. It estimated to be 
associated with approximately 70% of all bronchiolitis and 50% of all pneumonia 
hospitalizations during the winter season [18, 103]. RSV is estimated to hospitalize 1-2% 
of the U.S. general infant (<12 mo) population each winter [104]. Although young infants 
are at the highest risk for severe disease, the burden of RSV-illness, particularly for 
outpatient visits, remains high through the first 5 years of life, with 61% of outpatients 
being 24-59 months old [18].  
 
By age, annual RSV hospitalization rates in the U.S. are: 25.9 per 1000 child-years 
among infants <1 mo; 17.9 per 1000 child-years among infants <2 mo, 17 per 1000 child- 
years among infants <6 mo, and 3 per 1000 child-years among children less than 5 years 
of age [18, 105].  
 
Rates of hospitalization for RSV in the U.S. have been shown to be three times higher 
than those for influenza or parainfluenza viruses in the same populations; rates of RSV-
associated outpatient visits were roughly the same as for influenza in older children but 
significantly higher for RSV in infants less than 6 months old [18]. RSV is associated 
with 137 deaths per year in the U.S. in children less than 4 years old, compared to 38 per 
year from influenza [106]. 
 
RSV Burden in North American Indigenous Populations 
	
The infectious disease hospitalization rate for the American Indian / Alaskan Native 
(AI/AN) population has consistently been higher than that of the general U.S. population, 
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with a particularly pronounced disparity among infants that is largely due to an increased 
incidence of LRI [107]. Reasons for the increased risk of infectious disease in these 
settings may include poverty, household crowding, poor indoor air quality, reduced 
access to plumbing, and in some settings poor access to Indian Health Services (IHS) 
facilities [107, 108]. It has been suggested that LRI hospitalization rates in some of these 
communities may be enhanced by a lower threshold for hospitalization [109], but this has 
been assessed in the Navajo and White Mountain Apache reservations in the U.S. 
southwest and did not explain the high RSV hospitalization rates in those populations 
[110]. 
 
In multiple surveillance studies, Alaskan Natives and American Indians have been found 
to be at increased risk for bronchiolitis and RSV-associated hospitalization, with 
populations in Alaska and the Southwest United States at particularly elevated risk [109, 
111-113]. Prospective, population-level, hospital-based surveillance among Navajo and 
White Mountain Apache populations in the U.S. over three RSV seasons (1997-2000) 
have attributed 51.3% admissions for LRI among children less than 2 years old to RSV 
infection, with seasonal hospitalization rates of 63.6 per 1000 children <2 years old and 
91.3 per 1000 children <1 year old [110].  For comparison, in the year 2000, the RSV 
hospitalization rate for children <1 year of age in the general US population with high-
risk comorbidities including chronic lung disease, chronic heart disease, Down syndrome, 
congenital airway abnormalities, preterm birth, and other rare congenital and metabolic 
comorbidities was approximately 60 per 1000 children [114]. The increased risk of RSV 
illness in the Navajo and White Mountain Apache populations is consistent with the 
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increased incidence of LRI associated with other pathogens including S. pneumoniae and 
H. influenzae in the same populations [110].  
 
RSV Immunization Strategies: History and Current Landscape 
	
Currently, RSV is the only major etiologic agent of LRI for which no vaccine is 
available, though several vaccine candidates are in the development pipeline [95, 115]. 
The RSV vaccine pipeline is one of the most active of all pathogen focal areas, with two 
classes of products (subunit and live attenuated or recombinant vaccines) targeted 
towards four distinct populations (Table 1.1) [116]. The goal of achieving sterilizing 
immunity by vaccination (whereby infection of the upper respiratory tract is prevented) is 
unlikely to occur, and is therefore not required of vaccine candidates [99]. As of 
September 2017, there were more than 15 candidate products targeting passive and active 
immunization against RSV being evaluated in clinical trials [117]. In the United States, 
the following research gaps have been identified to address in preparation for RSV 
vaccine introduction: improving surveillance to generate outpatient and inpatient disease 
burden estimates (particularly within fine age strata and among pregnant women and high 
risk groups) and developing a better understanding of the impact of RSV infection on 
recurrent wheeze and asthma in child hood, maternal health and birth outcomes, and 
quality of life in the elderly [93]. The contribution of severe RSV illness in infancy to 
long-term outcomes, including the development of subsequent wheeze and asthma will be 
important to establish in preparation for vaccine policy decisions and to assist with cost-




Because the majority of global RSV disease burden occurs in otherwise healthy infants, 
immunization strategies that can be universally applied to protect infants from severe 
disease are key to achieving a meaningful reduction in disease burden [100, 118]. The 
World Health Organization (WHO) has identified infants less than 12 months of age as 
the priority target population for safe, effective, accessible and affordable vaccines to 
prevent RSV-associated illness and deaths, with particular focus on LMIC settings where 
disease burden is highest [119]. Young infants who are at highest risk of disease are a 
particularly challenging group to target for active immunization because of potential 
competition from maternal antibody as well as their immature immune systems. A 
notable vaccine failure in the 1960s, described in the next section, and the difficult 
balance of achieving both safety and immunogenicity further complicate RSV vaccine 
research in this age group.  Other challenging issues in the development and introduction 
of RSV vaccines include but are not limited to: imperfect animal models, the capacity of 
the virus to evade the immune system, varied target populations requiring specific 
vaccine strategies, gaps in existing disease burden data, and challenges in identifying case 
definitions for vaccine clinical trials. To effectively prevent the majority of RSV 
infections in childhood and substantially reduce RSV burden, a multipronged approach is 
likely needed, with maternal immunization pursued in combination with infant 
immunization [95]. Because the greatest burden of severe RSV disease and death is in 
developing countries, special consideration will have to be given to vaccination of these 
populations, including the development of clinical endpoint case definitions that can be 
compared across diverse settings, as well as consideration of factors that may affect 
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vaccine efficacy, such as maternal illness, HIV prevalence, crowding, and indoor air 
pollution [99].  
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n/a Infants <6 months of 
age 
Licensed Short half-life, available 
to high-risk populations 
only. New generation, 









Infants <6 months of 
age 
Phase 3 clinical 
trials 










Infants <6 months of 
age, as well as older 
infants 
Phase 2 clinical 
trials 
Safety and avoidance of 
enhanced disease 
response; competition 














1As of September, 2017 http://www.path.org/publications/files/CVIA_rsv_snapshot_final_0917r.pdf 
 
History of RSV Immunization  
In 1969, a formalin-inactivated (FI) RSV vaccine was developed that failed to protect 
against wild-type (wt) RSV infection, and also produced a ‘vaccine enhanced’ 
exaggerated clinical response at the time of natural infection in children who were RSV 
naïve prior to vaccination [6, 120].  Data from children who were vaccinated with the FI-
RSV vaccine as well as animal models suggest that it produced insufficient levels of 
serum neutralizing antibodies and did not induced local immunity [6]. The vaccine also 
primed for Th2-like response rather than a CD8+ cytotoxic T-cell response, so once 
infected with RSV, the virus could not be readily cleared and caused a direct cytopathic 
effect in the lower respiratory tract as well as increased inflammation and 
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bronchoconstriction [6]. Recently it has been discovered that the vaccine caused deficient 
toll-like receptor (TLR) activation of B cells, resulting in a lack of affinity maturation of 
the antibodies and the deposition of immune complexes in the lungs of children infected 
with RSV [121, 122]. As a result of the experience with the FI vaccine, live attenuated 
vaccines, which are most likely to induce protective levels of neutralizing antibody, CD8 
RSV-specific cytotoxic T-cells, and a pattern of CD4 response similar to that induced by 
wt RSV infection, are being pursued for use in infant populations [3, 6].  
 
Passive immunization of infants by monoclonal antibodies (mAbs) 
Palivizumab (licensed in 1998) is a neutralizing mAb against a conserved epitope in the 
RSV viral fusion (F) surface glycoprotein, and is the currently the only licensed antibody 
for the prevention of RSV in high-risk infants [3]. Palivizumab is directed against the 
neutralizing epitope on both the pre- and postfusion forms of the F protein, and blocks 
conformational change that allows viral entry into the cell. It is delivered by 
intramuscular injection and due to its constrained half-life, has to be delivered monthly 
during the RSV seasons. Given the cost of palivizumab and the inconvenience of monthly 
dosing, it is only recommended for use in high-risk infants (Table 1.2). The same 
constraints make routine use of palivizumab infeasible for use in LMIC settings, where 
the cost of mAbs have historically been considered prohibitive [95]. The market 
authorization for a more affordable, generic version of palivizumab is expected to be 
available at the end of 2018, but a monthly dosing regimen will remain a significant 




Table 1.2 American Academy of Pediatrics red book committee recommendations 
for Palivizumab (2014)* [123] 
 
High Risk Population AAP Recommendation 
Premature infants (<29 weeks gestation) who are 
younger than 12 months at the start of RSV 
season 
Palivizumab prophylaxis during the RSV season in 
the first year of life (a maximum of 5 monthly doses 
of 15 mg/kg; qualifying infants born during the 
RSV season may require fewer doses) 
Infants born at <32 weeks gestation with chronic 
lung disease of prematurity requiring ≥28 days 
of supplemental oxygen after birth, or certain 
chronic heart diseases, or airway clearance issues 
Same as above 
Infants born at <32 weeks gestation with chronic 
lung of prematurity requiring ≥28 days of 
supplemental oxygen after birth and who 
continue to require medical intervention during 
the 6-month period prior to the second RSV 
season 
Palivizumab prophylaxis during the RSV season in 
the first and second years of life 
Children younger than 24 months who will be 
profoundly immunocompromised during the 
RSV season 
Palivizumab prophylaxis considered during the 
RSV season 
*Due to the high burden of RSV disease and costs associated with transport from remote locations, a 




Motavizumab is a next-generation humanized IgG1 monoclonal antibody derived from 
palivizumab that acts against the same epitope on both the pre-fusion and post-fusion 
forms of the RSV F protein as paliviuzumab but was designed to have an increased 
affinity for RSV. Both palivizumab and motavizumab prevent virus-to-cell and cell-to-
cell fusion in a dose-dependent manner, the mechanism for which appears to be blocking 
a step in virus replication after attachment to RSV and before virus transcription [124]. 
Unlike palivizumab, which has only been shown to reduce RSV replication in the lower 
respiratory tract of cotton rats, motavizumab has been shown in in vivo studies to reduce 
RSV replication in the upper respiratory tract [125]. Owing to its increased potency and 
affinity for RSV, motavizumab has shown a greater reduction in medically attended LRI 
compared to palivizumab but also a three-fold higher rate of non-fatal hypersensitivity 
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adverse events [126, 127]. Because of these adverse events and subsequent additional 
studies requested by the US Food and Drug Administration, Medimmune is no longer 
pursuing licensure of this product.  
 
Current efforts are focused on the development of extended half-life mAbs (with the 
MEDI8897 product furthest in development) that would allow for just one dose to be 
given at birth or at the beginning of the RSV season and would protect for an entire, 
typically 5 month season [128]. Such an intervention could be applied to all infants rather 
than restricted high-risk populations, and could potentially be used in LMICs. If dosing 
with such a product were to be RSV season-dependent, improved surveillance data would 
be necessary to accurately track RSV seasonality across LMIC settings. 
 
Passive immunization of infants by maternal immunization  
 
Successful vaccination of pregnant women against RSV in the second or third trimester 
of pregnancy would result in trans-placental transfer of antibody and the immediate 
protection of the neonate at birth and for three or more months thereafter [129]. An 
advantage of this approach is that it protects against RSV-illness during peak 
susceptibility and also allows for direct vaccination of the infant to be delayed until a 
point when their immune systems are better equipped for antibody affinity maturation 
and more efficient antigen presentation [129]. An RSV F nanoparticle vaccine by 
Novovax is currently in phase III trials in multiple countries, including LMICs, and is the 
most advanced candidate vaccine for the prevention of RSV in early infancy [95]. 
Challenges to maternal vaccination include generation of adequate safety data to address 
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risks to maternal, fetal and neonatal outcomes, determining the optimum time to 
vaccinate pregnant women (vaccinating late in pregnancy is likely more immunogenic, 
but would not offer protection to preterm infants; vaccinating early in pregnancy brings 
the risk of inadvertently ascribing to the vaccine adverse events that are more common 
during that period), and assessing the potential of maternal antibodies to suppress or 
interfere with the infant immune response [129]. In LMICs, there are additional special 
considerations. While transplacental antibody transfer is very efficient in healthy 
populations, there is concern that underlying health conditions such as 
hypergammaglobulinema, HIV-infection, under-nutrition and helminth infections may 
impair antibody transfer [129, 130]. Further research is being done in this area and 
maternal immunization strategies in settings where such morbidities are common will 
need to take them into account. Based on current global disease burden estimates and a 
relatively high RSV CFR in the neonatal period, it estimated that an extended half-life 
monoclonal antibody or maternal immunization that offered 6 months of protection with 
80% efficacy and high coverage could avert up to 1.1 million RSV hospitalizations and 
22,000 in hospital deaths globally [29]. 
 
Active immunization of infants  
Candidate vaccines for active immunization of infants have not progressed as far through 
the vaccine development pipeline as passive immunization approaches. There are 
currently two active infant immunization strategies under development: those using viral 
vector platforms and live-attenuated vaccines. Two live-vectored vaccines targeting 
infants are currently in phase I and II clinical trials. Several live attenuated RSV strains 
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are being developed and are currently being evaluated as intranasal vaccines in phase 1 
trials [95]. An advantage of live vaccines, which must be highly attenuated, is that they 
induce broad humoral and cellular immunity without requiring an adjuvant. They are 
being pursued as the preferred vaccination type in infants because they are unlikely to 
cause enhanced disease, and so far have not been associated with this outcome in clinical 
trials [94]. Live attenuated intranasal vaccines have also been shown to replicate in 
infants in the presence of maternal antibody [6]. 
 
An important consideration for infant vaccination programs will be at what age to 
vaccinate in order to achieve maximum protection. Assuming that maternal antibodies 
impede response to vaccine, an age window for vaccination must be determined that 
minimizes the risk of maternal antibody interference while being delivered early enough 
to prevent severe illness that occurs in the high-risk period of infancy. Data from 
transmission modeling studies suggest that the ideal age of infant vaccination may be 5-
12 months, and may need to be optimized relative to the timing of the RSV season [131]. 
As an alternative to vaccinating young infants, models taking different levels of vaccine 
efficacy, lengths of protection, and varying coverage estimates into account suggest that 
disease transmission to this age group can be significantly reduced by vaccinating school 
aged children, who are largely responsible for bringing the virus into households [82]. 
With a vaccine that offers 6 months protection, such an approach could reduce the 




RSV, Subsequent Wheeze, and Asthma 
Measuring Wheeze and Asthma in Children 
	
Asthma, defined as a chronic inflammatory disorder associated with reversible airflow 
obstruction and bronchial hyper-responsiveness, is one of the most common chronic 
diseases of childhood globally, and has complex environmental and genetic components 
[71, 132, 133]. The heritability component is particularly strong, with estimates that 25-
95% (typical range 60-70%) of asthma is attributable to genetics [71]. Because young 
children are frequently unable to comply with traditional lung function tests, their 
diagnosis is usually based on a series of clinical criteria [134]. Asthma can be particularly 
challenging to distinguish clinically in this age group, however, because young children 
often present with overlapping features representing a mix of underlying respiratory 
disease processes [132, 134]. In developing countries, it is estimated that wheeze and 
asthma in young children are frequently falsely diagnosed as pneumonia, leading to 
inappropriate care and underestimates of asthma morbidity [135]. Untreated wheezing 
may contribute to malnutrition (via impaired breastfeeding) as well as serious bacterial 
pneumonia infections, putting asthmatic children at increased risk of respiratory mortality 
in these settings [135].  
 
Wheezing is characterized by a continuous whistling sound caused by the narrowing or 
obstruction of the airways and has many different causes in young children [134]. The 
most common causes are bronchiolitis and asthma, but other causes may include 
congenital anatomical abnormalities, foreign body aspiration, and other pulmonary, 
immune, cardiac and gastrointestinal disorders [134]. Despite the many potential 
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etiologies of wheeze in children, standardized questionnaires use reported wheeze as a 
proxy measurement for asthma because it is a highly sensitive tool to use across global 
settings with varied diagnostic capabilities [132]. Over the past two decades there have 
been attempts to use longitudinal cohort studies to develop classification systems to 
predict the risk of asthma in children based on their wheezing phenotype [134].  One of 
the first classification systems defines three primary childhood wheezing phenotypes: 
“transient early wheezing”, which occurs in the first three years of life and is unrelated to 
airway hyper responsiveness, “persistent wheezing” and “late-onset wheezing” – the 
latter two of which are most commonly associate with aeroallergen sensitization and 
asthma [136, 137].  
 
The Burden of Childhood Wheeze and Asthma 
	
In Europe and the United States, approximately one third of preschool aged children have 
experienced wheezing in the past six months, and almost 50% of children have had at 
least one wheezing episode by the time they are 6 years old [134]. Using standardized 
questionnaires, the International Study of Asthma and Allergies in Childhood (ISAAC) 
has estimated the prevalence of wheeze in the past 12 months among 6-7 year olds to be 
19.1% in North America, and 11.5% globally, while prevalence of severe asthma in the 
same age group is 7.1% in North America and 4.9% globally [138]. The prevalence of 
atopic conditions is lower in low-income than high-income countries (odds ratio (OR) 
0.49 (95% CI 0.37, 0.66)), which may reflect differences in microbial exposure between 
these settings (the ‘hygiene hypothesis’ [138, 139]). Prevalence of wheeze in Alaskan 
Native and American Indian populations appears to be consistent with that observed in 
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the general U.S. population, although data are limited and estimates can be difficult to 




Table 1.3 Prevalence of wheeze in early childhood in the United States  













26.8% Medically attended 
wheeze (MAW) in the 
past 12 mo 
     2.7% 3 or more MAW in past 
12 mo 
     14.9% Serious Early 
Childhood Wheeze (see 
footnote1) 
Patel et al. 
[141] 










Lai et al. 
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19.1% At least 1 parental 
reported wheeze 
















Parental report of 
cough, wheeze or 
breathlessness during 
the recent 6 winter 




et al. [143] 
1995 Arizona (Tucson 
Study) 
826 2 yrs 19.9% Parent report of 
transient early wheeze 
(wheeze with 
respiratory infection in 
first three years of life) 
 
Ball et al. 
[144] 
2000 Arizona (Tucson 










Frequent wheeze (>3 
wheeze episodes during 
preceding year, 











22.1% Wheezing or whistling 
in the chest in past year 
13 or more MAW events in 12 months or systemic steroids prescribed for MAW event, or asthma-controller 
medication for wheezing for >=3 consecutive months or 5 cumulative months within a 12 month period or 
>=1 hospitalization with MAW 
2One of the following: ISAAC study, with question “Have you had wheezing and whistling in the chest in 
the last 12 months?” (Yes/No), ISAAC question, but not an ISAAC study, or current wheezing without a 
diagnosis of asthma, or physician diagnosed asthma. 
	
	 42	
3International Study of Asthma and Allergies in Childhood 
 
 
RSV-associated Illness and Subsequent Wheeze / Asthma 
	
The onset, course, and severity of asthma are affected by many factors including 
infectious and non-infectious exposures. A major area of research concerns the 
elucidation of the role that severe viral respiratory illness in early life, specifically with 
HRV and RSV, plays in initiating the onset of childhood asthma.  
 
Through observational studies, it has been estimated that 40-50% of infants requiring 
hospital admission for bronchiolitis will experience subsequent wheezing episodes in 
early childhood, and 16-48% of infants hospitalized for RSV-LRI will later be diagnosed 
with childhood asthma [71, 146]. While the association between early life RSV-LRI and 
subsequent wheeze/asthma is well-established, it has not been established whether RSV 
lower respiratory tract infection in early life causes wheeze and asthma or whether such 
infections and RSV disease manifestations are simply more likely to occur in those 
children who are predisposed to develop wheeze/asthma as they age [2]. A third 
possibility is that RSV-LRI is both a marker of predisposition to childhood asthma and as 
well as a factor in the causal pathway [71].  In short, the question is whether or not RSV 
lower respiratory tract disease is in the causal pathway for subsequent childhood 
wheezing and if so, whether prevention of early RSV disease will reduce the incidence of 
childhood wheeze.  
 
Observed association between severe RSV and subsequent wheeze/ asthma 
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Retrospective and prospective observational studies over the past decades have 
demonstrated that RSV-associated LRI in infancy is associated with an increased risk of 
wheeze and asthma during childhood compared to infants who are not hospitalized with 
RSV-associated illness [2].   
 
Evidence from retrospective studies 
Several retrospective studies have established a specific association between bronchiolitis 
medical visits or hospitalization (without pathogen specific information) in infancy and 
subsequent wheeze or asthma [147-149]. The Tennessee Asthma Bronchiolitis Study 
(TABS) used their population-based birth cohort to retrospectively analyze the 
relationship between bronchiolitis hospitalization and subsequent asthma. They found 
that children who had bronchiolitis during the RSV season were more likely to develop 
asthma between 4 and 5.5 years of age (RR: 1.89; 95% CI: 1.80-2.00) than those who did 
not have bronchiolitis during RSV season, but they did not use virologic methods to 
confirm RSV as the cause of the bronchiolitis [150]. Retrospective studies that did 
virologically confirm RSV-associated severe illness have also found an association with 
subsequent wheeze or asthma [151-154]. While some of these studies found a high risk of 
wheeze around age three to four years that subsequently dropped off by age five to six 
[152] or ten years of age [147], one study found an increased risk of asthma up to age 20 
[154]. 
 
Evidence from Prospective Studies 
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In the 1990s, two large prospective cohort studies were conducted that established early 
life severe RSV illness as an important risk factor for asthma- and/or wheeze-associated 
illness through adolescence [137, 155]. In a cohort of Swedish infants who were 
hospitalized with RSV-bronchiolitis and followed through age 18 years, an increased risk 
of asthma, recurrent wheezing, or allergic sensitization was observed at three, seven, and 
18 years of age compared with the control group, and reduced lung function (independent 
of asthma) was observed through seven years of age [155-158]. Although RSV 
bronchiolitis in infancy was the most important risk factor for the development of 
subsequent asthma, family history of asthma/atopy increased the risk as well [158]. 
 
In the Tuscon Children’s respiratory study, a cohort of U.S. children followed through 13 
years of age produced somewhat different findings [137]. In this study, a broader 
definition of exposure was used (any medically attended RSV-confirmed LRI rather than 
limiting to hospitalized RSV-bronchiolitis as in the Swedish study), and an association 
was observed with increased wheeze at age 6 and 11 years, but not at age 13 years of age. 
The study also reported that RSV-LRI in the first three years of life was associated with 
transient early wheezing (defined as one lower respiratory tract illness wheezing during 
the first three years of life, but no wheezing at six years of age), or non-atopic wheezing 
later in life, but not with IgE-associated wheeze [159]. Observational studies of the RSV-
wheeze/asthma relationship from developing countries are fewer. One study from The 
Gambia found a significantly increased risk of wheeze within the first two years of life 
following hospital admission for severe RSV disease (IRR 7.33; 95%CI: 3.10,17.54), but 




Severity of RSV infection in relation to subsequent risk of wheeze or asthma 
Most studies of the relationship between RSV infection and wheeze/asthma have focused 
on medically attended RSV infections, and several use hospitalization to define their 
exposed groups. Within these studies, relationships between disease severity and 
increased risk of wheeze have been established using clinical and laboratory markers of 
severity. In the TABS cohort, more severe bronchiolitis was associated with greater odds 
of developing childhood asthma [150]. In a study using data from U.S. managed-care 
organizations, increased risk of wheeze through five years of age was observed in 
children who had been hospitalized with RSV, compared to those with outpatient visits, 
though those with outpatient RSV visits still had a slightly elevated risk of wheeze 
compared to those who had no RSV-associated visit [161].  A retrospective study of full-
term, previously healthy infants who were hospitalized for bronchiolitis during the first 
year of life and subsequently experienced recurrent wheeze (defined as two or more 
physician-verified episodes of wheezing a year for three consecutive years) found that 
those who presented with wheeze in the first 36 months of life had higher RSV viral 
loads during their bronchiolitis event in infancy, compared to wheezing-negative patients 
[146]. 
 
 Mechanisms by which RSV-illness may predispose to wheeze and asthma 
RSV lower respiratory infection in infancy is hypothesized to predispose children to 
asthma through several biological mechanisms including chronic epithelial and airway 
reactivity changes to the developing infant lung; lung injury altering lung function; and 
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immunomodulatory changes [2]. Because severe RSV disease is associated with Th2 
polarization of the infant immune system, it may sensitize the host immune response to 
other allergens [162], and this response may be further exacerbated in children with a 
high genetic risk of atopy, who have a heightened deficit in Th1 function [163]. It has 
also been demonstrated that RSV-illness in early life promotes overexpression of nerve 
growth factor (NGF), which can cause airway hyperreactivity that drives short and long 
term changes in the behavior nerves across the pulmonary system [2]. Severe RSV-illness 
is associated with reduced lung function that persists through childhood; whether or not 
this causes persistent hyperreactivity and asthma is an area of research [2]. The 
relationship between viral infection and asthma is further complicated by recent research 
highlighting a potential interaction with colonizing bacteria of the respiratory tract [164]. 
In particular, studies of the nasopharyngeal microbiome found that early asymptomatic 
colonization with Streptococcus was a strong risk factor for asthma, and that bacterial co-
colonization at the time of upper viral infection during infancy was associated with the 
spread of virus to the lower airways and subsequent inflammatory responses that may 
contribute to risk of asthma development [165]. Additional research is needed in this area 
to better understand the implications of specific bacterial co-infections with RSV and the 
risk of subsequent wheeze and asthma.  
Contrasting evidence comes from animal and clinical studies demonstrating that upper 
respiratory tract RSV infections may in fact reduce the risk of asthma development, 
presumably by modulating pathogenic immunity through early activation and expansion 
of T regulatory cells [166-168]. If this is indeed the case, it has significant implications 




Evidence for shared host factors for both asthma and acute severe bronchiolitis 
An important limitation of the observational studies described here is that the children 
who develop severe RSV illness early in life may be different from those who do not 
develop severe illness during the same RSV season, and these features themselves may 
be the causal risk factor for subsequent wheezing. Several studies have found evidence of 
this phenomenon. In the Copenhagen Prospective Study of Asthma in Childhood birth 
cohort, increased neonatal bronchial responsiveness was associated with increased risk of 
medically assessed viral bronchiolitis, including RSV-bronchiolitis [169]. In another 
cohort of infants, maternal asthma was found to be a risk factor for respiratory infection 
in infants, independent of subsequent childhood wheezing illness [170]. Decreased lung 
function at birth, preceding RSV-LRI has also been found to be a risk factor for severe 
RSV-LRI as well as for subsequent wheeze [171]. Preterm birth has been shown to have 
a dose-response relationship to the risk of developing asthma in childhood, though a large 
retrospective study establishing this association did not control for exposure to RSV-LRI 
[172].  
 
A number of genes that are associated with both increased risk of asthma and RSV-illness 
have been identified, though most studies focus on single genes and more complex gene-
gene and gene-environment relationships may be important for determining the RSV-
asthma relationship [2, 71, 173]. Genetic epidemiology shows promise as a means to 
identify common biologic pathways for asthma and RSV-illness, and to potentially 
quantify the extent to which these two outcomes share common genetic predispositions 
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[71]. Compared to asthma studies, there have been very few studies of candidate genes 
for risk of severe RSV-illness, and so far no genome wide association studies, reducing 
the number of common genes that can be identified between the two conditions [71]. 
Studies of genetic risk for severe RSV-illness can be challenging due to environmental 
factors that influence exposure to RSV infection, such as exposure to RSV season during 
periods of immune development and peak susceptibility [71].  
 
Evidence from intervention studies 
In the absence of a licensed RSV vaccine, immunoprophylaxis intervention studies offer 
the most promising method for discerning the causal role of RSV-illness on incidence of 
subsequent wheeze and asthma, but there are relatively few of these (Table 1.4). The 
intervention studies that have been conducted include a mix of randomized and non-
randomized trials among mostly non-representative populations using nonstandard case-
definitions, making cross-study comparisons and extrapolation to the general population 
difficult [174].  
 
In all but one of the intervention studies, a reduction in wheezing outcome was observed 
among the exposed (prophylaxed) participants (Table 1.4). The only study to assess the 
impact of RSV immunoprophylaxis on the risk of subsequent medically-attended wheeze 
in healthy full-term infants found no protective effect of the intervention; those who 
received motavizumab had a similar risk of subsequent wheeze through 3 years of age 
compared to placebo recipients [140]. One other double-blind randomized intervention 
trial has been conducted in preterm infants, and found a 73% relative reduction (95% CI: 
	
	 49	
66-80%) in total number of wheezing days over the first year of life outside of the RSV 
season in those who received palivizumab, compared to placebo [175]. Unlike the study 
conducted in healthy full-term infants, this study used parent-reported wheeze as an 
outcome, rather than medically attended wheeze, making comparisons between the two 
studies difficult. It is also possible that the relationship between RSV LRI and subsequent 
wheeze is different in preterm infants than it is in term infants due to differences in lung 
and immune system development. The conflicting observations from these intervention 
studies casts doubt on the assumption that preventing RSV-illness in infancy will 
necessarily produce a population-level reduction in wheeze and asthma in later 
childhood. It also highlights the need to develop standardized outcome measures by 
which to evaluate this relationship. It will be very important for future RSV vaccine trials 
to measure subsequent wheeze in a standardize manner in order to better understand this 




Table 1.4 Study characteristics and wheezing outcomes of respiratory syncytial 
virus prophylaxis trials and observational studies 
 




















Study Type RCT and 
Observational 
Observational Observational RCT RCT 





Non-treated Non-treated Placebo Placebo 
Study Years 1999-2000 2001-2004 2007-10 2008-11 2004 -10 
Length of 
follow-up for 
wheeze outcome  
single observation 
in each child 






7 – 10 years 2-5 years 4 mo – 3 years; 
6 years 
0-12 mo 1-3 years 
Study 
population 
Preterm ≤35 wGA 
with BPD/CLD 
Preterm ≤35 wGA with no 
CLD 
Preterm 33-35 
wGA with no 
CLD 
Preterm 33-35 
wGA with no 
CLD 
Healthy term 















atopy or food 
allergies)  





     
Recurrent 
wheeze (parent) 





 26% (59/230)b    





 16% (37/230) at 4 mo – 3 
years: 19% 
(18/95)c 














































   18.2% (12/66)   
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Family history (Comparison group) 
Asthma >8% and <12% 
(4% mother; 
8% father) 























Atopy >23% and <38% 
(23% mother; 
15% father) 






with a  smoker 







58%    16% 6%e 

















 49%b    






[RR 0.49 (95%CI: 0.28, 
0.86)] 
At 4 mo – 3 yrs: 
66%  
[RR 0.34 (95% 
CI: 0.19, 0.60)] 
 










 No difference  
[RR 1.10 (95% 
CI: 0.61, 1.97)]  















aIncludes wheezing occurring during the first RSV season [175], whereas other studies exclude this period 
bObtained from earlier published analysis of entire control cohort [180] 
cActive medical care seeking for all respiratory symptoms stipulated by protocol [178] 
dSevere Early Childhood  Wheeze (SECW) was defined as medically attended recurrent wheeze, one or 
more hospitalizations for wheezing, systemic steroids for a medically attended wheezing event, or asthma 




eDenominator is entire ITT control cohort, n=710 [140]  
fDocumented hospitalization for RSV in the first year before enrollment. Participants were enrolled if they 
were ≤36 months of age [177] 
gCalculated by combining results of the 130 children with family history of atopy presented in Table II with 
the 100 control children without such history [177] 
hInferred from paragraph 2, page 629 [176] 
iFigure 1, univariate analysis [177] 




Ongoing research on wheeze and asthma following RSV infection 
Currently, a population-based longitudinal cohort study (The Infant Susceptibility to 
Pulmonary Infections and Asthma Following RSV Exposure (INSPIRE) Study) 
is being conducted in Tennessee to better understand how the spectrum of early RSV 
infection (from mild to severe) influences the development of wheeze and asthma [168]. 
Specifically, it will (1) characterize the host phenotypic response to RSV infection in 
infancy and risk of recurrent wheeze and asthma, (2) identify the immune response and 
lung injury patterns of RSV infection that are associated with the development of early 
childhood wheezing and asthma, and (3) determine the contribution of specific RSV 
strains to early childhood wheezing and asthma development [168].  Nearly 2,000 healthy 
term infants living in Tennessee have been enrolled over two years and will have surveys 
conducted every two weeks during November to March in the first year of life, receive 
in-person visits when criteria are met for respiratory illness, and have the primary study 
endpoint (wheezing illness) assessed annually up to age 3-4 years. Samples collected will 
allow baseline and follow-up measurements of the respiratory and gut microbiomes, 
inflammation, immune response and lung injury, as well as RSV and HRV detection 
during respiratory illnesses [168]. This study design, however, will be unable to avoid the 
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Chapter 2: A review of the interaction between Streptococcus pneumoniae and RSV 
in acute lower respiratory illness 
 
 
Acute respiratory illness is an important cause of childhood morbidity and mortality 
globally, with pneumonia accounting for 16% of all under-five deaths in 2015 [181]. In 
2015, after more than 130 countries had introduced pneumococcal conjugate vaccine 
(PCV), there remained an estimated 335,000 deaths from pneumococcal disease among 
children under five years, accounting for more than one third of total pneumonia deaths 
[182]. Respiratory syncytial virus (RSV) is another important pathogen, recognized as 
one of the most common causes of lower respiratory infection (LRI) in children, and 
particularly among young infants [46]. There is currently no licensed vaccine to prevent 
RSV, which causes approximately 59,600 - 118,200 RSV-associated deaths in children 
less than five annually, accounting for 7-13% of pneumonia deaths in this age group [29]. 
Mixed pathogen infections are common in LRI, including pneumonia, where it is 
increasingly understood that most cases are a result of sequential or coincident multi-
pathogen infections [183-186]. A growing body of evidence suggests that the clinical 
severity of lower respiratory disease may be increased in the context of such mixed 
infections [187].  Mechanisms by which viruses can predispose to bacterial infections are 
well described and include increased bacterial adherence, reduced bacterial clearance in 
the presence of virus, exacerbated host immunopathology, and suppression of the 
immune response following viral infection [188, 189]. The best understood example of 
this type of interaction is the phenomenon of influenza virus predisposing to secondary 
pneumococcal infection, which was responsible for much, if not most, of the massive 
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mortality suffered during the 1918 influenza pandemic [190]. Over the past 20 years, a 
body of evidence has grown describing a complex, multifactorial process whereby 
bacterial and viral factors, in combination with the host immune response, result in more 
severe disease with pneumococcus and influenza compared to influenza alone [190].  The 
evidence for an interaction between RSV and pneumococcus is not as well established as 
that for influenza and pneumococcus, but there is plausibility for a causal, potentially bi-
directional, interaction between these two common pathogens in children with lower 
respiratory disease. Understanding interactions between RSV and pneumococcus and 
their role in pediatric LRI may be relevant to the improvement of prevention and 
treatment strategies, as well as for the for the investment case for RSV vaccines and 
continued investment case for pneumococcal vaccines. We aimed to collect, evaluate, and 
synthesize the experimental and epidemiologic data that provides evidence for an 
interaction between pneumococcus and RSV in causing lower respiratory illness in 
children, highlighting strengths and identifying where gaps may remain in our 




Figure 2.1 Evidence for an interaction between RSV and Streptococcus pneumoniae 




Evidence of interaction between RSV and pneumococcus from in vitro studies 
In vitro studies provide evidence that RSV infection preceding pneumococcal 
colonization results in enhanced bacterial attachment to host cells and increased bacterial 
virulence, and that simultaneous rather than sequential infection with the two pathogens 
may result in even greater propensity for enhanced disease. There is also evidence, albeit 
limited, of a potentially bidirectional relationship whereby preceding pneumococcal 
colonization could facilitate RSV infection. 
 
The respiratory epithelium provides the first line of immune defense against invading 
bacteria, and preceding viral infection can disrupt this layer to allow for enhanced 
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bacterial infection [187]. Increased bacterial adhesion to virus-infected epithelial cells has 
been observed for several pathogen combinations and is considered an important step in 
the process leading to secondary bacterial infection [191]. Pneumococcus and RSV have 
been shown to interact in this way, with increased adhesion of pneumococcus to RSV-
infected epithelial cells demonstrated experimentally in vitro [192-196]. Proposed 
mechanisms for this phenomenon include up-regulation of bacterial receptors in RSV-
infected cells, direct binding of pneumococcus to RSV glycoprotein, and increased 
expression of bacterial neuraminidase in the presence of RSV, discussed below.  
 
RSV glycoprotein G (RSV-G) is a transmembrane viral protein that mediates attachment 
to host cells and is expressed on the surface of RSV-infected eukaryotic cells [197]. 
When expressed on epithelial cells, it results in increased transcription and expression of 
several host bacterial receptors that lead to enhanced adherence by pneumococcus [195, 
196, 198]. Consistent with this increase in receptors, pneumococcus in cell cultures forms 
bacterial aggregates around the ciliary tips of RSV-infected structures where RSV-G 
proteins are expressed [199]. Pneumococcal adherence is further enhanced by the 
demonstrated ability of the bacteria to bind to RSV-G protein directly [194, 198].  The 
binding site for RSV-G has been identified as a protein expressed in the bacterial cell 
wall (pneumococcal penicillin binding protein 1a (PBP1a)) [199], and no difference in 
binding to RSV-G has been observed by pneumococcal serotype [194]. In addition, 
pneumococcus can bind directly to free virions via the RSV-G protein, thereby forming 
RSV-pneumococcal complexes that infect previously uninfected cells [194, 198]. 
Adherence of pneumococci to uninfected cells increases dramatically following the 
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formation of such complexes [194]. Finally, increased expression of the enzyme 
neuraminidase in the presence of RSV may further facilitate bacterial adhesion [199].  
 
In addition to enhancing bacterial adherence to the epithelium, RSV may promote 
pneumococcal infection by exacerbating damage to the epithelial cilia and increasing 
pneumococcal virulence. Pneumococci that have been incubated with RSV or purified 
RSV-G protein produce more of the chemokine responsible for neutrophil recruitment 
into the airways and cause greater ciliary damage, leading to reduced bacterial clearance 
[199]. The binding of RSV-G and PBP1a also results in upregulation of the gene 
pneumolysin, which encodes a toxin that has been shown to be critical for the 
development of invasive pneumococcal disease [199].  
 
Additional experimental evidence supports a bidirectional relationship between the two 
pathogens, whereby preceding or simultaneous pneumococcal exposure may enhance the 
ability of RSV to infect the host. Bacterial neuraminidases produced by pneumococcus 
enhance RSV infection in vitro, potentially by improving the interaction between RSV 
transmembrane glycoprotein and its cellular receptor through the removal of sialic acids 
[200]. Additionally, a synthetic bacterial lipopeptide has been shown to enhance RSV 
attachment to host cells when simultaneously added to cell culture with RSV (but not 
when added after virus) [201].  Prior colonization with pneumococcal serotypes 8, 15A or 
19F, but not 19A or 23F, has been shown to result in significantly higher numbers of 
RSV-infected epithelial cells [202]. These results were not fully consistent in cotton rats, 
however, where serotypes 19F and 23F, but not 8 or 15A, were associated with higher 
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subsequent viral loads [202]. Because only one strain of each serotype was tested in this 
study, however, it was not possible to determine whether differences were indeed 
serotype related [202]. In another study, cells incubated with pneumococcus prior to RSV 
infection showed no difference in the amount of inflammatory cytokines IL-6 and IL-8 
secreted compared to RSV-infected cells that were not pre-exposed to pneumococcus, 
though the authors speculated that the use of heat-inactivated bacteria could have altered 
the pneumococcal virulence and may have obscured the results [203]. 
 
 
Evidence of interaction between RSV and pneumococcus from in vivo studies 
In vivo studies provide strong evidence that RSV and pneumococcal co-infection can lead 
to increased disease severity compared to infection by either pathogen alone. Infecting 
mice with RSV and then pneumococcus, or with RSV and pneumococcus together, 
increased the incidence and level of subsequent bacteremia compared to those infected 
with pneumococcus alone [194]. The greatest effect was observed with simultaneous 
infection, supporting the hypothesis that greater bacterial binding occurs in the context of 
pneumococcal-RSV infecting complexes, and was consistent with another study where 
simultaneous treatment of mice with RSV and pneumococcus lead to significant disease 
and rapid death [199]. Similar patterns of enhanced bacteremia have been observed with 
simultaneous infection of streptococcus and influenza virus [204]. A relationship in the 
opposite direction, with pneumococcal inoculation preceding RSV infection, was not 




RSV pre-infection also results in increased risk of pneumococcal pneumonia in mice. In a 
sequential pulmonary infection mouse model, infection with even very low titers of RSV 
followed by intratracheal inoculation of pneumococcus resulted in higher bacterial loads 
and decreased bacterial clearance from the lungs compared to mice without preceding 
RSV infection [205]. Bacterial clearance was depressed even in the presence of increased 
macrophages and neutrophils in bronchoalveolar lavage samples, leading the 
investigators to hypothesize that RSV may have induced functional changes in the 
recruited neutrophils or other changes in the inflammatory/cytokine milieu in the mouse 
lung [205]. In this study, a similar effect was observed with RSV infection preceding 
inoculation with Staphylococcus aureus or Pseudomonas aeruginosa, was dependent on 
the dose of virus and bacteria used, and persisted beyond the time that RSV could be 
detected in the lungs [205].  The effect of pneumococcal infection preceding RSV was 
not investigated in the mouse pulmonary model.  
Finally, in vivo models of influenza and pneumococcus have demonstrated immune cell 
infiltration after dual infection to be greater than by either infection alone, and although it 
has not yet been specifically demonstrated for RSV and pneumococcus, it is possible that 
the combination of these two pathogens similarly triggers an overactive immune response 
and subsequent immunopathogology [204, 206].  
 
Evidence from epidemiologic studies 
 




Co-detection of pneumococcal bacteremia is rare in children with severe RSV-LRI, and 
occurs most frequently in very young infants or those with underlying health conditions 
including preterm birth. A number of retrospective case-series studies have attempted to 
define the proportion of children with severe RSV-LRI who have bacteremia, primarily 
for the purpose of informing treatment guidelines and identifying children at increased 
risk of death (Table 2.1). These studies included hospitalized and outpatient cases with 
RSV-LRI confirmed by antigen testing or antigen testing in combination with viral 
culture, were for the most part conducted in low mortality settings prior to PCV 
introduction, and reported positive blood cultures in 0%-2.8% of severe RSV-LRI cases 
[207-217]. In studies that limited cases to those admitted to intensive care units (ICUs), 
the proportion blood culture positive rose to 0.6%-3.7% [218-221]. A significant 
exception to the trend occurred in a high-mortality setting (Pakistan in the 1980s), where 
more than one third of children <5 with RSV-LRI had bacteremia and 12.4% of children 
with RSV-LRI had pneumococcus detected by blood culture [216].  
 
Risk factors for bacteremia in children with RSV-LRI have been assessed and include 
preterm birth, age less than three months, nosocomial RSV, underlying medical 
conditions and ICU admission [211, 212, 215]. Co-occurrence of severe RSV-LRI and 
serious bacterial infection (not limited to pneumococcus) was associated with more 
severe disease, longer hospitalization periods and increased requirements for mechanical 




Although bacteremia is usually a rare complicating event in children with RSV-LRI, 
pneumococcus makes up a large proportion of the pathogenic blood culture isolates in 
most studies (Table 2.1). It is possible that these studies may also be underestimating the 
true prevalence of pneumococcal pneumonia co-infection as a result of antibiotic 
exposure and low sensitivity of blood culture methods. Bacteremia has a very low 
sensitivity for detection of true bacterial pneumonia, and studies reporting on bacteremia 
in children with RSV-LRI should be interpreted with that lack of sensitivity in mind. In 
children with RSV-LRI for whom bacteremia was defined by positive blood culture or 
blood PCR the proportion with bacteria detected in blood was higher, with 10% overall 
bacteria positive, and 3.7% pneumococcal PCR positive [215]. 
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Table 2.1 Pneumococcal bacteremia in children with RSV-LRI1 

















LRI with blood 
culture taken 





861 11 (0.6%); higher 
incidence among 
those admitted to 
ICU4 (2.9%) 
6 (0.7%) Sp+ 
6/11 (56%) 
Byington, low 
mortality, US [223] 
(prospective) 
Febrile infants 




















3 (4.5%) Sp+ 













127  3 (2.4%)  
2 (1.6%) Sp+ 









491 175 (36%) 
 
61 (12%) Sp+ 
 
61/175 (35%) 
Hall, low mortality, 






565 3 (0.5%) 









to ICU for 
respiratory 
failure or apnea  
Blood 
culture   
275 1/27 (3.7%)  
0 (0.0%) Sp+ 
0/1 (0.0%)  
Liebelt, Low 









120 0 (0.0%) n/a 
Oray-Schrom, Low 









120 1 (0.8%) 
0 (0.0%) Sp+ 
 0/1 (0.0%) 
Purcell, Low 










2,396 0 (0.0%) n/a 
Randolph, low 







Blood  165 1 (0.6%) Sp+ 1/1 (100%)  
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464 2 (0.4%) 
0 (0.0%) Sp+ 
0/2 (0.0%) 
Rice, low mortality, 
US [217] (prospective) 
<2 yrs RSV-




38 1 (2.6%) Sp+ 1/1 (100%) 
Titus and Wright, 
Low mortality, US 
[210] (retrospective) 
Infants ≤8 


















108 3 (2.8%) Sp+ n/a (it was not 
reported whether 
other bacteria were 
detected) 
Tristram, low 
mortality, US [224] 
(retrospective) 
Inpatient 









189 4  (2.1%) Sp+ 4/4 (100%) 
1We excluded studies that assessed bacteremia in bronchiolitis cases where RSV infection was not confirmed, as well 
as studies that reported bacterial outcomes in RSV-LRI cases without specifying the number of pneumococcal-positive 
cases among those with RSV-LRI 
2Percentages rounded to first decimal place if <10%; percent all-cause bacteremia unless “Sp+” specified  
3Streptococcus pneumoniae detected 
4Intensive care unit 
5n=82 children were included in this study but only 27 had blood cultures collected 




The proportion of children with pneumococcal pneumonia, rather than bacteremia, in the 
presence of RSV-LRI was assessed in several studies using a combination of blood 
culture, serology, and/or tracheal aspirate culture and ranged from <1%-25% (Table 2.2). 
Serology for pneumococcus has been found to be sensitive for the detection of 
bacteremic pneumococcal pneumonia in children, but these methods are insufficiently 
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validated for the detection of non-bacteremic pneumococcal pneumonia owing to the lack 
of a gold-standard comparator [225]. Pneumococcal pneumonia was diagnosed by 
serology in 8.3% of inpatient RSV-LRI cases with radiographic pneumonia [226], and in 
approximately one quarter of inpatient RSV-LRI cases with or without radiographic 
pneumonia [227, 228]. Tracheal aspirates, while not meeting the same specificity for 
etiology as blood cultures, may have higher specificity for pneumococcal disease than 
nasopharyngeal aspirates, and studies using these specimens reported a prevalence of 
pneumococcal pneumonia as high as 16% [218-221]. Pneumococcus was cultured from 
the expectorated sputum in a similar proportion (12.8%) of hospitalized RSV-LRI cases 
[229]. Interpretation of these results is complicated by the fact that both tracheal and 
sputum specimens can be contaminated with flora from the upper respiratory tract, and 
that findings from tracheal aspirates may not be representative of children who are not 
intubated.  
 
We found only two studies that assessed prevalence of RSV among children with 
pneumococcal disease, both with significant limitations. One was a retrospective review 
of the hospital records of 82 children between the ages of 2 months and 18 years who 
were admitted to the hospital with IPD and were tested for viruses at the discretion of the 
clinician, with RSV detected in 5 (6%) [230].  The criteria for viral testing in these 
children were unknown and results were not stratified by age. The second study tested for 
RSV in children 7mo – 16 years with pneumococcal-associated radiologic pneumonia 
and found 10% positive, but most of these pneumococcal pneumonia cases were 
diagnosed by urine antigen testing only, which has low specificity for pneumococcal 
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disease in children given their frequent carriage of the bacteria, and age-stratified results 
were also not presented for this study [231].  
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Table 2.2 Co-occurrence of pneumococcal pneumonia in children with RSV-LRI 
 Author, Setting, 
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[227] prospective 
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9/25 (36%)  
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 Author, Setting, 


























































      













24/82 (29%)  
1Percentages rounded to first decimal place if <10%  
2 RSV lower respiratory illness 
3Pneumococcus test positive  
4Intensive Care Unit 
5Endotracheal tube aspirate 
 
A common feature of many of these studies of pneumococcal bacteremia and pneumonia 
in patients with RSV LRI is a reliance on retrospective review of hospital records, which 
presents the possibility of an initial viral diagnosis that has been changed to a diagnosis 
of bacterial infection once the latter was identified [209]. Another important limitation is 
their cross-sectional nature, which prevents them from being used to draw inferences 
regarding temporal associations. Furthermore, the majority of the investigations took 
place in low mortality settings, and as evidenced by the findings in Pakistan, may not be 




Very few studies have been designed to compare rates of pneumococcal disease in 
children with RSV-LRI to those without RSV-LRI. The few that have attempted to do so 
report mixed findings and have several limitations. One study of infants <2 months with 
fever (not necessarily associated with LRI) presenting to emergency departments found a 
lower incidence of bacteremia in infants with RSV-infection compared to those without 
RSV, but did not restrict the study population to children with LRI, and only 38% of 
infants with documented RSV infection had clinical bronchiolitis [209]. A study of 
bacterial and viral co-detection in children with radiographic pneumonia aged 6 months – 
15 years found no association between the detection of RSV and pneumococcus in 
sputum samples, but had a very low overall detection rate for RSV (perhaps influenced 
by the older ages included) [233]. A study of inpatients with pneumococcal pneumonia 
and/or RSV-LRI with or without radiographic evidence of pneumonia, assessed for both 
pathogens using serology, and found increased pneumococcal pneumonia in children 
with RSV-LRI compared to those with non RSV-LRI [227], while another serological 
study of hospitalized children with pneumonia found no specific association between 
RSV-LRI and detection of pneumococcus [234].     
 
Ecological studies show a temporal association between RSV-LRI hospitalizations 
and subsequent pneumococcal disease hospitalizations 
 
Ecological studies have used hospitalization surveillance data to investigate a temporal 
relationship between peaks in RSV-LRI activity and cases of pneumococcal disease 
(Table 2.3). Several found a contemporaneous correlation between RSV-LRI and 
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pneumococcal hospitalizations [89, 235-238], and two found increased pneumococcal 
disease persisting for up to four weeks following peaks in RSV activity [89, 235]. Others 
found a 1.5 [90] or 4-week [239] lag between peaks in RSV activity and subsequent 
increases in incidence of pneumococcal disease. These lags are consistent with the 
hypothesis that RSV infection predisposes for increased risk of pneumococcal disease by 
altering the host respiratory environment. Only one study found no temporal association 
between RSV-LRI and pneumococcal disease in children [240], and one found a trend of 
IPD cases peaking slightly before RSV-LRI cases [241]. The only study to assess 
pneumococcal pneumonia in young children (rather than IPD) found a greater association 
between RSV hospitalizations and pneumococcal pneumonia compared to RSV 
hospitalizations and pneumococcal bacteremia [90]. The effect of age was not consistent 
across studies, with some finding stronger temporal associations in younger ages [90, 
237, 238] but most observing a greater correlation between RSV hospitalization and 
pneumococcal hospitalizations in teens and adults compared to young children [235, 236, 
239, 241].  
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Table 2.3 Temporal associations between RSV LRI and pneumococcal disease in 
ecological studies 
 
Study, Location Ages 
included 




All 1997-2003 RSV and IPD positively 
associated in all age 
groups, IPD appeared to 
peak before RSV; after 
adjustment for season 
association was weakened 
in <18 yrs but still 
significant in adults 
Yes, incidence of 









1992-2008 IPD cases peaked 1.5 
weeks after RSV-LRI 
hospitalizations 





All 1995-2002 RSV associated with IPD 
in all ages within 4 weeks 
from the start of RSV peak 
activity; less pronounced in 
<18 yrs olds 
No 
Kim, United States 
[239] 
All 1990-1993 IPD incidence peaked in 
infants and children 4 
weeks after RSV peak, 





<18 yrs 2001-2007  
 
Correlation between IPD 
and RSV up to 4 weeks 






RSV associated with 
increased IPD in children 
<5 years; overall 3-4% of 
IPD cases attributable to 
RSV across all ages 
Yes, meteorological 




All 1996-2009 4% of IPD cases (all ages 
could be attributed to o 
RSV)  
Yes, meteorological 






<7 yrs 1996-2012 15.5% bacteremic 
pneumonia attributable to 
bronchiolitis (RSV proxy); 
invasive non pneumonia 
infections not associated 
Yes, sine and cosine 





All 2000 RSV activity correlated 
with IPD in children (no 
lag period), but not adults 
No 
 
Discerning the independent effects of RSV epidemics on pneumococcal epidemics is 
challenging due the fact that they tend to have shared seasonal patterns in temperate 
climates. Some studies therefore include temperature or other seasonal variables in their 
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analyses as a way to account for factors such as shorter photoperiods and lower 
temperatures that could increase the risk of transmission of both pathogens due to 
increased crowding and increased host susceptibility. In studies that took this approach, 
the correlations between RSV and IPD activity remained significant [90, 237, 241].   
 
It is noteworthy that all of these studies were conducted in temperate climates where RSV 
and pneumococcal disease epidemics have shared seasonality, and it will be important to 
replicate them in tropical and sub-tropical settings with different patterns of weather and 
disease. One of the temporal association studies in the United States included data from 
Florida, which has an earlier and less pronounced RSV peak than the rest of the country 
as well as a sub-tropical to tropical climate. RSV activity and pneumococcal disease 
remained associated in Florida, but the lag between the two epidemic peaks was much 
longer (approximately 10 weeks) compared to the 1.5-week lag observed in other states 
[90]. A trend of pneumococcal disease peaking slightly after RSV epidemics appears to 
be consistent in a pneumonia etiology study in the high mortality setting of Pakistan, 
although it was not formally studied in that context [216]. 
 
Individual-level studies are critical for confirming the temporal associations found 
between RSV-LRI and pneumococcal disease in these ecologic studies. We are aware of 
only one individual-level study so far that has looked at this association (also in a 
temperate climate), and showed an increased risk of IPD following RSV-LRI 
hospitalization in children <2 years [242]. No association was found for increased risk of 




Increased pneumococcal carriage density in the nasopharynx is associated with 
RSV-LRI 
Pneumococcal colonization of the nasopharynx is a prerequisite for the development of 
pneumococcal disease [243], and evidence indicates that it is facilitated by RSV-
infection.  Increased pneumococcal colonization prevalence [244, 245] as well as density 
[245] are associated with RSV in children <5 with LRI, with the strongest associations 
found in those <24 months old. A marginally statistically significant association between 
RSV (type B only) and pneumococcal carriage prevalence was found in a mixed 
population of children and adults with acute respiratory symptoms, but the analysis was 
not stratified by age [184]. In studies restricted to children with radiographic pneumonia 
there was no difference in pneumococcal carriage prevalence by RSV status, but RSV 
infection was significantly associated with increased pneumococcal density among those 
colonized [246-250].  In children <5 years hospitalized with WHO-defined severe or very 
severe pneumonia, RSV-pneumonia was not associated with increased pneumococcal 
carriage density, but children with RSV-pneumonia were more likely to have 
pneumococcal carriage densities above a threshold associated with confirmed 
pneumococcal pneumonia than children without RSV-pneumonia [249]. Neither rates of 
pneumococcal carriage, nor density, have been found to be elevated at 4-6 weeks 
following hospital discharge in children previously ill with RSV-LRI compared to the 




One study assessed the role of pneumococcal serotype in RSV-associated pneumococcal 
carriage in children with inpatient radiographic pneumonia, finding RSV-positive 
samples to be more frequently colonization by non-invasive serotypes and RSV-negative 
samples to be more frequently colonized with invasive serotypes [251]. This supports the 
hypothesis that invasive pneumococcal serotypes may be virulent enough to cause 
disease on their own, while non-invasive serotypes may require preceding viral illness in 
order to cause disease.    
 
RSV-pneumococcal co-detection and increased severity 
Overall, the available evidence indicates an association between co-detection of 
pneumococcal carriage with RSV-LRI and increased disease severity (Table 2.4). 
Pneumococcal carriage in children <2 years presenting to the emergency room with RSV-
LRI is associated with higher clinical severity scores compared to those presenting with 
RSV alone [245], and the requirement for hospitalization with RSV-LRI is greater for 
those with nasopharyngeal microbiome profiles enriched for Streptococcus species, 
independent of age [74]. In the same study, increased expression of genes associated with 
the inflammatory response were also found in the Streptococcus enriched microbiome 
profiles, indicating that microbial co-signaling may contribute to enhanced neutrophil 
recruitment and activation, which in turn leads to more severe illness [74]. In another 
microbiome study, however, Streptococcus dominant nasopharyngeal profiles were not 
associated with increased risk of fever in children <1 with RSV-LRI [165]. In 
hospitalized children <2 years with RSV-LRI, pneumococcal colonization was associated 
with a requirement for supplemental oxygen, and pneumococcal density was positively 
	
	 86	
correlated with RSV viral loads, but high pneumococcal colonization density associated 
with reduced requirement for mechanical ventilation [246]. Notably, children that 
required mechanical ventilation also tended to be younger and have less daycare 
attendance than the other two groups, which are factors associated with reduced 
pneumococcal carriage [246]. 
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Table 2.4 Association between detection of pneumococcal carriage in the 
nasopharynx and RSV-LRI disease severity  
 
Study Study Pop Spn1 detection RSV detection Severity marker Association 
Brealey [245] <2 yrs presenting 
to ER w LRI 




score in children 
with RSV+Spn 
than with one 
pathogen in the 
absence of the other 
Teo [165] <1 year birth 
cohort at high 
risk of atopy, 
samples collected 
at regular visits 






NP PCR Fever with LRI Streptococcus not 
associated with 
fever, among those 
with RSV-LRI 
Vissers [246] <2 yrs 
hospitalized with 
RSV-LRI 
NP PCR NP PCR Mild illness = no 
hypoxia 
 












































Co-detection of RSV and pneumococcus in the lung is rare 
 
RSV and pneumococcus are rarely co-detected in lung aspirates (LA), even in settings of 
high pneumococcal disease burden. Lung aspirates are the gold standard specimen for 
determining LRI etiology, but are not commonly collected, and most data comes from 
older studies where viral testing was not conducted [252]. Many LA studies in children 
with pneumonia that incorporated viral testing by traditional culture techniques have 
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reported no viruses in the lung [253-257]. Others found only non-RSV viruses [258-260]. 
Studies using traditional culture methods and, more recently, PCR, have been conducted 
in the high pneumonia burden settings of the Gambia, Papua New Guinea, and Malawi. 
These investigations, conducted from 1984 through the present, have concluded that co-
infection of the lung with pneumococcus and RSV does occur, but is a relatively rare 
occurrence, even in the context of high pneumococcal pneumonia disease prevalence 
[261].   
 
In the Gambia, lung aspirates were collected from 94 children aged 3mo – 5yrs with 
radiographic pneumonia with clear consolidation that could be reached by a needle. 
Pneumococcal pneumonia was confirmed by blood, pleural or lung fluid culture in 15% 
of the study population. Less than half (46%, [43/94]) of LA specimens were positive for 
any virus or bacteria, with 4% (4/94) positive for RSV by culture. Two of the RSV-
positive LA specimens were from a case with pneumococcal disease, indicating that 2/94 
(2%) patients had probable co-infection of the two pathogens in the lung that was 
detectable by these traditional diagnostic methods [261].  In Papua New Guinea, 18/83 
(22%) of children <12mo with radiographic pneumonia had pneumococcus isolated from 
blood or lung fluid. RSV was isolated in culture from 1/62 (2%) of lung aspirates but it 
was not reported whether or not pneumococcus was isolated from the same child [262]. 
 
RSV is more frequently detected in lung aspirate studies that incorporate PCR testing. In 
the Gambia, 90% (47/52) of children aged 2-59 months with radiographic pneumonia and 
clear consolidation had LA collected. Forty-eight (91%) of the children had 
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pneumococcus detected by molecular methods in lung or pleural aspirates (results not 
disaggregated by specimen type) and 19% (10/52) had a virus detected in the presence of 
bacteria. The frequency of specific bacterial-viral combinations was not specified, but 
RSV was noted as the most commonly detected virus in the lungs [263]. In 95 Malawian 
children aged 2mo-15 years (median age 2.6 years) with radiological consolidation, 
pneumococcus was detected in the blood and/or lungs of 39% of cases, but RSV was not 
detected in any cases [264].  
 
Given the disproportionate burden of severe RSV-illness in young infants, comparisons 
across case series of different ages such as those reported here should be made with 
caution. It is also important to note that children who have lung aspirates collected 
represent a clinically distinct subset of children presenting with severe lower respiratory 




Co-detection of RSV and pneumococcus in lung autopsy studies 
 
The limited available data from lung autopsy studies in children provide no supporting 
evidence for an interaction between RSV and pneumococcus. Postmortem lung tissue 
investigations can increase the identification of causative pathogens in cases of fatal 
lower respiratory disease and can provide confirmation of antemortem laboratory 
diagnoses, but such data, especially from children, are extremely limited [265]. Autopsy 
studies of 264 Zambia children aged 1-16 years who died of respiratory disease identified 
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RSV by histology staining in two fatal cases; whether or not either of these cases was co-




Vaccine probe studies 
 
Evidence for causal associations between RSV and pneumococcus in LRI can most 
efficiently be explored through probe studies using vaccines or monoclonal antibodies 
[186, 267]. One vaccine trial has directly assessed the impact of nine-valent 
pneumococcal conjugate vaccine (PCV-9) on the rate of RSV-pneumonia in South Africa 
[268, 269]. In the trial, a diagnosis of RSV-associated pneumonia required either clinical 
or radiological evidence of pneumonia plus a RSV-positive immunofluorescence assay 
result from nasopharyngeal aspirate [269].  PCV efficacy for prevention of RSV-
associated pneumonia was 32% (95%CI: 6%, 50%) among HIV-uninfected children <3 
yrs in a per protocol analysis of fully immunized participants (in the per-protocol analysis 
of all children, inclusive of those with HIV, the trend was similar, but not statistically 
significant, with 22% efficacy for prevention of RSV-associated pneumonia (95% CI: -3, 
41) [268].  There was no demonstrated efficacy of PCV for all-cause or viral-associated 
bronchiolitis. This study provides quantitative evidence of the importance of 
pneumococcal co-infection in virus-associated pneumonias in hospitalized children and 
highlights the limitations of using blood cultures to identify this association. Of the 199 
children with RSV-LRI in the control arm of the trial, only 3 (1.5%) had vaccine-type 
pneumococcal bacteremic pneumonia detected, despite the fact that 14 (7.0%) likely had 
vaccine-type pneumococcal disease based on vaccine attributable rate reduction for RSV-
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LRI [268].  The association was observed despite a transient increase in RSV-LRI 
hospitalizations in the PCV arm for one to eight days after vaccination, which the 
investigators speculated may have be due to increased susceptibility to pneumococcal 
pneumonia among those already colonized with pneumococcus and infected with RSV, 
potentially due to a vaccine-induced depletion in pneumococcal capsular-antibody-
specific B cells before the development of opsonophagoctyic antibodies [269]. 
 
In a randomized trial of 13-valent pneumococcal conjugate vaccine (PCV-13) in the 
Gambia, bronchiolitis (without RSV confirmation, defined as clinical pneumonia with 
wheeze detectable on auscultation without dullness to percussion, bronchial breathing, or 
radiographic pneumonia) was reduced by 39% in 2-11 month olds and 19% in 12-24 
months following vaccination [270]. Although children with bronchiolitis in the Gambia 
were not tested for RSV, this is consistent with the magnitude of the RSV-specific 
reduction observed in the South Africa PCV trial.  
 
A time series analysis of IPD and RSV hospitalizations reported an 18% reduction in 
RSV-coded hospital admissions in children <3-11 mo in the US following PCV-7 
introduction (but no decline in children <3 months) [90]. It is possible that pneumococcal 
disease was driving these hospitalizations, a proportion of which were RSV-coinfected, 
with fewer cases of RSV being detected as a result of the decreased IPD incidence [90]. 
Consistent with this, a trend in declining in RSV-LRI hospitalization following PCV 
introduction in Alaska was also observed [271]. In western Australia, a review of hospital 
records found a 16% (95%CI 6-24%) reduction in RSV hospitalization rates in aboriginal 
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children and a 6% (95% CI 1-11%) reduction in RSV hospitalization rates in non-
aboriginal children <5 years of age, following PCV introduction (calculated from [272]).  
 
There is not yet a licensed vaccine for RSV, which would allow for an investigation of 
the impact of RSV prevention on rates of subsequent pneumococcal disease, but future 
studies could be designed to assess this relationship. An evaluation of a completed RSV 
immunoprophylaxis randomized trial [140] is currently under way for this purpose, with 




Summary and future directions 
A convincing and growing body of evidence suggests that RSV and pneumococcus 
interact synergistically in children with lower respiratory illness. While much of the 
evidence supports the hypothesis that preceding RSV infection contributes to subsequent 
pneumococcal disease, there are also signals of a potential a bi-directional relationship 
between the two pathogens that merits further investigation. It is apparent from this 
review that more individual-level data in carefully defined study populations are needed 
to better understand the implications of the interaction between RSV and pneumococcus 
on LRI in children. Additionally, there is some evidence that RSV-pneumococcal 
interactions may be mediated in part by serotype, though this requires further 




Mechanisms for interactions between RSV and pneumococcus in the respiratory 
epithelium are well described by experimental studies, and animal models show increased 
disease severity with RSV and pneumococcal co-infection compared to infection by 
pneumococcus alone. More research is needed, however, to understand the implications 
of sequence, timing and dosage of exposure to these two pathogens.  
 
Among observational studies, the strongest evidence for an association between RSV-
LRI and pneumococcal disease comes from (1) studies showing a temporal correlation 
between RSV-LRI hospitalizations and IPD hospitalizations, including an individual-
level study of children in Sweden, and (2) investigations of children with severe RSV-
LRI that use pneumococcal carriage density as a proxy indicator for risk of 
pneumococcal pneumonia. The majority of pneumonia etiology studies assessing co-
infection with RSV and pneumococcus are retrospective, cross-sectional, case series 
studies that offer little insight into an association between the two pathogens. The cross 
sectional nature of most etiology studies is a weak design for the evaluation of the 
causative association between RSV and pneumococcus, particularly given that RSV virus 
preceding bacterial infection may have cleared by the time the child develops illness 
severe enough to warrant medical attention. Attempts to gain insights from etiologic 
studies of children with pneumonia are further challenged by reliance on upper 
respiratory tract specimens that are not specific for bacterial infection in the lung, and the 
low sensitivity of blood culture for pneumococcal pneumonia. Were they more readily 
available, lung aspirate and autopsy studies using advanced diagnostics might shed more 
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light on the frequency of co-infection of the lung with these two pathogens versus either 
pathogen alone.  
 
A gold-standard study to investigate interactions between pneumococcus and RSV could 
be a randomized trial of an RSV-immunoprophylaxis or vaccine candidate that includes 
respiratory tract sampling periodically starting from birth with regular sampling of the 
upper respiratory tract for RSV and pneumococcal carriage, continuing through early 
childhood, and with standardized collection of specimens and clinical data at all 
respiratory illness events.  
 
In the absence of such a potentially resource-intensive investigation, conventional 
vaccine probe studies offer potential for assessing causal associations between RSV and 
pneumococcus, and have several advantages over observational studies. Evidence from 
pneumococcal conjugate vaccine probe studies provide a strong basis for the argument 
that future pneumococcal vaccine and RSV immunoprophylaxis / vaccine trials should 
include testing for RSV-LRI and pneumococcal disease, respectively, as part of their 
assessment of primary endpoints. This would contribute greatly to our understanding the 
broader impact of these interventions and to making the investment case for RSV 
vaccines and sustained investment case for pneumococcal vaccines.   
 
With the exception of the PCV trials, a consistent feature of many of the epidemiological 
studies of associations between RSV-LRI and pneumococcal disease is that they have 
taken place in predominantly low-mortality, high-income settings.  Additional data are 
	
	 95	
needed from settings where the population is at greater risk of disease from both 
pathogens and where underlying host risk factors, co-morbidities, and environmental risk 
factors may contribute to increased rates of co-transmission and to the clinical 
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Chapter 3: Thesis Objectives 
Objective 1: To evaluate the role of RSV MALRI prevention on the prevalence and 
density of Streptococcus pneumoniae carriage in the infant nasopharynx  
  
Background: 
Respiratory syncytial virus (RSV) and Streptococcus pneumoniae are common causes of 
lower respiratory illness (LRI) in children. A growing body of evidence suggests that 
these two pathogens may act synergistically in the development of LRI, with greater 
incidence and severity of disease occurring with both pathogens than with either alone. 
Recently, a phase three double blinded randomized trial of a next-generation RSV 
monoclonal antibody, motavizumab, showed high efficacy for the prevention of RSV 
associated medically attended lower respiratory illness (MALRI) in a population of 
healthy full term infants. We used samples collected at these MALRI events to assess 
whether S. pneumoniae nasopharyngeal carriage, a necessary precursor to the 
development of pneumococcal LRI, was associated with RSV MALRI and if 
motavizumab prophylaxis altered its prevalence and density. 
Methods: 
Infants less than six months of age by December 31st of any of the four years of 
enrollment in the motavizumab trial were enrolled and prophylaxed with monthly doses 
of motavizumab or placebo for five total doses through the RSV season (150 days 
following randomization). Nasopharyngeal secretions (washes or aspirates) were 
collected at every MALRI for the first 150 days following randomization and tested for 
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RSV. We tested stored samples from these events for S. pneumoniae carriage by 
quantitative PCR. 
Results: 
We found no difference in prevalence of S. pneumoniae carriage by RSV status (65.6% 
of RSV associated MALRI and 64.9% of non-RSV MALRI had S. pneumoniae detected, 
(p=0.87)), but mean carriage density was greater in RSV associated MALRIs compared 
to those without RSV(6.01 log(10) copies/mL vs. 5.73 log(10) copies/mL, p=0.03). The 
proportion of events with pneumococcal carriage density greater than 6.9 log(10) 
copies/mL was also greater in RSV-associated MALRI compared to non RSV MALRI 
(14.8% vs. 9.0%, p=0.03).There was a corresponding reduction in the density of 
pneumococcal carriage at MALRI events that occurred in the motavizumab treatment 
group compared to the placebo treatment group, although this did not reach statistical 
significance. 
Discussion: 
Our results support the hypothesis that S. pneumoniae and RSV may interact 
synergistically and suggest that preventing RSV illness with a monoclonal antibody, or 
potentially a vaccine, in infancy may decrease rates of high-density pneumococcal 
carriage in the nasopharynx. This may in turn reduce pneumococcal transmission in 
communities, as well as lowering the risk of development of pneumococcal disease. 
Future studies of RSV immunoprophylaxis products and vaccines should consider 
measuring rates of pneumococcal disease as outcome measures to evaluate this 
association. 
Conclusion:   
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Preventing RSV lower respiratory illness in infancy likely reduces pneumococcal 
carriage density in the infant nasopharynx, and this may lead to a corresponding 




Objective 2: To evaluate the impact of RSV MALRI prevention in infancy on 
MALRI with other respiratory viruses, and on subsequent medically attended 
wheezing at ages one to three years 
 
Background: A double-blinded placebo controlled randomized trial of motavizumab in 
healthy, full term infants reported high efficacy against respiratory syncytial virus (RSV) 
inpatient and outpatient medically attended lower respiratory illness (MALRI), but no 
efficacy against subsequent medically attended wheezing through 3 years of age. We 
evaluated the risk of non-RSV MALRI and the basis for the lack of efficacy against 
subsequent wheezing.  
Methods: Infants less than six months of age by December 31st of any of the four years 
of enrollment in the motavizumab trial were enrolled and prophylaxed with monthly 
doses of motavizumab or placebo for five total doses through the RSV season (150 days 
following randomization). We tested stored nasopharyngeal specimens from MALRIs 
occurring during the first 150 days of the trial follow up period by viral multiplex and 
Streptococcus pneumoniae PCR. Human rhinovirus (HRV) positive samples were 
subtyped. We evaluated these and other exposures for medically attended wheeze at ages 
1-3 years of age (subsequent wheeze).   
Results: Motavizumab reduced MALRI with RSV alone and in the presence of other 
viruses in inpatients [RR 0.13 (95%CI:  0.06, 0.24) and RR 0.12 (95%CI 0.05, 0.25), 
respectively], and in outpatients [RR 0.15 (95%CI 0.07, 0.30) and RR 0.48 95%CI (0.30, 
0.79), respectively]. Rates of outpatient influenza type A (Flu A) and human 
metapneumovirus (HMPV) associated MALRIs were increased in motavizumab 
compared to placebo participants. A family history of asthma, exposure to children in 
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daycare, and MALRI with HRV subtype A and C, parainfluenza virus (PIV), or 
coronavirus during the first 150 days of follow up, were independently associated with 
subsequent wheeze at ages 1-3 years. RSV (inpatient) MALRI was associated with 
subsequent wheeze in the motavizumab group (i.e. children who broke through 
motavizumab prophylaxis) but not the placebo group. 
Discussion: Motavizumab prevents MALRI with RSV alone and in combination with 
other viruses. The comparatively reduced efficacy for outpatient RSV MALRI with other 
viruses suggests that that as disease severity is reduced, RSV test-positivity becomes less 
specific for LRI causality, which has implications for future efficacy trials. RSV MALRI 
was not independently associated with subsequent medically attended wheeze at ages 1-3 
years in this study population, but PIV, coronavirus and HRV MALRIs were. Participants 
who experienced motavizumab break through were at significantly increased risk of 
subsequent wheeze after adjusting for other risk factors, and may represent a subgroup of 
children at high risk both for severe disease given RSV infection and for subsequent 
wheeze, regardless of RSV-illness exposure.   
Conclusion: Globally, RSV is associated with significant child morbidity, particularly in 
early infancy, but the role that these severe illness episodes play in the causal pathway to 
wheeze and asthma in later childhood is unclear. We found that motavizumab prevents 
MALRI with RSV alone as well as MALRI with RSV in combination with other viruses, 
and that certain non-RSV viral MALRIs in infancy, particularly rhinovirus, PIV and 
coronaviruses, may increase the risk of subsequent wheezing in some settings. 
Additionally, there may be a subgroup of children at high risk for both 
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immunoprophylaxis failure and risk of wheezing in early childhood, and this merits 




Objective 3: To evaluate the risk of RSV MALRI in the second year of life following 




Respiratory syncytial virus (RSV) associated lower respiratory illness is a leading cause 
of child morbidity and is most severe in early infancy. To what extent this is attributable 
to young age and to what extent it is due to the experience of a primary infection is not 
fully understood. Recently, a phase three randomized trial of a next-generation RSV 
monoclonal antibody, motavizumab, was shown to have high efficacy for the prevention 
of inpatient and outpatient RSV-associated medically attended lower respiratory illness 
(MALRI) in a population of healthy full term infants during their first winter RSV 
season. We assessed whether there was increased risk of RSV MALRI in this population 
in the second RSV season following RSV MALRI prevention in the first season.	
	
Methods: 	
Infants less than six months of age by December 31st of any of the four years of 
enrollment in the motavizumab trial were enrolled and prophylaxed with monthly doses 
of motavizumab or placebo for five total doses through the first winter RSV season (150 
days following randomization). Nasopharyngeal samples were collected at every MALRI 
for three years following enrollment in the motavizumab trial. We tested stored 
nasopharyngeal samples collected at MALRI events that occurred during the RSV season 





We observed no increased relative risk of RSV-MALRI events in the second season for 
the motavizumab group compared to the placebo group (RR 1.09 (95%CI 0.79, 1.50, 
equivalent to a <1% increase in absolute risk). Participants with RSV MALRI in the first 
RSV season were less likely to have an RSV MALRI, but more likely to have a non-RSV 




We found no statistical difference in rates of medically attended RSV illness, either 
inpatient or outpatient or both, by treatment group in the second RSV season. This 
reassures that there is not a substantial increased risk of medially attended respiratory 
events attributable to RSV in the second year of life among children who had protection 
against RSV disease as infants. We did observe a 9% relative increase in the rate of any 
RSV MALRI in the second RSV season for the motavizumab treatment group compared 
to the placebo treatment group that was not statistically significant, and which 
corresponded to a <1% absolute increase in the rate of any RSV MALRI. We also 
observed a trend of decreased severity of RSV MALRI in the second season compared to 
the first season for both treatment groups. The proportion of MALRI events in the second 
RSV season with samples collected within the analytic window that were available for 
RSV testing reduced our statistical power to detect true differences in rates of RSV 
MALRI between treatment groups in this time period. However, the small magnitude of 
the increase in risk that we observed in the motavizumab group, combined with less 
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severe RSV MALRI in the second compared to the first year of life, provides strong 
support for the benefit of delaying primary RSV lower respiratory illness beyond infancy. 
 
Conclusion:  
Young age and the experience of a primary infection are both thought to contribute to 
elevated risk of severe illness with RSV in infancy. We found no significant increase in 
RSV MALRI in the second RSV season after preventing RSV MALRI with 
motavizumab in the first RSV season.  Our results support the argument of a significant 
overall public health benefit to delaying the primary lower respiratory illness until the 





Chapter 4: Methods 
 
 
This thesis research rests on the foundation of a phase 3 randomized double-blind 
placebo controlled clinical trial of the RSV monoclonal antibody motavizumab that was 
conducted by the Center for American Indian Health (CAIH) at the Johns Hopkins 
Bloomberg School of Public Health in partnership with MedImmune, the study sponsor. 
Methods for the clinical trial are described in section 4.1 below; methods for the 
additional data collection that makes up this thesis work are described in section 4.2.  
4.1 Methods for the motavizumab clinical trial  
	
From 2004 - 2009, CAIH conducted a phase-3 efficacy trial of the motavizumab RSV F 
monoclonal antibody under the direction of principal investigator Kate O’Brien. The trial 
was sponsored by the manufacturer (MedImmune) and was designed to evaluate the 
safety and efficacy of motavizumab for the prevention of medically attended RSV-
associated respiratory disease, otitis media, and subsequent wheezing in a population of 
healthy, full-term American Indian infants.  This trial is the only study to date that has 
evaluated RSV immunoprophylaxis in a population of healthy full-term infants. All other 
trials have been conducted in preterm infants or those with medical conditions putting 
them at high risk of RSV disease.  
 
Study Population 
Study participants were infants from three southwest American Indian tribes: the Navajo, 
the White Mountain Apache, and the San Carlos Apache. RSV hospitalization rates 
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among infants and young children in these communities have been shown to be nearly 2-
5 times higher than among the general U.S. population, and are similar to those of infants 
whose medical condition puts them at high-risk for RSV disease. These latter infants are 
now eligible for palivizumab prophylaxis according to policies of the American Academy 
of Pediatrics and the Advisory Committee on Immunization Practices (Table 4.1.1) [110]. 
Participants were enrolled from 11 research sites within the three participating Indian 




Table 4.1.1 American Academy of Pediatrics (AAP)1 red book committee 
recommendations for Palivizumab (2014)2 [123]  
 
High Risk Population AAP Recommendation 
Premature infants (<29 weeks gestation) who are 
younger than 12 months at the start of RSV 
season 
Palivizumab prophylaxis during the RSV season in 
the first year of life (a maximum of 5 monthly doses 
of 15 mg/kg; qualifying infants born during the 
RSV season may require fewer doses) 
Infants born at <32 weeks gestation with chronic 
lung disease of prematurity requiring ≥28 days 
of supplemental oxygen after birth, or certain 
chronic heart diseases, or airway clearance issues 
Same as above 
Infants born at <32 weeks gestation with chronic 
lung of prematurity requiring ≥28 days of 
supplemental oxygen after birth and who 
continue to require medical intervention during 
the 6-month period prior to the second RSV 
season 
Palivizumab prophylaxis during the RSV season in 
the first and second years of life 
Children younger than 24 months who will be 
profoundly immunocompromised during the 
RSV season 
Palivizumab prophylaxis considered during the 
RSV season 
1The Advisory Committee on Immunization Practices refers to these AAP guidelines in their 
recommendations 
2Due to the high burden of RSV disease and costs associated with transport from remote locations, a 












The study was a phase three, double-blind, placebo-controlled, 2:1 randomized trial. 
Participants randomized to the intervention arm received five intramuscular doses of 
motavizumab (15 mg/kg), 30 days apart. Participants randomized to the control arm 
received a visually identical placebo dosed on the same schedule. The primary aim of the 
trial was to assess whether motavizumab could safely and effectively reduce the 
incidence of serious RSV disease requiring hospitalization in the Native American full 
term infant population. It also assessed whether motavizumab could prevent outpatient 
RSV medically attended acute lower respiratory illness (MALRI), medically attended 
otitis media (OM) and medically attended wheezing through 3 years of age. The 
originally planned study sample size was 2,100-3,000 participants, providing statistical 
power between 77% and 90% (2-sided alpha 0.05) to observe a 45% reduction in RSV 
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hospitalization, assuming a true RSV hospitalization rate of 6% in the placebo group and 
3.3% in the motavizumab group.  
 
Study Drug 
Motavizumab (MEDI-524) was shown to have enhanced potency over palivizumab and 
to have the potential for an anti-RSV effect in both the upper and lower respiratory tract 
in preclinical trials. All participants were evaluated monthly for the first five months (150 




The period of enrollment was October – December, 2004-2007 (four calendar-year RSV 
seasons included in the study, in total).  Participants were healthy infants of ≥36 weeks 
gestational age who were less than six months of age by December 31st of any of the four 
years of enrollment. Exclusion criteria in addition to <36 weeks gestational age included 
chronic lung disease of prematurity, chronic heart disease, long-term hospitalization, 
current or past wheezing, current RSV infection, receipt of palivizumab or any other 
antibody within the three months prior to randomization, as well as other serious medical 
conditions specified in the study protocol.  
 
Clinical Endpoints and Study Follow up 
Participants were followed for 150 days following the first dose of motavizumab or 
placebo (study day 0) for medically-attended respiratory events, with RSV-associated 
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hospitalizations as the primary study endpoint (defined below).  Nasopharyngeal 
secretions were collected at every MALRI event.  All specimens collected during the 
150-day follow up period were tested for RSV by RT-PCR. Following study day 150, 
participants continued to be followed for medically-attended respiratory events through 
age three years, with nasopharyngeal specimens collected and stored but not tested until 
now for any respiratory pathogens. 
 
Specimen collection and testing 
The collection of nasal wash secretions involved instilling 15 – 20 cc of Ringer’s lactate 
solution into each nostril of a seated child with a bulb syringe and collecting it from the 
opposite nostril. In children who could not have a nasal wash specimen collected, a nasal 
aspirate was obtained by instilling 3 – 6 cc of sterile saline into the nose and withdrawing 
nasal mucus using a feeding tube with a suction device.  One milliliter of nasopharyngeal 
specimen was mixed with 6 ml viral transport medium and then divided into 4 – 8 
aliquots which were snap frozen immediately using liquid nitrogen or an ethanol/dry ice 
bath, and stored at -70°C. At facilities where snap freezing was not possible, aliquots 
were immediately stored at -80°C.  After freezing, aliquots were shipped to central 
laboratories for storage. Those collected within 150 days of randomization (the RSV 
season) were tested for RSV A and B by PCR assay. Aliquots of untested specimen 
remained in storage at -80°C with continuous temperature monitoring. Nasopharyngeal 
secretions collected within +/- five days of the MALRI event date (hospital admission for 
inpatient events; doctor visit date for outpatient events) were considered to be within the 
analytic window and were included in the analysis. Whenever possible, study staff 
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attempted to collect the specimens within +/- three days of the event. In instances where 
nasopharyngeal secretions were not collected in the facility, a study nurse would attempt 
collection at a home visit.  
 
Clinical Endpoints and Case definitions:  
Primary study endpoint for the trial: 
• RSV –associated hospitalization and/or death (study days 0 – 150) 
Secondary study endpoints for the trial: 
• RSV outpatient MALRI episodes (study days 0 – 150) 
• Otitis media (physician diagnosed acute OM, acute tympanic membrane 
perforation, bulging tympanic membrane, red tympanic membrane with fever, 
OM with effusion, or acute middle ear effusion) 
• Subsequent medically attended wheezing events with discharge diagnosis of 
asthma, bronchiolitis, reactive airways disease, or if wheezing was documented 
by examining physician (from age 1-3 years) 
 
RSV hospitalization (inpatient RSV MALRI) case definition:  
An RSV hospitalization was defined as either 1) a respiratory hospitalization with a 
positive RSV PCR test within the analytic window (primary hospitalization) or 2) new 
onset of lower respiratory symptoms in an already hospitalized child, with an objective 
measure of worsening respiratory status, such as new requirement for supplemental 
hospitalization, increase in supplemental oxygen requirement from prior to the onset of 
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lower respiratory illness symptoms, or need for new mechanical ventilation, along with a 
positive RSV PCR test (nosocomial RSV inpatient event).  
 
Outpatient RSV MALRI case definition:  
Outpatient lower respiratory tract illness events were reviewed for inclusion by study 
investigators and were defined as a medical diagnosis of bronchiolitis or pneumonia. In 
the absence of such a medical diagnosis, the occurrence of the lower respiratory illness 
was determined by the study investigator’s review of the medical records for the presence 
of lower respiratory signs and symptoms including cough, retractions, ronchi, wheezing, 
crackles or rales, as well as associated signs or symptoms including coryza, fever and 
apnea. As with RSV hospitalizations, outpatient RSV illness was confirmed by PCR 
testing. 
 
Definition of wheeze:  
Participants were followed from study day 0 (day of first study drug) through three years 
of age for the occurrence of medically attended wheezing events. Medically attended 
wheezing was counted as an outcome event if there was a discharge diagnosis of asthma, 
bronchiolitis, reactive airway disease, or documentation of wheezing in the medical 
record by the treating physician. A new wheezing episode was defined as one that 
occurred more than two weeks after the diagnosis of the previous episode and did not 
represent a persistence of the previous episode according to medical opinion. Only new 




Subsequent wheeze events were those medically attended wheeze events occurring 
between one and three years of age. Another approach would have been to count 
subsequent wheeze events as those medically attended wheeze events occurring after 150 
days of follow up (i.e. following the RSV season). However, given that children could 
have been enrolled between birth and six months of age, they would have been different 
ages at the end of the RSV season. The one to three year age range was therefore selected 
so that all children would be assessed for subsequent medically attended wheeze 
outcomes within the same age interval, which was also a simpler outcome for the 
purposes of reporting and comparing to other studies.  
 
Subsequent medically attended wheeze was classified using three outcome definitions: 
(1) ≥1 medically attended wheeze event, (2) serious early childhood wheeze, and (3) 
recurrent wheeze. Serious early childhood wheeze and recurrent wheeze are two 
overlapping but distinct subsets of medically attended wheeze. A child was considered to 
have serious early childhood wheeze if s/he met any one of four conditions between one 
and three years of age: (1) three or more attended wheezing events during any 12-month 
period, (2) a need for one or more courses of systemic steroids for treatment of a 
medically attended wheezing event, (3) a need for asthma control medications over a 12-
month period for at least three consecutive months (i.e., ≥90 days) or five cumulative 
months (i.e. ≥150 days), with duration assessed by a combination of parental interviews 
and medical records, or (4) a least one inpatient wheezing event. Recurrent medically 
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attended wheeze was defined as three or more medically attended wheezing events during 
any 12-month period between one and three years of age.  
 
Analyses 
Intention-to-treat analyses were the primary analyses for the trial, with participants 
analyzed according to treatment group of randomization. According-to-protocol analyses 
were also conducted including participants who received ONLY motavizumab or placebo 
(either prior to meeting primary endpoint definition or for all five doses). Participants 
who were not followed through day 150 (lost to follow up) and did not have a 
hospitalization event prior to this were counted as not having met the RSV hospitalization 
endpoint; Kaplan-Meier analyses were done to account for the reduced length of follow-
up for some participants.  
 
Study Results  
A total of 1,417 infants were randomized to the motavizumab intervention group and 710 
were randomized to the control group (2,127 participants total). Among the motavizumab 
participants, 21/1,417 (1%) experienced an RSV hospitalization, compared to 80/710 
(11%) in the placebo group (relative risk (RR) 0.13 (95% 0.08, 0.21)). There was an 
overall 50% rate reduction in all-cause hospitalization for respiratory illnesses. Outpatient 
RSV-MALRI occurred in 41/1,417 (3%) of motavizumab participants compared to 
71/710 (10%) of placebo participants (RR 0.29 (95% CI 0.20-0.42)). The proportion of 
non-RSV MALRI inpatient and outpatient events was slightly higher in the motavizumab 
group compared to the placebo group, but the difference did not reach statistical 
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significance. Overall, motavizumab reduced the proportion of patients with any medically 
attended RSV ALRI by 80% (RR 0.20, (95% CI 0.15, 0.27)) from 21.3% (151/710) to 
4.3% (61/1,417). Importantly, there was no difference by treatment group in medically 
attended wheeze events between the ages of 1 and 3 years. Results from the according-to-
protocol analyses were consistent with the intention-to-treat analyses. 
 
4.2 Methods for this thesis research 
	
This thesis research used stored, untested, nasopharyngeal specimens collected at 
inpatient and outpatient MALRI events that occurred during the motavizumab clinical 
trial (the parent study). Informed consent for the parent study was obtained from a parent 
or guardian of participants. The Navajo Nation IRB, the Phoenix Area Indian Health 
Service IRB, the San Carlos Apache IRB, and the Johns Hopkins Bloomberg School of 
Public Health IRB provided ethical approval for the parent study. The original consent 
documents included permission to test the nasopharyngeal specimens collected at 
medically attended respiratory illnesses for other respiratory pathogens in addition to 
RSV. We obtained additional approvals from the Navajo Nation IRB and the Indian 
Health Services IRB for the testing of non-RSV respiratory pathogens that took place at 
the University of Wisconsin-Madison and the Centers for Disease Control and Prevention 
Arctic Investigations Program laboratory. Approval for additional testing of specimens 
from San Carlos Apache participants was not sought, and their specimens were excluded 
from testing. We therefore included 2,088 of 2,127 of the original trial participants in the 








a Medically attended acute lower respiratory illness 
bNo sample collected within the analytic window 
cAll calculated proportions are taken using the total number of events above as the denominator 
 
Objective 1 Methods 
The first research objective was to assess the relationship between RSV MALRI 
prevention and pneumococcal carriage and density. For this objective, stored 
nasopharyngeal specimens collected at MALRI events in the first RSV season were 
tested for Streptococcus pneumoniae by a quantitative real-time PCR assay. The testing 
was done at the Centers for Disease Prevention and Control, Division of Preparedness 
and Emerging Investigations, Arctic Investigations Program laboratory in Anchorage, 
Alaska. Nucleic acid extraction for the S. pneumoniae assay was by GeneJET Genomic 
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DNA Purification Kit (Thermo Fisher Scientific, Waltham, MA). Two hundred 
microliters of DNA were eluted from the original specimen and 5 µl were used in the 
PCR reaction. The final PCR reaction volume was 25 µl and performed by use of the 
TaqMan Universal Master Mix kit (Applied Biosystems, Foster City, CA) with primers 
and probes targeting the lytA gene [273]. Each run included a no-template control and a 
S. pneumoniae positive control, with DNA amplified using a Stratagene Mx3005P system 
(Agilent, Santa Clara, CA) with the following cycling parameters: 95°C for 10 min, 
followed by 40 cycles of 95°C for 15 seconds, and 60 °C for 1 minute. Amplification 
data were analyzed by Stratagene software and results with cycle thresholds <40 were 
accepted. Quantification of S. pneumoniae was obtained using a five-point standard curve 
of serial S. pneumoniae plasmid dilutions of known quantities ranging from 103 to 107 
copies/ml.  All plasmid dilutions were run in duplicate with the exception of the 103 
dilution, which was run in triplicate.  
 
Objective 2 Methods 
The second research objective was to evaluate the impact of motavizumab on non-RSV 
respiratory illness during the first RSV season, and to assess the contribution of RSV and 
other pathogens to risk of subsequent wheeze at ages one to three years. The 
pneumococcal test results obtained by the methods described above were included in this 
analysis. In addition to the pneumococcal testing, nasopharyngeal specimens from the 
same events were tested for other common respiratory viruses. The viral testing was done 
in the laboratory of James Gern at the University of Wisconsin-Madison, in Madison, 
Wisconsin. For the viral multiplex PCR panel, 350ul of nasal sample was extracted using 
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the NucliSENS EasyMag kit (bioMerieux, Marcy l’Etoile, France) with an RNA eluate 
volume of 25ul. 10ul of eluate was used for the real-time NxTAG® Respiratory Pathogen 
Panel (Luminex Corporation, Austin, Texas). The NxTAG® panel includes influenza 
virus A (multiple subtypes) and B (Flu A and Flu B), RSV A and B, coronaviruses 
(subtypes 229E, HKU1, NL63, and OC43), human metapneumovirus (HMPV), human 
rhinovirus/enterovirus (HRV/EV), adenovirus, parainfluenza viruses 1-4, bocavirus, and 
the bacterial pathogens Chlamydophila pneumoniae and Mycoplasma pneumonia. cDNA 
was generated with the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA) and 10ul of RNA eluate.  Rhinovirus/enterovirus positive 
samples were typed using a molecular typing assay [274]. In instances where there was 
discordance between the RSV result from the NxTAG® panel and the RSV result from 
the testing done as part of the primary testing for the clinical trial, we deferred to the 
primary result. 
 
Objective 3 Methods 
The third research objective was to assess whether there was an increase in RSV disease 
in the second RSV season following immunoprophylaxis in the first. The second RSV 
season was defined as the continuous time period between the middle of October of one 
year until the end of May of the next year.  This definition is consistent with the 
enrollment and follow up periods for the motavizumab parent study, where children were 
enrolled between October 15th and December 31st, and were followed for medically 
attended RSV illness for 150 days following enrollment, with the end of 150 day follow 
up falling between March 16th and May 30th, depending on the enrollment date. For all 
participants in this analysis, the second RSV season was defined as the period of time 
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between October 15th and May 30th in the calendar year(s) following study enrollment 
(Table 4.2.1).  Specimens eligible for testing were those collected within five days of an 
inpatient or outpatient event that occurred during the second RSV season and that was 




Table 4.2.1 Dates corresponding to RSV Season 1 enrollment for the four study 
cohorts 
 
  RSV Season 1 RSV Season 2 










       
 Start Enroll1  11/15/04 4/14/05 10/15/05 334 5/30/06 561 
 End Enroll2 12/30/04 5/29/05 10/15/05 289 5/30/06 516 
        
Enrollment 
Cohort 2 
       
 Start Enroll  10/17/05 3/16/06 10/15/06 363 5/30/07 590 
 End Enroll 12/30/05 5/29/06 10/15/05 289 5/30/07 516 
        
Enrollment 
Cohort 3 
       
 Start Enroll  11/30/06 4/29/07 10/15/07 319 5/30/08 547 
 End Enroll 12/31/06 5/30/07 10/15/07 288 5/30/08 516 
        
Enrollment 
Cohort 4 
       
 Start Enroll  10/15/07 3/13/08 10/15/08 366 5/30/09 593 
 End Enroll 12/31/07 5/29/08 10/15/08 289 5/30/09 516 
1The first date of enrollment of a participant in this cohort 
2The last date of enrollment of a participant in this cohort 
Samples collected at second season events were tested for RSV using the respiratory 
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Chapter 5: Probing the interaction of respiratory syncytial virus and Streptococcus 






Respiratory syncytial virus (RSV) and Streptococcus pneumoniae are common causes of 
lower respiratory illness (LRI) in children. A growing body of evidence suggests that 
these two pathogens may act synergistically in the development of LRI, with greater 
incidence and severity of disease occurring with both pathogens than with either alone. 
Recently, a phase three double blinded randomized trial of a next-generation RSV 
monoclonal antibody, motavizumab, showed high efficacy for the prevention of RSV 
associated medically attended lower respiratory illness (MALRI) in a population of 
healthy full term infants. We used samples collected at these MALRI events to assess 
whether S. pneumoniae nasopharyngeal carriage, a necessary precursor to the 
development of pneumococcal LRI, was associated with RSV MALRI and if 
motavizumab prophylaxis altered its prevalence and density. 
Methods: 
Infants less than six months of age by December 31st of any of the four years of 
enrollment in the motavizumab trial were enrolled and prophylaxed with monthly doses 
of motavizumab or placebo for five total doses through the RSV season (150 days 
following randomization). Nasopharyngeal secretions (washes or aspirates) were 
collected at every MALRI for the first 150 days following randomization and tested for 
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RSV. We tested stored samples from these events for S. pneumoniae carriage by 
quantitative PCR. 
Results: 
We found no difference in prevalence of S. pneumoniae carriage by RSV status (65.6% 
of RSV associated MALRI and 64.9% of non-RSV MALRI had S. pneumoniae detected, 
(p=0.87)), but mean carriage density was greater in RSV associated MALRIs compared 
to those without RSV (6.01 log(10) copies/mL vs. 5.73 log(10) copies/mL, p=0.03). The 
proportion of events with pneumococcal carriage density greater than 6.9 log(10) 
copies/mL was also greater in RSV-associated MALRI compared to non RSV MALRI 
(14.8% vs. 9.0%, p=0.03). There was a corresponding reduction in the density of 
pneumococcal carriage at MALRI events that occurred in the motavizumab treatment 
group compared to the placebo treatment group, although this did not reach statistical 
significance. 
Discussion: 
Our results support the hypothesis that S. pneumoniae and RSV may interact 
synergistically and suggest that preventing RSV illness with a monoclonal antibody, or 
potentially a vaccine, in infancy may decrease rates of high-density pneumococcal 
carriage in the nasopharynx. This may in turn reduce pneumococcal transmission in 
communities, as well as lowering the risk of development of pneumococcal disease. 
Future studies of RSV immunoprophylaxis products and vaccines should consider 
measuring rates of pneumococcal disease as outcome measures to evaluate this 
association. 
Conclusion:   
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Preventing RSV lower respiratory illness in infancy likely reduces pneumococcal 
carriage density in the infant nasopharynx, and this may lead to a corresponding 
reduction in pneumococcal transmission and disease. 
Introduction 
 
Respiratory syncytial virus (RSV) is the most commonly identified virus in children with 
lower respiratory illness (LRI), with 33.1 million RSV-associated LRI cases in 2015, and 
with peak incidence occurring in infants <6 months [29]. Streptococcus pneumoniae 
(pneumococcus) is a leading cause of bacterial LRI in children under five years of age, 
with 3.7 million severe pneumococcal pneumonia episodes in this age group in 2015 
[275]. A growing body of evidence suggests that RSV and pneumococcus may interact in 
lower respiratory illness in a synergistic manner. Epidemiologic studies of the association 
between RSV-LRI and pneumococcal pneumonia are limited, however, by difficulty in 
obtaining clinical specimens directly from lower respiratory tract, poor diagnostic 
sensitivity for bacterial pneumonia, and by the challenge of determining the true etiology 
of an LRI event. Colonization of the nasopharynx with S. pneumoniae is a necessary 
precursor to pneumococcal disease [276, 277], and several studies have found RSV-LRI 
in children to be associated with increased pneumococcal colonization density [245, 247-
250, 278]. High pneumococcal carriage density in the nasopharynx has also been shown 
to be associated with pneumococcal pneumonia in children [249]. Vaccine probe studies 
offer a unique opportunity to identify causal interactions between pathogens, with 
pneumococcal conjugate vaccine (PCV) impact studies allowing for the quantification of 
the fraction of RSV-LRI that includes some vaccine-preventable pneumococcal 
contribution to disease [267]. In South Africa, PCV use was associated with a 32% 
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reduction in incidence of RSV-associated pneumonia among children <5 years, and in the 
Gambia it was associated with 39% reduction in incidence of all-cause bronchiolitis in 
infants 2-11 months [268, 270].  The inference from these studies is that the causal chain 
for these RSV-attributed events must include S. pneumoniae if they can be prevented by 
PCV. Experimental studies support this inference, with evidence that RSV infection 
preceding or simultaneous to exposure to S. pneumoniae increases bacterial adherence 
and virulence and, in animal models, leads to increased disease severity compared to 
RSV infection alone [193-195, 199, 205]. If RSV infection of the upper airway 
epithelium facilitates pneumococcal colonization and allows for increased carriage 
density, which then increases the risk of subsequent pneumococcal disease, we would 
expect that preventing RSV-illness in children would be associated with decreases in 
pneumococcal carriage and disease. There are currently no licensed RSV vaccines with 
which to evaluate this relationship, but a recent large-scale efficacy trial of a next 
generation anti-RSV monoclonal antibody, motavizumab, serves as a probe to assess the 
role of RSV-prevention on S. pneumoniae colonization in a population of healthy full-
term infants.  In this randomized, placebo-controlled trial conducted over the course of 
four consecutive RSV seasons, receipt of motavizumab was associated with an 87% 
reduction in inpatient medically attended RSV-associated LRI (RSV-MALRI) and a 71% 
reduction in outpatient RSV-MALRI [140]. In addition to preventing RSV-MALRI, 
motavizumab has been shown to reduce RSV infection of the upper airway in pre-clinical 
studies, although this finding has not been confirmed in humans [125]. It is conceivable 
that motavizumab prophylaxis could therefore prevent disease with S. pneumoniae by 
reducing pneumococcal colonization in the upper respiratory tract, or by preventing RSV 
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infection from progressing to lower respiratory tract illness and thereby removing the 
opportunity for the two pathogens to interact synergistically in the lower airways.  We 
undertook an evaluation of the prevalence and density of S. pneumoniae nasopharyngeal 
colonization during MALRI events in this trial with the hypothesis that those who had 
received motavizumab and were relatively protected from RSV disease would also have 




The full methods of the phase 3 double-blinded placebo controlled randomized trial of 
motavizumab (the parent study) have been published elsewhere [140]. Briefly, healthy 
Native American infants living on the Navajo Nation, White Mountain Apache and San 
Carlos Apache Indian reservations who were born at full-term (≥36 weeks gestation) and 
were less than 6 months of age at the time of enrollment, were randomized to receive 
either motavizumab or placebo during the winter RSV season (5 monthly doses, 2:1 
randomization). Four cohorts of infants were enrolled over four consecutive RSV seasons 
between 2004 and 2009, for a total of 2,127 participants.  The current sub-study excluded 
the San Carlos Apache reservation participants, bringing the total number of participants 
to 2,088 (1,392 participants randomized to motavizumab, 696 randomized to placebo). 
 
Evaluation of medically attended lower respiratory tract illness  
Study participants were followed from the time of study enrollment through three years 
of age and assessed for inpatient and outpatient MALRI. Lower respiratory tract illness 
events were reviewed for inclusion by study investigators and were defined as a medical 
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diagnosis of bronchiolitis or pneumonia. In the absence of such a medical diagnosis, the 
occurrence of the lower respiratory illness was determined by the study investigator’s 
review of the medical records for the presence of lower respiratory signs and symptoms 
including cough, retractions, ronchi, wheezing, crackles or rales, as well as associated 
signs or symptoms including coryza, fever and apnea.  
 
Nasopharyngeal secretions collected within five days of the MALRI event date (hospital 
admission for inpatient events; doctor visit date for outpatient events) were considered to 
be within the analytic window and were included in the analysis. A nasopharyngeal 
specimen was collected at every MALRI visit. The collection of nasal wash secretions 
involved instilling 15 – 20 cc of Ringer’s lactate solution into each nostril of a seated 
child with a bulb syringe and collecting it from the opposite nostril. In children who 
could not have a nasal wash specimen collected, a nasal aspirate was obtained by 
instilling 3 – 6 cc of sterile saline into the nose and withdrawing nasal mucus using a 
feeding tube with a suction device.  One milliliter of nasopharyngeal specimen was 
mixed with 6 ml viral transport medium and then divided into 4 – 8 aliquots which were 
snap frozen immediately using liquid nitrogen or an ethanol/dry ice bath, and stored at -
70°C. At facilities where snap freezing was not possible, aliquots were immediately 
stored at -80°C.  After freezing, aliquots were shipped to central laboratories for storage. 
Those collected within 150 days of randomization (the RSV season) were tested for RSV 
A and B by PCR assay. Aliquots of untested specimen remained in storage at -80°C with 




Specimen testing for this sub-study 
 
 
For the present sub-analysis, stored nasopharyngeal secretions from events that occurred 
during the first 150 days of follow up were tested for S. pneumoniae by a quantitative 
real-time PCR assay at the Centers for Disease Prevention and Control, Division of 
Preparedness and Emerging Investigations, Arctic Investigations Program laboratory in 
Anchorage, Alaska.  Nucleic acid extraction for the S. pneumoniae assay was by 
GeneJET Genomic DNA Purification Kit (Thermo Fisher Scientific, Waltham, MA). 
Two hundred microliters of DNA were eluted from the original specimen and 5 µl were 
used in the PCR reaction. The final PCR reaction volume was 25 µl and performed by 
use of the TaqMan Universal Master Mix kit (Applied Biosystems, Foster City, CA) with 
primers and probes targeting the lytA gene [273]. Each run included a no-template control 
and a S. pneumoniae positive control, with DNA amplified using a Stratagene Mx3005P 
system (Agilent, Santa Clara, CA) with the following cycling parameters: 95°C for 10 
min, followed by 40 cycles of 95°C for 15 seconds, and 60 °C for 1 minute. 
Amplification data were analyzed by Stratagene software and results with cycle 
thresholds <40 were accepted. Quantification of S. pneumoniae was obtained using a 
five-point standard curve of serial S. pneumoniae plasmid dilutions of known quantities 
ranging from 103 to 107 copies/ml.  All plasmid dilutions were run in duplicate with the 
exception of the 103 dilution, which was run in triplicate.  
 
Statistical Analyses 
Statistical analyses were performed using STATA13 (StataCorp. 2013. College Station, 
TX). χ2, Fisher’s exact, Kruskal-Wallis and Student’s t-tests were used for pairwise 
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comparisons. Linear and logistic regression models were used for continuous and 
dichotomous outcomes, respectively. P-values <0.05 were considered significant. Age 
was analyzed as a continuous and categorical predictor.  
 
Ethical Approval 
Informed consent for participation in this study was obtained from a parent or guardian of 
participants. Approval for this study was obtained from the Johns Hopkins Bloomberg 
School of Health IRB, the Phoenix Area Indian Health Service IRB, and the Navajo 




Medically Attended Lower Respiratory Illness Events 
During the 150 days following randomization, there were 276 respiratory hospital 
admissions among 231 participants (192 children with one admission; 33 children with 
two admissions, and 6 children with three admissions), and 653 outpatient LRI visits 
among 511 participants (395 children with one visit; 94 children with two visits, 18 
children with three visits, and 4 children with four visits each). The mean age at inpatient 
events was 3.9 months while the mean age at outpatient events was 5.2 months 
(p<0.001). Nasopharyngeal secretions were collected in 264/276 (96%) of hospital 
admissions and 516/653 (79%) of outpatient visits. RSV test results were available for 
261/276 (95%) of inpatient events and 499/653 (76%) of outpatient visits, and as reported 
previously in the primary efficacy analysis, both inpatient and outpatient RSV MALRI 
were significantly reduced in the motavizumab compared to the placebo group [140].  All 
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of the stored nasopharyngeal specimens that could be located (81% [223/276] of inpatient 
events and 68% [444/653] of outpatient events) were tested for pneumococcal carriage 
(Figure 5.1). We compared treatment group, RSV-status and age at event for samples 
with test results available for S. pneumoniae compared to those without. Inpatient events 
were more likely to be missing results for S. pneumoniae if they were from the 
motavizumab group, or if they were RSV-positive; outpatient events were also less likely 
to be tested for S. pneumoniae if they were RSV-positive, but with no difference by 
treatment group. There there was no difference in mean age at event for those with 
samples available for testing compare to those with samples not available for testing 
(Table 5.1).  
 
Of 667 samples tested, S. pneumoniae was detected in 435 (65.2%), with no significant 
difference in colonization prevalence between inpatient (142/223 [63.7%]) and outpatient 
(293/444 [66.0%]) samples (p=0.55). Among all positive pneumococcal samples, mean 
density was 5.80 log(10) copies/ml (95% CI 5.70, 5.91), with mean density of 5.71 
log(10) copies/ml (95% CI 5.53, 5.88) in samples from inpatient events and 5.85 log(10) 
copies/ml (95% CI 5.73, 5.98) in samples from outpatient events (p=0.19).  The 
probability of pneumococcal colonization was lowest in the 0-1 month age group, 
increased through three months of age and then remained relatively constant, with a 
marginally statistically significant trend of increasing colonization by month of age (odds 
ratio (OR) 1.07, (95%CI 1.00, 1.15) (Figure 5.2).  Mean pneumococcal density was 
highest in the oldest age group (10-11 months) but there was no overall statistically 
significant trend for increasing density with age (Kruskal-Wallis χ2 13.8, p=0.24) (Figure 
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5.3). The mean age at RSV-MALRI events during the first 150 days of follow up was not 
different than the mean age at non-RSV viral MALRI events (3.80 mo vs. 3.81 mo, 
respectively, for inpatient events p=0.78), and (5.37 mo vs. 5.12 mo, respectively, for 
outpatient events p=0.30). After stratifying by event type (inpatient vs. outpatient), there 
were no statistically significant differences in mean age for children colonized with 
pneumococcus compared to those not colonized, by RSV-status (Figure 5.4). While 
detection of RSV at MALRI events showed a distinct seasonal pattern, detection of S. 
pneumoniae was consistent over time (Figure 5.5).  There was no observed difference in 
S. pneumoniae detection frequency or density for samples collected up to five days prior 
to the event date (78/250 [68.8%]), compared to those collected on or up to five days 
after the event date (263/417 [63.1%])  (p=0.13). 
 
Stratifying by RSV-status at the MALRI event, there was no statistically significant 
difference in prevalence of S. pneumoniae detection between RSV-positive and RSV-
negative events, but there was a mean increase in carriage density for RSV associated 
MALRIs compared to those without RSV (6.01 log(10) copies/mL in RSV associated 
MALRI vs. 5.73 log(10) copies/mL in non RSV associated MALRI, p=0.03)  (Table 5.2 
and Figure 5.6). We also assessed the proportion of events with pneumococcal carriage at 
or above a density threshold (6.9 log(10) copies/mL), which has been shown in another 
population to be associated with severe pneumococcal pneumonia [249] and found that it 
was higher in RSV-MALRI compared to non RSV-MALRI events (14.8% vs. 9.0%, 
p=0.03) (Table 5.2). Adjusting for age did not alter any of these associations. Despite the 
associations we observed between RSV-MALRI and increased pneumococcal carriage 
	
	 139	
density, a receiver operator characteristic curve analysis did not identify a density 
threshold that could be used to distinguish RSV-positive from RSV-negative events in 
our study population (Figure 5.7). 
 
When we stratified the analysis of RSV-MALRI and pneumococcal carriage prevalence 
and density by treatment group, the trends remained the same with the exception of 
outpatient events in the motavizumab group, where pneumococcus was significantly 
more likely to be detected in RSV-positive MALRIs than RSV-negative MALRIs (Table 
5.3). Conversely, there was reduced pneumococcal carriage in the RSV-positive inpatient 
events compared to RSV negative inpatient events, though this did not reach statistical 
significance.  
 
We found no difference in overall colonization prevalence by treatment group (Table 
5.4). There was a trend of increased colonization density in the placebo compared to the 
motavizumab group, however, and a higher proportion of placebo participants had 
pneumococcal densities above the density threshold for pneumococcal disease, although 




As previously reported, a double-blinded randomized trial of the RSV mAb motavizumab 
found 87% efficacy for the prevention of inpatient RSV MALRI and 71% efficacy for the 
prevention of outpatient RSV MALRI in a population of healthy, full-term infants who 
had been randomized to receive either motavizumab or placebo treatment [140]. We 
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tested nasopharyngeal specimens collected during these MALRI events for S. 
pneumoniae and found pneumococcal colonization of the nasopharynx to be more dense, 
but not more prevalent, in lower respiratory illnesses that were associated with RSV 
compared to those not associated with RSV. We observed a corresponding reduction in 
the density of pneumococcal carriage at MALRI events that occurred in the motavizumab 
treatment group compared to the placebo treatment group, although this did not reach 
statistical significance. Mean S. pneumoniae carriage density was approximately two-fold 
greater in nasopharyngeal specimens where RSV was also detected, compared to those 
without RSV. This is consistent with a study that found RSV-associated LRI 
hospitalizations to be associated with a 3-fold increase in pneumococcal density in the 
nasopharynx compared to RSV-negative LRI hospitalizations [244], as well other studies 
that similarly found an association between pneumococcal carriage density and RSV LRI 
[246, 248].  
Pneumococcus is commonly carried in the nasopharynx of healthy children, and is a 
precondition for lower respiratory tract pneumococcal disease.  We cannot infer from this 
study whether RSV lower respiratory illness is associated with pneumococcal pneumonia 
or whether motavizumab may have prevented pneumococcal pneumonia cases during the 
RSV season. Furthermore, the magnitude of the difference in mean density between 
samples collected at RSV LRI events compared to non-RSV LRI events may not be 
clinically significant. It has been demonstrated, however, that high pneumococcal 
carriage density is associated with microbiologically confirmed severe pneumococcal 
pneumonia in children [249]. We assessed the proportion of MALRI events in our study 
with carriage densities above a threshold associated with pneumococcal pneumonia and 
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found the proportion of illness events with densities above this threshold to be higher in 
the placebo compared to the motavizumab group, although this also did not reach 
statistical significance. This suggests that there may be a potential role for RSV 
prevention in the reduction of pneumococcal disease episodes, and that this relationship 
merits further investigation. Furthermore, pneumococcal colonization density likely plays 
a role in pneumococcal transmission, and lowering the bacterial load of pneumococcus in 
the nasopharynx could have important implications for control of the pathogen in the 
community. 
An exception to the overall trend we observed was that within the motavizumab 
treatment group, S. pneumoniae carriage prevalence was significantly higher in outpatient 
RSV MALRI events, compared to outpatient events not associated with RSV. We 
hypothesize that some of the prophylaxed infants who had RSV detected at an outpatient 
lower respiratory illness may have had LRI that was causally associated with 
pneumococcus rather than RSV. Paradoxically, pneumococcus was less likely to be co-
detected with RSV among inpatient events in the motavizumab group than with non-RSV 
inpatient events. This is counter to our expectation that pneumococcus would be more 
frequently detected in RSV-positive specimens, and was not consistent with what we 
observed in the placebo arm. 
Our study did not find a difference in S. pneumoniae carriage frequency or density by 
disease severity using inpatient/outpatient event status as an indicator of severity. Other 
studies of infants hospitalized with RSV respiratory illness have shown mixed results 
regarding the association between pneumococcal carriage and clinical severity in children 
hospitalized with RSV LRI [74, 165, 245, 246].  
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We are unable to infer from the current study whether RSV infection preceded an 
increase in pneumococcal density, or whether infants with high pneumococcal density 
were more likely to develop RSV LRI, but the available evidence demonstrates several 
mechanisms whereby preceding RSV infection facilitates increased bacterial adherence 
and virulence in a way that could allow for increased density [199, 205]. There is also 
evidence from the United States, as well as other temperate climate settings, of a 
temporal relationship with peaks in invasive pneumococcal disease following RSV 
seasonal epidemics [90].  
A limitation of our study was our reliance on available nasopharyngeal specimens. RSV-
positive samples and inpatient samples from the motavizumab group were less likely to 
be available for testing, and while we are unable to construct an obvious scenario where 
this would produce bias in our results, it is possible that one exists. There may have been 
a difference in the density of pneumococcus detected in nasal wash compared to nasal 
aspirate samples, but sample type did not differ by treatment group, so is not likely to 
influence our overall interpretation of the results. Our study’s power to detect statistically 
significant associations was limited by the number of events in the parent trial and the 
number of specimens that were collected in the analytic window and available for 
additional testing.  
To our knowledge, this is the first time that the impact of RSV immunoprophylaxis on 
pneumococcal carriage and density has been assessed. An extension of the current study 
would be to evaluate the distribution of pneumococcal serotypes detected among RSV-
associated compared to non-RSV respiratory events. At least one previous study has 
shown RSV infection to be associated with non-invasive pneumococcal serotypes, but the 
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finding was only marginally statistically significant and the study population was 
restricted to children with radiographically confirmed pneumonia [251].  S. pneumoniae 
density has also been shown to vary by serotype [279], and the difference in colonization 
densities we observed between RSV-associated and non-RSV-associated events could in 
part be driven by differential serotype distribution between these two groups.  
As promising RSV vaccine and long-acting monoclonal antibody candidates continue to 
progress through clinical trials, the likelihood of a licensed product for the prevention of 
RSV illness in the general infant population grows closer. A better understanding of how 
the prevention of RSV illness may lead to reductions in the transmission of S. 
pneumoniae and potentially prevent pneumococcal disease not just in vaccinated infants 
but also in their communities will be an important component of the investment case for 
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Tables and Figures 
	
Figure 5.1 Nasopharyngeal specimens tested for Streptococcus pneumoniae 	
Key: 
amedically attended lower respiratory illness 
bwithin 5 days of event (analytic window) 
Cdenominator for sample collection and testing is total number of events 
dStreptococcus pneumoniae 
edenominator for results is total number tested 
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Table 5.1 Characteristics of MALRI1 samples according to testing for S. 
pneumoniae, by treatment group and RSV status 
 


















   n=136 n=128  n=105 n=156  
Tested  3.8 (2.2) 0.52 105 (77.2) 118 (92.2) <0.01 98 (93.3) 125 (80.1) <0.01 
Not 
Tested  
4.1 (2.4)  31 (22.8) 10 (7.8)  7 (6.7) 31 (19.9)  
 
Outpatient Events 
   n=309 n=207  n=109 n=383  




5.0 (2.4)  40 (12.9) 32 (15.5)  18 (16.5) 32 (8.4)  
All Events 
   n=445 n=335  n=214 n=539  
Tested  
 
4.8 (2.3) 0.67 374 (84.0) 293 (87.5) 0.18 189 (88.3) 476 (88.3) 0.99 
Not 
Tested  
4.7 (2.4)  71 (16.0) 42 (12.5)  25 (11.7) 63 (11.7) 
 
 
1Medically attended lower respiratory illness 
2Three inpatient events and 24 outpatient events have no RSV result in the database, though NP specimens 
were indicated as collected; 0/3 of the inpatient events had samples located and tested for S. pneumoniae; 
2/24 outpatient events had samples located and tested for S. pneumoniae – one was collected 1 day after 





Figure 5.2 Proportion colonized with S. pneumoniae at MALRI1 event, by age with 
95% confidence intervals 
 
 









































































Age at MALRI Event (Months)
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Figure 5.3 Mean S. pneumoniae colonization density at MALRI1 event, by age 
 
































































































Figure 5.4 Age distribution of participants with S. pneumoniae Carriage at MALRI1 
event, by RSV status  
 
 

















RSV- (n=81) RSV+ (n=142) RSV- (n=151) RSV+ (n=293)
No SPN Carriage SPN Carriage
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Table 5.2 Association between RSV-associated medically attended lower respiratory illness and colonization with 
Streptococcus pneumoniae 
 
 RSV status1 Spn Col. 
N (%) 
OR (95% CI) Age-adjusted 















          
 RSV-positive 
(n=98) 
60 (61.2) 0.83  (0.48, 1.43) 0.81 (0.46, 1.41) 0.50 11 (11.2) 2.13 (0.82, 5.55) 0.13 5.90 (1.03) 0.06 
 RSV-negative 
(n=125) 
82 (65.6)    7 (5.6)   5.56 (1.05)  
           
Outpatient 
MALRI 
          
 RSV-positive 
(n=91) 
64 (70.3) 1.29  (0.79, 2.13) 1.29 (0.78, 2.12) 0.31 17 (18.7) 2.01 (1.08, 3.75) 0.03 6.12 (1.07) 0.03 
 RSV-negative 
(n=351) 
227 (64.7)    36 (10.3)   5.78 (1.12)  
           
Any 
MALRI 
          
 RSV-positive 
(n=189) 
124 (65.6) 1.03 (0.72, 1.47) 1.05 (0.73, 1.49) 0.87 28 (14.8) 1.75 (1.06, 2.90) 0.03 6.01 (1.05) 0.01 
 RSV-negative 
(n=476) 
309 (64.9)    43 (9.0)   5.73 (1.10)  
1Denominators include events with specimen collected and tested for pneumococcal carriage 





Figure 5.6 Pneumococcal carriage density by RSV-MALRI1 status 
 
1 RSV-associated medically attended lower respiratory illness	
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Figure 5.7 Receiver Operator Characteristic Analysis of Streptococcus pneumoniae 
colonization density to distinguish RSV-positive from RSV-negative MALRI1 events 
 
1Medically attended lower respiratory illness
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Table 5.3 Association between RSV-associated medically attended lower respiratory illness and colonization with 




































Motavizumab        
Inpatient        
 RSV-Positive (n=19) 9 (47.4) 0.15 1 (5.2) 0.91 5.71 (1.05) 0.57  
 RSV-Negative (n=86) 56 (65.1)  4 (4.7)  5.50 (1.08)  
Outpatient        
 RSV-Positive (n=33) 6 (81.2) 0.04 5 (15.1) 0.44 5.88 (1.13) 0.76 
 RSV-Negative (n=235) 150 (63.8)  25 (10.6)  5.81 (1.12)  
        
Placebo         
Inpatient RSV-Positive (n=79) 51 (64.6) 0.82 10 (12.7) 0.42 5.93 (1.03) 0.37 
 RSV-Negative (n=39) 26 (66.7)  3 (7.7)  5.71 (0.99)  
Outpatient        
 RSV-Positive (n=58) 37 (63.8) 0.73 12 (20.7) 0.04 6.29 (1.00) 0.01 
 RSV-Negative (n=116) 77 (66.4)  11 (9.5)  5.73 (1.12)  
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Table 5.4 Association between treatment group and colonization with Streptococcus pneumoniae at medically attended lower 
respiratory illness events 
 















       
 Motavizumab (n=105) 65 (61.9) 0.60 5 (4.8) 0.09 5.53 (1.07) 0.06 
 Placebo (n=118) 77 (65.3)  13 (11.0)  5.86 (1.01)  
        
Outpatient 
MALRI 
       
 Motavizumab (n=269) 178 (66.2) 0.92 30 (11.12) 0.53 5.81 (1.12) 0.43 
 Placebo (n=175) 115 (65.7)  23 (13.1)  5.92 (1.11)  
        
Any MALRI        
 Motavizumab (n=374) 243 (65.0) 0.88 35 (9.4) 0.22 5.74 (5.60) 0.14 
 Placebo (n=293) 192 (65.8)  36 (12.3)  5.89 (1.07)  












Chapter 6: The impact of preventing respiratory syncytial virus lower respiratory 
illness on other respiratory pathogens and on subsequent medically attended wheeze 
Abstract 
 
Background: A double-blinded placebo controlled randomized trial of motavizumab in 
healthy, full term infants reported high efficacy against respiratory syncytial virus (RSV) 
inpatient and outpatient medically attended lower respiratory illness (MALRI), but no 
efficacy against subsequent medically attended wheezing through 3 years of age. We 
evaluated the risk of non-RSV MALRI and the basis for the lack of efficacy against 
subsequent wheezing.  
Methods: Infants less than six months of age by December 31st of any of the four years 
of enrollment in the motavizumab trial were enrolled and prophylaxed with monthly 
doses of motavizumab or placebo for five total doses through the RSV season (150 days 
following randomization). We tested stored nasopharyngeal specimens from MALRIs 
occurring during the first 150 days of the trial follow up period by viral multiplex and 
Streptococcus pneumoniae PCR. Human rhinovirus (HRV) positive samples were 
subtyped. We evaluated these and other exposures for medically attended wheeze at ages 
1-3 years of age (subsequent wheeze).   
Results: Motavizumab reduced MALRI with RSV alone and in the presence of other 
viruses in inpatients [RR 0.13 (95%CI:  0.06, 0.24) and RR 0.12 (95%CI 0.05, 0.25), 
respectively], and in outpatients [RR 0.15 (95%CI 0.07, 0.30) and RR 0.48 95%CI (0.30, 
0.79), respectively]. Rates of outpatient influenza type A (Flu A) and human 
metapneumovirus (HMPV) associated MALRIs were increased in motavizumab 
compared to placebo participants. A family history of asthma, exposure to children in 
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daycare, and MALRI with HRV subtype A and C, parainfluenza virus (PIV), or 
coronavirus during the first 150 days of follow up, were independently associated with 
subsequent wheeze at ages 1-3 years. RSV (inpatient) MALRI was associated with 
subsequent wheeze in the motavizumab group (i.e. children who broke through 
motavizumab prophylaxis) but not the placebo group. 
Discussion: Motavizumab prevents MALRI with RSV alone and in combination with 
other viruses. The comparatively reduced efficacy for outpatient RSV MALRI with other 
viruses suggests that that as disease severity is reduced, RSV test-positivity becomes less 
specific for LRI causality, which has implications for future efficacy trials. RSV MALRI 
was not independently associated with subsequent medically attended wheeze at ages 1-3 
years in this study population, but PIV, coronavirus and HRV MALRIs were. Participants 
who experienced motavizumab break through were at significantly increased risk of 
subsequent wheeze after adjusting for other risk factors, and may represent a subgroup of 
children at high risk both for severe disease given RSV infection and for subsequent 
wheeze, regardless of RSV-illness exposure.   
Conclusion: Globally, RSV is associated with significant child morbidity, particularly in 
early infancy, but the role that these severe illness episodes play in the causal pathway to 
wheeze and asthma in later childhood is unclear. We found that motavizumab prevents 
MALRI with RSV alone as well as MALRI with RSV in combination with other viruses, 
and that certain non-RSV viral MALRIs in infancy, particularly rhinovirus, PIV and 
coronaviruses, may increase the risk of subsequent wheezing in some settings. 
Additionally, there may be a subgroup of children at high risk for both 
	
	 160	
immunoprophylaxis failure and risk of wheezing in early childhood, and this merits 





Respiratory syncytial virus (RSV) is a leading cause of child morbidity and mortality 
globally, with approximately 3.2 million annual hospital admissions and 59,600 – 
118,200 deaths in children less than five years of age [29]. The greatest burden of severe 
RSV disease and mortality occurs in infants less than six months of age [29]. An anti-
RSV monoclonal antibody (mAb), palivizumab, is effective for the prevention of severe 
disease in high-risk infants and is licensed for use in many countries.  No RSV vaccines 
or mAbs are currently available for use in the general population [95]. Recently, a 
double-blinded randomized trial of a next-generation RSV mAb, motavizumab, found 
high efficacy for the reduction of RSV-associated medically attended lower respiratory 
illness (MALRI) in healthy full-term infants [140].  This product was designed to have 
increased affinity and enhanced efficacy compared to the licensed first-generation mAb, 
palivizumab. The rate of all-cause MALRI was also significantly reduced in the 
motavizumab treatment group, although not by the same magnitude. A slight (2.5%, not 
statistically significant) increase in the absolute rate of non-RSV MALRIs in the 
motavizumab compared to the placebo group signaled potential antagonism between 
RSV and other pathogens, whereby the reduction in the presence of RSV may have 
allowed for increased presence by these other pathogens [140]. Potential antagonism 
between RSV and other pathogens was previously observed in a randomized controlled 
trial of palivizumab mAb in preterm infants where there was no overall reduction in all-
cause MALRI despite a significant reduction in RSV MALRI [175]. A negative 
association between detection of RSV and human rhinovirus in infants has also been 
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observed in a prospective cohort study [280]. In the motavizumab study that makes up 
the basis for this research, samples were not tested for non-RSV respiratory pathogens. 
 
Participants in the motavizumab trial continued to be followed for medically attended 
subsequent wheeze, with a finding of no difference by treatment group for wheezing 
between 1-3 years of age by any of the case definitions developed before un-blinding 
[140]. This contrasts with several, mostly observational, studies that have reported an 
association between severe RSV disease in infancy and increased risk of wheeze and 
asthma in later childhood [2, 175-178, 281]. Whether RSV disease is indeed causally 
associated with subsequent wheeze and asthma or whether it is merely more likely to 
occur in children who are predisposed to these conditions is unclear and a topic of 
considerable debate. There are proposed mechanisms to explain how acute RSV illness 
may play a causative role in long-term wheezing episodes. These include chronic 
epithelial and airway reactivity changes to the developing infant lung, lung injury that 
alters lung function, and immunomodulatory changes [2]. Against a causal association 
are the identification of genes that are associated with increased risk of both severe RSV 
illness and asthma, as well as reduced lung function at birth, which is also associated with 
both conditions [71, 171]. Human rhinovirus (HRV) is another virus that may increase 
risk of subsequent wheeze and childhood asthma, and in several studies has been shown 
to be a greater predictor of these outcomes than RSV illness [136]. Furthermore, in the 
nasopharyngeal microbiome, early asymptomatic colonization with Streptococcus 
pneumoniae has also been shown to be a strong risk factor for asthma, where bacterial co-
colonization with viral infection of the upper airways is associated with the spread of 
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virus to the lower airways and subsequent inflammatory responses that may contribute to 
risk of asthma development [165]. A better understanding of the specific role of RSV 
disease in the development of long-term respiratory sequelae, as well as an understanding 
of how RSV disease prevention in infancy may modify the risk of acute illness with other 
respiratory pathogens, is essential for estimating the potential value of future RSV 
passive and active vaccination programs [93].  
 
 In this study, we hypothesized that no impact of RSV prevention on wheeze was 
observed because there were other viruses causing acute lower respiratory illness which 
were themselves associated with subsequent wheeze, and that the frequency of these 
MALRI events were the same or more common in the motavizumab group than the 
placebo group (the latter scenario being explained by antagonism between RSV and other 
pathogens). To address this hypothesis, we used the prior double-blind randomized trial 
of motavizumab in Native American children [3] to assess the following a priori 
questions: (1) whether motavizumab was equally effective in preventing RSV MALRI 
with and without other viral co-infections in the first 150 days following randomization, 
(2) whether increased rates of MALRI with non-RSV viruses occurred as a result of 
motavizumab prophylaxis in the first 150 days following randomization (3) the manner in 
which RSV and other respiratory pathogens contribute to the risk of subsequent 
medically attended wheeze in this study population, and (4) how infants in the 
motavizumab arm who were hospitalized with RSV lower respiratory illness (i.e. children 







The full methods of the phase 3 double-blind placebo-controlled randomized trial of 
motavizumab (the parent study) have been published elsewhere [140]. Briefly, healthy 
Native American infants living on the Navajo Nation, White Mountain Apache and San 
Carlos Apache Indian reservations who were born at full-term (≥36 weeks gestation) and 
were less than six months of age by December 31st of any of the four years of enrollment 
were randomized to receive either motavizumab or placebo during the winter RSV season 
(5 monthly doses, 2:1 randomization). Four cohorts of infants were enrolled over four 
consecutive RSV seasons between 2004 and 2009, for a total of 2,127 participants.  The 
current sub-analysis excluded the San Carlos Apache reservation participants, bringing 
the total number of participants to 2,088 (1,392 participants randomized to motavizumab, 
696 randomized to placebo). 
 
Evaluation of medically attended lower respiratory tract illness  
Study participants were followed from the time of study enrollment through three years 
of age and assessed for inpatient and outpatient medically attended lower respiratory tract 
illness (MALRI). Lower respiratory tract illness events were reviewed for inclusion by 
study investigators and were defined as a medical diagnosis of bronchiolitis or 
pneumonia. In the absence of such a medical diagnosis, the occurrence of the lower 
respiratory illness was determined by the study investigator’s review of the medical 
records for the presence of lower respiratory signs and symptoms including cough, 
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retractions, ronchi, wheezing, crackles or rales, as well as associated signs or symptoms 
including coryza, fever and apnea.  
 
Nasopharyngeal secretions collected within five days of the MALRI event date (hospital 
admission for inpatient events; doctor visit date for outpatient events) were considered to 
be within the analytic window and were included in the analysis. A nasopharyngeal 
specimen was collected at every MALRI visit. The collection of nasal wash secretions 
involved instilling 15 – 20 cc of Ringer’s lactate solution into each nostril of a seated 
child with a bulb syringe and collecting it from the opposite nostril. In children who 
could not have a nasal wash specimen collected, a nasal aspirate was obtained by 
instilling 3 – 6 cc of sterile saline into the nose and withdrawing nasal mucus using a 
feeding tube with a suction device.  One milliliter of nasopharyngeal specimen was 
mixed with 6 ml viral transport medium and then divided into 4 – 8 aliquots which were 
snap frozen immediately using liquid nitrogen or an ethanol/dry ice bath, and stored at -
70°C. At facilities where snap freezing was not possible, aliquots were immediately 
stored at -80°C.  After freezing, aliquots were shipped to central laboratories for storage. 
Those collected within 150 days of randomization (the RSV season) were tested for RSV 
A and B by PCR assay. Aliquots of untested specimen remained in storage at -80°C with 
continuous temperature monitoring.  
 
 
Evaluation of wheeze  
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Participants were followed from study day 0 (day of first study drug) through three years 
of age for the occurrence of medically attended wheezing events. Medically attended 
wheezing was counted as an outcome event if there was a discharge diagnosis of asthma, 
bronchiolitis, reactive airway disease, or documentation of wheezing in the medical 
record by the treating physician. A new wheezing episode was defined as one that 
occurred more than two weeks after the diagnosis of the previous episode and did not 
represent a persistence of the previous episode according to medical opinion. Only new 
wheezing episodes were included in the wheezing analyses.  
 
Subsequent wheeze events were those medically attended wheeze events occurring 
between one and three years of age, and were classified using three outcome definitions: 
(1) ≥1 medically attended wheeze event, (2) serious early childhood wheeze, and (3) 
recurrent wheeze. Serious early childhood wheeze and recurrent wheeze are two 
overlapping but distinct subsets of medically attended wheeze. A child was considered to 
have serious early childhood wheeze if s/he met any one of four conditions between one 
and three years of age: (1) three or more medically attended wheezing events during any 
12-month period, (2) a need for one or more courses of systemic steroids for treatment of 
a medically attended wheezing event, (3) a need for asthma control medications over a 
12-month period for at least three consecutive months (i.e., ≥90 days) or five cumulative 
months (i.e. ≥150 days), with duration assessed by a combination of parental interviews 
and medical records, or (4) a least one inpatient wheezing event. Recurrent medically 
attended wheeze was defined as three or more medically attended wheezing events during 




Specimen testing for this sub-analysis 
For the present sub-analysis, stored nasopharyngeal secretions from events that occurred 
during the first 150 days of follow up were tested by a real-time PCR multiplex viral 
panel and by a S. pneumoniae uniplex PCR assay. For the multiplex panel, 350ul of nasal 
sample was extracted using the NucliSENS EasyMag kit (bioMerieux, Marcy l’Etoile, 
France) with an RNA eluate volume of 25ul. 10ul of eluate was used for the real-time 
NxTAG® Respiratory Pathogen Panel (Luminex Corporation, Austin, Texas). The 
NxTAG® panel includes influenza virus A (multiple subtypes) and B (Flu A and Flu B), 
RSV A and B, coronaviruses (subtypes 229E, HKU1, NL63, and OC43), human 
metapneumovirus (HMPV), human rhinovirus/enterovirus (HRV/EV), adenovirus, 
parainfluenza viruses 1-4, bocavirus, and the bacterial pathogens Chlamydophila 
pneumoniae and Mycoplasma pneumonia. cDNA was generated with the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) and 10ul of 
RNA eluate.  Rhinovirus/enterovirus positive samples were typed using a molecular 
typing assay [274]. In instances where there was discordance between the RSV result 
from the NxTAG® panel and the RSV result from the testing done as part of the primary 
testing for the clinical trial, we deferred to the primary result. Nucleic acid extraction for 
the S. pneumoniae assay was by GeneJET Genomic DNA Purification Kit (Thermo 
Fisher Scientific, Waltham, MA). Two hundred microliters of DNA were eluted from the 
original specimen and 5 µl were used in the PCR reaction. The final PCR reaction 
volume was 25 µl and performed by use of the TaqMan Universal Master Mix kit 
(Applied Biosystems, Foster City, CA) with primers and probes targeting the lytA gene 
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[273]. Each run included a no-template control and a S. pneumoniae positive control, 
with DNA amplified using a Stratagene Mx3005P system (Agilent, Santa Clara, CA) 
with the following cycling parameters: 95°C for 10 min, followed by 40 cycles of 95°C 
for 15 seconds, and 60 °C for 1 minute. Amplification data were analyzed by Stratagene 
software and results with cycle thresholds <40 were accepted.  
 
Statistical Analyses 
Rates of MALRI with RSV and other viruses in the motavizumab and placebo treatment 
arms were calculated using the intention to treat study population of the respective 
treatment arm as the denominator. Relative risks for MALRI with RSV and other viruses 
were calculated using these rates and were then used to calculate efficacy estimates for 
motavizumab. Proportions of MALRI events positive for a pathogen were calculated 
using denominators that included only those MALRI events with a specimen tested for 
the pathogen of interest. Binary outcomes were compared using Fisher’s exact test. 
Multiple logistic regression was used for adjusted analyses. Backwards, stepwise 
selection with alpha equal to 0.05 was used to select the final adjusted models. All p-





Informed consent for participation in this study was obtained from a parent or guardian of 
participants. Approval for this study was obtained from the Phoenix Area Indian Health 





During the 150 days following randomization (first 150 days of follow up), 276 
respiratory hospital admissions (inpatient MALRI events) occurred among 231 
participants: 192 (83%) infants with one admission, 33 (14%) infants with two 
admissions, and 6 (3%) infants with three admissions. Within the same time period, there 
were 653 outpatient visits for lower respiratory illness (outpatient MALRI events) among 
511 participants: 395 (77%) children with one visit, 94 (18%) children with two visits, 18 
(4%) children with three visits, and 4 (<1%) children with four visits each. A total of 705 
stored nasopharyngeal specimens were located and tested for the presence of other 
respiratory pathogens (76% of 929 MALRI events) (Figure 6.1.A and Figure 6.1.B).  
There was agreement between the original RSV result from the trial and the RSV result 
from the Luminex multiplex panel for 654/702 (93.2%) specimens; where the results 
differed we deferred to the original result. We compared treatment group, RSV infection 
status and age at event for samples with test results available for non-RSV pathogens 
compared to those without. Among inpatient events, placebo recipients were more likely 
than motavizumab recipients to have results for non-RSV pathogens, and RSV-positive 
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events were more likely to have non-RSV testing completed than RSV-negative events; 
outpatient events were equally likely to have complete test results regardless of treatment 
group, RSV status or age at event (Table 6.1).  
 
Consistent with the primary efficacy analysis, there was a lower rate of any RSV MALRI 
in the motavizumab group compared to the placebo group in the subset of participants 
included in our analysis [4% (61/1392) vs. 22% (151/696), respectively] [140]. We 
stratified RSV MALRI events in the first 150 days of follow up into those with RSV 
detected alone and RSV detected in combination with another virus, and found efficacy 
for motavizumab for the prevention of both (Figure 6.2). The efficacy of motavizumab 
for prevention of inpatient MALRI with RSV alone was the same as that for RSV with 
another virus, while the efficacy for prevention of outpatient MALRI with RSV alone 
was greater than for RSV detected in the presence of another virus. Only RSV events that 
were also tested for other viruses were included in the stratified analysis of motavizumab 
efficacy. Three RSV-positive inpatient samples from two participants in the 
motavizumab arm were unavailable for additional viral testing, while none of the 
outpatient samples unavailable for additional viral testing from the motavizumab arm 
were positive for RSV. Because inpatient samples from the motavizumab group were less 
likely to be available for testing for other viruses than were the inpatient samples from 
the placebo group, we did a sensitivity analysis assigning the two motavizumab 
participants with RSV inpatient MALRI events not tested for other viruses to the ‘RSV 
plus other virus’ group. The subsequent re-calculated relative risk for inpatient MALRI 
with RSV plus another virus in the motavizumab compared to the placebo group was 
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0.15 (95% CI 0.07, 0.30), which did not change our original interpretation of the efficacy 
of motavizumab for the prevention of inpatient MALRI with RSV along with other 
viruses.  As expected, efficacy was not demonstrated for prevention of inpatient or 
outpatient events associated with only non-RSV viruses (Figure 6.2). 
 
While there was no difference by treatment group in the overall frequency of non-RSV 
viral MALRI events, some differences were noted when results were stratified by 
pathogen (Table 6.2.A and Table 6.2.B). Participants in the placebo group were more 
likely to have inpatient or outpatient MALRI with rhinovirus type A, and inpatient 
MALRI with rhinovirus type B, parainfluenza viruses or coronaviruses than 
motavizumab participants. However, after excluding instances of co-infection with RSV, 
the distribution of these viruses was the same in both treatment groups (Table 6.2.A and 
Table 6.2.B). The rate of outpatient MALRI with human metapneumovirus or influenza 
type A, however, was higher in the motavizumab group compared to the placebo group 
(Table 6.2.B).   
 
At least one virus was detected in 91% (212/232) of inpatient MALRI events, and in 88% 
(415/473) of outpatient MALRI events occurring in the first 150 days of follow up with 
specimens available for testing (Figure 6.3.A and 6.3.B). The most common viruses 
detected across all events were HRV (40%, 284/705) and RSV (29%, 207/705). HRV 
predominated among all MALRI events with the exception of inpatient MALRI in the 
placebo group, where RSV was the predominant pathogen. With the exception of RSV, 
no viruses were more commonly detected in nasopharyngeal samples from the placebo 
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group compared to the motavizumab group. Some viruses were more commonly detected 
in nasopharyngeal samples from the motavizumab group compared to the placebo group, 
but only among outpatient events [coronavirus (50/280 (17.9%) vs. 13/193 (6.7%), 
p<0.001; human metapneumovirus (35/280 (12.5%) vs. 11/193 (5.7%), p=0.02; influenza 
type A (24/280 (8.6%) vs. 5/193 (2.6%), p=0.01; and parainfluenza viruses 40/280 
(14.3%) vs. 15/193 (7.8%), p=0.04] (Figure 6.3.B).  
 
The mean age was the same for RSV MALRI and non-RSV MALRIs during the first 150 
days of follow up (3.80 mo vs. 3.81 mo, respectively, for inpatient events p=0.78), and 
(5.37 mo vs. 5.12 mo, respectively, for outpatient events p=0.30). Among those tested for 
other viruses, the proportion of inpatient RSV-positive specimens with another virus 
detected did not differ by treatment group (42% [8/19] in the motavizumab group vs. 
44% [35/80] in the placebo group, respectively (p=1.00)). The proportion of outpatient 
RSV-positive specimens with another virus detected was higher in the motavizumab 
compared to the placebo group (76% [31/41] vs. 48% [33/69], respectively (p <0.01)). 
Influenza type A, HRV-A, parainfluenza viruses and coronaviruses were more likely to 
be detected in RSV-negative samples than RSV-positive samples (Figures 6.4.A – 6.4.D). 
No pathogen was more likely to be detected in RSV-positive samples than RSV-negative 
samples with the exception of S. pneumoniae (marginally statistically significant; Figure 
6.4.C).  
 
Baseline characteristics associated with subsequent medically-attended wheeze in 
univariate analyses included family history of asthma, wheeze, hay fever, or eczema, the 
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presence another child <18 yrs of age in the household, another child <6 yrs of age in the 
household who attends daycare, and household crowding. Each of these were associated 
with at least one of the subsequent wheeze outcomes for one of the treatment groups 
(Table 6.3.A and 6.3.B). All-cause inpatient and outpatient MALRI events occurring 
during the first 150 days of follow up were associated with all three subsequent 
medically-attended wheeze outcomes, even after adjusting for baseline risk factors 
(Supplemental Table 6.1).  
 
We assessed the univariate association of each pathogen detected at inpatient and 
outpatient MALRI events in the first 150 days of follow up with subsequent medically 
attended wheeze, and assessed for interactions by treatment group. (Supplemental Tables 
6.2 through 6.4). We then did multiple logistic regression analyses including baseline 
characteristics and pathogen-specific MALRIs that were associated with wheeze in the 
univariate analyses. The following were associated with one or more subsequent 
medically attended wheeze outcomes in the adjusted analyses: inpatient MALRI with 
RSV (motavizumab group only), inpatient or outpatient MALRI with HRV type-A, 
inpatient MALRI with parainfluenza viruses, outpatient MALRI with HRV type-C, 
outpatient MALRI with coronaviruses, family history of asthma, and the presence of 
another child in the household under 6 years of age who attends daycare (Figure 6.5).  
 
Among participants with an RSV hospitalization in the first 150 of follow up, we 
observed a substantially increased risk of all three subsequent wheeze outcomes in the 
motavizumab group (i.e. those who broke through motavizumab) compared to the 
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placebo group (Figure 6.6).  Among the 21 participants in the motavizumab arm who 
developed an RSV inpatient MALRI (i.e. breakthrough disease), there were 31 total 
inpatient MALRI events [72% (22/31) of which were RSV-associated] during the first 
150 days of follow up (Supplemental Table 6.5). Specimens were collected within the 
analytic window for 97% (30/31) of the events. Testing for additional viruses was 
completed in 83% (25/30) of the events with a specimen, of which 44% (11/25) were 
positive for RSV alone, 32% (8/25) were positive for RSV plus at least one other virus, 
17% (4/25) were positive only for viruses other than RSV, and 8% (2/25) were negative 
for all viruses. Samples from the remaining 5 events were not tested because they could 
not be located. Nine (43%) of the 21 participants with motavizumab breakthrough disease 
also experienced an outpatient MALRI event during the first 150 days following 
randomization, of which only one was RSV-associated. Although the majority [81% 
(17/21)] of participants with motavizumab breakthrough RSV disease had at least one 
missed or late dose of study drug at some point during the first 150 days of follow up 
(compared to 633/1,371 [46.2%] of the participants in the motavizumab without 
breakthrough illness), only 29% (6/21) had a missed or late dose immediately prior to 
their inpatient RSV-MALRI event (Supplementary Table 6.5). Compared to participants 
in the motavizumab group who did not have RSV MALRI in the first 150 days of follow 
up, children with motavizumab breakthrough RSV disease were more likely to 
experience household crowding, live in a household with other children, including other 
children who attended daycare, have a family history of wheeze, have a missed or late 
study dose at some point during the first 150 days of follow up, and to have had an 
outpatient MALRI (Table 6.4). They also had a greater average number of inpatient 
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MALRI events in the first 150 days of follow up than placebo participants with at least 
one RSV-MALRI in the same time period. After adjusting for these variables, as well as 
the presence of other viruses shown to be associated with increased risk of subsequent 
wheeze, the interaction by treatment group of the association between inpatient RSV-




As previously reported, a double-blinded randomized trial of the RSV mAb motavizumab 
found 87% efficacy for the prevention of inpatient RSV MALRI and 71% efficacy for the 
prevention of outpatient RSV MALRI in a population of healthy, full-term infants who 
had been randomized to receive either motavizumab or placebo treatment [140]. We 
evaluated nasopharyngeal specimens from MALRI events that occurred during the first 
150 days of follow up in the motavizumab trial for the presence of other pathogens and 
detected one or more non-RSV viruses in >40% of RSV-MALRI events. We found 
efficacy for the prevention of MALRI events where RSV was detected alone, as well for 
as MALRI events where RSV was detected alongside other respiratory viruses. Efficacy 
for inpatient RSV MALRI events remained consistent regardless of whether RSV was 
detected alone (87%) or with another virus (86%), suggesting that in lower respiratory 
illness cases severe enough to merit hospitalization, RSV is likely the etiologic cause of 
disease. Among outpatient events, however, the efficacy of motavizumab for the 
prevention of MALRI with RSV detected alone was significantly higher than for MALRI 
with RSV in combination with other viruses (85% vs. 52%, respectively). This may 
indicate that RSV is highly likely to be the causal agent for MALRI-RSV events that are 
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severe (i.e. hospitalized), but that for those of lower severity, treated as outpatients, the 
finding of RSV in a child is less predictive of causality. To our knowledge, this has not 
been previously shown in other studies. In some of these cases, co-infecting viruses are 
likely partially causally associated with illness that would otherwise be uniquely ascribed 
to RSV on the basis of detecting RSV in a child with a compatible clinical syndrome.  
The primary efficacy analysis showed no overall disease replacement occurring with 
motavizumab prevention of RSV events [140]. In the current analysis, we found evidence 
for antagonism between RSV and influenza type A, and RSV and human 
metapneumovirus. Both viruses had higher rates of detection in the motavizumab group 
at outpatient (but not inpatient) medically attended lower respiratory illness events.   
We found a family history of asthma and the presence of a young child in the household 
who attends day care to be independently associated with subsequent medically attended 
wheeze. As previously reported, these characteristics were distributed evenly across the 
treatment groups [282].  We also found parainfluenza, HRV-A, HRV-C, and coronavirus 
associated MALRI in the first 150 days of follow up to be independently associated with 
subsequent medically attended wheeze regardless of treatment group. We found that 
treatment group modified the risk of subsequent medically attended wheeze among those 
who had RSV MALRI. There was a substantially increased risk of wheezing in the years 
following RSV prophylaxis among children who were hospitalized with RSV respiratory 
disease despite motavizumab prophylaxis, compared with children who likewise had had 
an inpatient RSV MALRI in their first RSV season, but had received placebo. We 
hypothesize that there are a subset of children who have a host risk factor, or set of risk 
factors, that not only put them at risk of serious MALRI when they have their first RSV 
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infection, but that also increase their risk for subsequent wheeze in the future, 
independent of the RSV infection itself. According to this hypothesis, motavizumab acts 
like a probe, revealing through prophylaxis failures a subgroup of children in the 
community who are inherently at high risk for wheezing (Figure 6.7).   
Our study differs in important ways from other intervention trials of RSV 
immunoprophylaxis (palivizumab) where a population-level reduction in subsequent 
wheezing was observed in the treatment group [175-178]. Only one of these studies was 
also double-blinded and randomized [175]. In that study, the subsequent wheeze outcome 
was parental reported wheeze events occurring before the first birthday [175], making it 
difficult to draw direct comparisons with our subsequent medically attended wheeze 
outcomes between ages one to three years. Ours was also the only study that included full 
term rather than preterm infants, and the role of severe RSV illness in subsequent 
wheezing may be different in this population than in preterm infants.  
The increased risk of future wheeze following HRV-lower respiratory illness observed in 
this study is consistent with several other reports [283]. HRV has been shown to provoke 
an airway inflammatory response with the induction of respiratory symptoms that can 
lead to sustained bronchial hyperactivity, predominantly in predisposed individuals with 
atopic tendencies [284]. We did not have direct measures of atopic characteristics in the 
infants in our study, but controlling for family history of atopy and asthma did not alter 
the relationship of HRV-illness to future wheeze. Increased risk of subsequent wheeze 
following parainfluenza virus and coronavirus illnesses, has not, to our knowledge, been 
reported in other studies.  
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Our study was limited by our inability to locate nasopharyngeal specimens from all of the 
medically attended respiratory events with samples collected, with inpatient samples less 
likely to be available for testing by the viral multiplex panel if they came from the 
motavizumab group. We measured rates of viral illnesses in the first RSV season using 
the full ITT population as the denominator, and only samples with complete testing 
results could be assigned to the ‘RSV only’ or ‘RSV plus other viruses’ numerators in our 
rate calculations. Because there were more missing results from the motavizumab group, 
there could have been differential misclassification bias whereby participants in the 
placebo group were more likely to be assigned as having inpatient RSV or other viral 
lower respiratory illness compared to the motavizumab group. This could have led to an 
overestimation of the true efficacy of motavizumab for the prevention of inpatient viral 
lower respiratory illness. However, our efficacy point estimate for overall prevention of 
inpatient RSV MALRI was the same as that reported in the parent trial, indicating that the 
exclusion of events with specimens not tested by the viral multiplex did not bias our 
efficacy estimates in favor of motavizumab. To assess whether our result of similar 
efficacy of motavizumab for the prevention of inpatient MALRI with RSV alone versus 
RSV together with another viruses was influenced by the fact that we did not test three 
RSV positive samples from the motavizumab group for other viruses, we conducted a 
sensitivity analysis and found no meaningful change in efficacy even after assuming all 
three events had other viruses detected. While we did observe increased rates of inpatient 
MALRI with some non-RSV viruses in the placebo group, the fact that these differences 
disappeared after excluding those events where RSV was detected along with those 
viruses suggests that the observed increases were not due to additional availability of 
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samples from the placebo group – if that had been the case we would expect to see 
increased detection of non-RSV viruses alone, as well as with RSV, in the placebo group.  
Additionally, the fact that we did not observe overall efficacy of motavizumab for 
prevention of MALRI with only non-RSV viruses provides further assurance that 
misclassification due to missing results did not occur in a substantial number of 
participants. There was no differential testing of outpatient MALRI events by treatment 
group, and therefore no obvious source of potential bias in our estimates of efficacy of 
motavizumab for outpatient MALRI. In analyses of the proportions of MALRIs with 
specific pathogens detected by treatment group and RSV status, the denominators 
included only those MALRIs with specimens tested for the pathogen(s) of interest, and 
missing data should therefore not have affected these results.  
 Another limitation of this study is that without direct measures of lung function or risk 
for asthma or atopy in these infants, we were forced to rely family histories as proxy 
indicators for baseline risk of future disease. Because follow up ended three years after 
randomization, we were unable to evaluate children at an age where asthma diagnoses 
could be established. Long-term follow up of the study cohort is now ongoing for asthma 
outcomes.  
The results of this study have implications for future research. The reduced efficacy we 
observed for outpatient RSV MALRI in combination with other viruses has particular 
implications for efficacy evaluations of vaccine and monoclonal antibody products that 
do not produce sterilizing immunity. While a substantial proportion of medically attended 
RSV disease burden occurs in outpatient settings, the fraction of lower respiratory illness 
in these settings that is causally associated with RSV is likely reduced compared to 
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illness severe enough to warrant hospital admission. If the clinical severity threshold for 
RSV MALRI case definitions in efficacy trials is lowered in an effort to accrue greater 
numbers of outcome events over a shorter period of time, the product efficacy may be 
simultaneously driven down as the proportion of those events that are not causally 
associated with RSV increases. Further work is needed to address the potential impact of 
RSV prevention on asthma and lung function, which can only be measured later in 
childhood. The previously reported findings from the motavizumab efficacy trial cast 
doubt on the assumption that RSV illness prevention will necessarily impact subsequent 
wheezing and asthma at the population level. Our results indicate the potential for RSV 
monoclonal antibodies, and possibly vaccines, to impact RSV-associated subsequent 
wheeze differentially according to the distribution of underlying host risk factors and co-
circulating viruses in the population. Further investigation of these host factors is needed, 
and future trials of RSV vaccines or monoclonal antibodies should be designed to assess 
long-term respiratory sequelae in their study populations. Finally, our results signal that 
rates of influenza type A and human metapneumovirus illness could increase when RSV-
illness is prevented, presumably due to antagonism between these pathogens. There are 
suggestions from other studies of potential interference between influenza type A and 
RSV [285]. This finding should not be over interpreted, however, given that the point 
estimates for the relative increase in detection of both viruses had confidence intervals 
that came close to overlapping the null value. It should rather be used to generate 
hypotheses for future investigations that assess how the prevention of one of these 
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Tables and Figures 
 
Figure 6.1.A Inpatient medically attended lower respiratory illness events during 





amedically attended lower respiratory illness 
bwithin 5 days of MALRI admission date (analytic window) 
Cdenominator for sample collection and testing is total number of inpatient MALRI events 
dStreptococcus pneumoniae carriage in the nasopharyx  
edenominator for results is total number tested 
Test result percentages may not sum to 100% due to rounding 
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Figure 6.1.B Outpatient medically attended lower respiratory illness events during 





amedically attended lower respiratory illness 
bwithin 5 days of MALRI doctor visit (analytic window) 
Cdenominator for sample collection and testing is total number of outpatient MALRI events 
dStreptococcus pneumoniae carriage in the nasopharyx  
edenominator for results is total number tested 




Table 6.1 Characteristics of MALRI1 samples according to testing for other viruses, 
by treatment group and RSV status 
 




















   n=1444 n=132  n=105 n=156  
Tested  3.8 (2.2) 0.52 112 (77.8) 120 (90.9) <0.01 99 (94.3) 133 (85.3) 0.02 
Not 
Tested  
4.1 (2.4)  32 (22.2) 12 (9.1)  6 (5.7) 23 (14.7)  
 
Outpatient Events 
   n=396 n=257  n=112 n=387  




5.0 (2.4)  116 (29.3) 64 (24.9)  5 (7.0) 24 (6.2)  
All Events 
   n=540 n=389  n=217 n=543  
Tested  
 
4.8 (2.3) 0.67 392 (72.6) 313 (80.5) <0.01 206 (93.6) 496 (85.2) 0.09 
Not 
Tested  
4.7 (2.4)  148 (27.4) 76 (19.5)  11 (6.4) 47 (14.8) 
 
 
1Medically attended lower respiratory illness 
2Denominator for testing by treatment group includes all MALRI events regardless of whether a sample 
was collected within the analytic window 
3Denominator for testing by RSV status is the subset of events with sample collected and tested for RSV  





Figure 6.2 Relative risk of medically attended lower respiratory illness outcomes in 
the first 150 days of follow up in the motavizumab treatment group compared to the 
placebo treatment group  
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Relative risk  
(95% CI) 
p-value1 Absolute rate 
reduction, cases per 
100 children (95%CI) 
      
RSV only2 11 (0.8) 44 (6.3) 0.13 (0.06, 0.24) <0.001 5.5 (3.7, 7.4) 
RSV with other virus 8 (0.6) 34 (4.9) 0.12 (0.5, 0.25) <0.001 4.3 (2.7, 6.0) 
Other virus only 70 (5.0) 34 (4.9) 1.03 (0.69, 1.53) 0.91 -0.1 (-2.1, 1.8) 
Virus Negative 15 (1.1) 5 (0.7) 1.50 (0.55, 4.11) 0.49 -0.4 (-1.2, 0.5) 
      
RSV with 1 other virus 5 (0.4) 25 (3.6) 0.10 (0.04, 0.26) <0.01 3.2 (1.8, 4.7) 
RSV with >1 other virus 3 (0.2) 93 (1.3) 0.17 (0.05, 0.61) <0.01 1.1 (0.2, 2.0) 
Other virus only      
1 virus 48 (3.5) 19 (2.7) 1.26 (0.75, 2.13) 0.43 -0.7 (-2.2, 0.8) 
>1 virus 25 (1.8) 163 (2.3) 0.78 (0.42, 1.45) 0.50 0.5 (-0.8, 1.8) 
      
Rhinovirus4 (any) 32 (2.3) 32 (4.6) 0.50 (0.31, 0.81) <0.01 2.3 (0.6, 4.0) 
Rhinovirus with RSV  2 (0.1) 18 (2.6) 0.06 (0.01, 0.24) <0.001 2.4 (1.2, 3.6) 
Rhinovirus without RSV 31 (2.2) 16 (2.3) 0.97 (0.53, 1.760 1.00 0.0 (-1.3, 1.4) 
      
Rhinovirus type A 18 (1.3) 14 (2.0) 0.64 (0.32, 1.28) 0.26 0.7 (0.00, 1.9) 
Rhinovirus type A with RSV 0 (0.0) 6 (0.9) - <0.01 0.9 (0.2, 1.5) 
Rhinovirus type A without RSV 18 (1.3) 9 (1.3) 1.00 (0.45, 2.21) 1.00 0.0 (-1.0, 1.0) 
      
Rhinovirus type B 2 (0.1) 2 (0.3) 0.50 (0.07, 3.54) 0.61 0.1 (-0.3, 0.6) 
Rhinovirus type B with RSV 0 (0.0) 1 (0.1) - 0.33 0.1 (-0.01, 0.4) 
Rhinovirus type B without RSV 2 (0.0) 1 (0.1) 1.00 (0.06, 11.01) 1.00 0.0 (-0.3, 0.3) 
      
Rhinovirus type C 15 (1.1) 19 (2.7) 0.39 (0.21, 0.77) <0.01 1.7 (0.3, 3.0) 
Rhinovirus type C with RSV 2 (0.1) 11 (1.6) 0.09 (0.02, 0.41) <0.001 1.4 (0.5, 2.4) 
Rhinovirus type C without RSV 14 (1.0) 8 (1.2) 0.88 (0.37, 2.08) 0.82 0.1 (-0.8, 1.1) 
      
Parainfluenza Virus 1-4 14 (1.0) 16 (2.3) 0.44 (0.21, 0.89) 0.03 1.3 (0.0, 2.5) 









Relative risk  
(95% CI) 
p-value1 Absolute rate 
reduction, cases per 
100 children (95%CI) 
Parainfluenza Virus 1-4 without RSV 13 (0.9) 10 (1.4) 0.65 (0.29, 1.47) 0.37 0.5 (-0.5, 1.5) 
      
Human metapneumovirus 12 (0.9) 12 (1.7) 0.50 (0.23, 1.11) 0.09 0.9 (-0.2, 1.2) 
Human metapneumovirus with RSV  1 (0.1) 5 (0.7) 0.10 (0.01, 0.85) 0.02 0.6 (0.0, 1.3) 
Human metapneumovirus without RSV  11 (0.8) 7 (1.0) 0.79 (0.31, 2.02) 0.62 0.2 (-0.7, 1.1) 
      
Adenovirus 18 (1.3) 10 (1.4) 0.90 (0.42, 1.94) 0.84 0.1 (-0.1, 1.2) 
Adenovirus with RSV  4 (0.3) 6 (0.9) 0.33 (0.09, 1.18) 0.10 0.6 (-0.1, 1.3) 
Adenovirus without RSV  15 (1.1) 4 (0.6) 1.88 (0.62, 5.62) 0.33 0.5 (-1.3, 0.3) 
      
Influenza type A 12 (0.9) 7 (1.0) 0.86 (0.34, 2.17) 0.81 0.1 (-0.7, 1.0) 
Influenza type A with RSV 1 (0.1) 1 (0.1) 0.50 (0.03, 7.98) 1.00 0.0 (-0.2, 0.3) 
Influenza type A without RSV 11 (0.8) 6 (0.9) 0.92 (0.34, 2.47) 1.00 0.0 (-0.8, 0.9) 
      
Influenza type B 5 (0.4) 1 (0.1) 2.50 (0.29, 21.36) 0.67 -0.2 (-0.6, 0.2) 
Influenza type B with RSV 0 (0.0) 0 (0.0) - - - 
Influenza type B without RSV 5 (0.4) 1 (0.1) 2.50 (0.29, 21.36) 0.67 -0.2 (-0.6, 0.2) 
      
Enterovirus 1 (0.1) 1 (0.1) 0.50 (0.03, 7.98) 1.00 0.0 (-0.2, 0.4) 
Enterovirus with RSV 0 (0.0) 0 (0.0) - - - 
Enterovirus without RSV 1 (0.1) 1 (0.1) 0.50 (0.03, 7.98) 1.00 0.0 (-0.2, 0.4) 
      
Coronavirus5 13 (0.9) 15 (2.2) 0.43 (0.21, 0.91) 0.03 1.2 (0.0, 2.4) 
Coronavirus with RSV 1 (0.1) 5 (0.7) 0.10 (0.01, 0.85) 0.02 0.6 (0.0, 1.3) 
Coronavirus without RSV 12 (0.9) 10 (1.4) 0.60 (0.26, 1.38) 0.26 0.6 (-0.4, 1.6) 
      
Bocavirus 4 (0.3) 2 (0.3) 1.00 (0.18, 5.45) 1.00 0.0 (-0.5, 0.5) 
Bocavirus with RSV 1 (0.1) 2 (0.3) 0.25 (0.02, 2.75) 0.26 0.2 (-0.2, 0.6) 
Bocavirus without RSV 3 (0.2) 0 (0.0) - 0.56 -0.2 (-0.5, 0.0) 
	
	 189	
1Fishers exact test, alpha =0.05 
2Excludes n=2 motavizumab and n=2 placebo participants positive for RSV in the motavizumab trial but without a specimen available for testing for additional 
viruses. Only samples tested for RSV and other viruses could be categorized as ‘RSV only’ or ‘RSV with other viruses’. Denominators for calculation of relative 
risk and absolute rate reduction include the entire intention to treat population for each treatment arm. 
3One placebo participant had both a non-RSV viral event with 1 virus only, and with multiple viruses 
4Some Rhinovirus positive secretions were positive for more than one subtype, in which case they were counted as both; therefore the sum of participants with 
HRV-A + HRV-B + HRV-C  > total participants HRV. 
5Includes coronavirus types 229E, NL63, OC43, and HKU1
	
	 190	











p-value1 Absolute rate 
reduction, cases per 
100 children (95%CI) 
RSV only2 10 (0.7) 34 (4.9) 0.15 (0.07, 0.30) <0.001 4.2 (2.5, 5.8) 
RSV with other virus 30 (2.2) 31 (4.5) 0.48 (0.30, 0.79) <0.01 2.3 (0.6, 4.0) 
Other virus only 172 (12.4) 90 (12.9) 0.96 (0.75, 1.21) 0.73 0.6 (-2.5, 3.6) 
Virus Negative 34 (2.4) 22 (3.2) 0.77 (0.46, 1.31) 0.39 0.7 (-0.8, 2.3) 
      
      
RSV with 1 other virus 18 (1.3) 25 (3.6) 0.36 (0.20, 0.66) <0.01 2.3 (0.8, 3.8) 
RSV with >1 other virus 13 (0.9) 8 (1.2) 0.81 (0.34, 1.95) 0.65 0.2 (-0.7, 1.2) 
Other virus only      
1 virus 121 (8.7) 73 (10.5) 0.83 (0.63, 1.09) 0.20 1.8 (-0.9, 4.5) 
>1 virus 62 (4.5) 19 (2.7) 1.63 (0.98, 2.71) 0.06 -1.7 (-3.3, -0.1) 
      
Rhinovirus3 (any) 109 (7.8) 79 (11.4) 0.69 (0.52, 0.91) <0.01 3.5 (0.8, 6.3) 
Rhinovirus with RSV  17 (1.2) 17 (2.4) 0.50 (0.26, 0.97) 0.04 1.2 (-0.1, 2.5) 
Rhinovirus without RSV 96 (6.9) 65 (9.3) 0.74 (0.55, 1.00) 0.05 2.4 (-0.1, 5.0) 
      
Rhinovirus type A 57 (4.1) 45 (6.5) 0.63 (0.43, 0.93) 0.03 2.4 (0.3, 4.5) 
Rhinovirus type A with RSV 9 (0.7) 9 (1.3) 0.50 (0.20, 1.25) 0.26 0.6 (-0.3, 1.6) 
Rhinovirus type A without RSV 48 (3.5) 36 (5.2) 0.67 (0.44, 1.02) 0.08 1.7 (-0.2, 3.6) 
      
Rhinovirus type B 6 (0.4) 2 (0.3) 1.50 (0.30, 7.41) 0.73 0.1 (-0.7, 0.41) 
Rhinovirus type B with RSV 1 (0.07) 0 (0.0) - 1.00 -0.1 (-0.2, 0.1) 
Rhinovirus type B without RSV 5 (0.4) 2 (0.3) 1.25 (0.24, 6.43) 1.00 -0.1 (-0.6, 0.4) 
      
Rhinovirus type C 48 (3.5) 37 (5.3) 0.65 (0.43, 0.99) 0.04 1.9 (-0.1, 3.8) 
Rhinovirus type C with RSV 6 (0.4) 9 (1.3) 0.33 (0.12, 0.93) 0.05 0.9 (0.0, 1.8) 
Rhinovirus type C without RSV 44 (3.2) 29 (4.2) 0.76 (0.48, 1.20) 0.26 1.0 (-0.7, 2.8) 
      
Parainfluenza Virus 1-4 40 (2.9) 15 (2.2) 1.33 (0.74, 2.40) 0.39 -0.7 (-2.1, 0.7) 











p-value1 Absolute rate 
reduction, cases per 
100 children (95%CI) 
Parainfluenza Virus 1-4 without RSV 39 (2.8) 14 (2.0) 1.39 (0.76, 2.55) 0.31 -0.8 (-2.1, 0.6) 
      
Human metapneumovirus 34 (2.4) 11 (1.6) 1.55 (0.79, 3.03) 0.26 -0.8 (-2.1, 0.4) 
Human metapneumovirus with RSV  5 (0.4) 6 (0.9) 0.42 (0.13, 1.36) 0.20 0.5 (-0.3, 1.3) 
Human metapneumovirus without RSV  29 (2.1) 5 (0.7) 2.90 (1.13, 7.46) 0.03 -1.4 (-2.3, -0.4) 
      
Adenovirus 27 (1.9) 15 (2.1) 0.90 (0.48, 1.68) 0.74 0.2 (-1.1, 1.5) 
Adenovirus with RSV  5 (0.4) 8 (1.2) 0.31 (0.10, 0.95) 0.04 0.8 (-0.1, 1.6) 
Adenovirus without RSV  23 (1.7) 8 (1.2) 1.44 (0.65, 3.20) 0.45 -0.5 (-1.5, 0.5) 
      
Influenza type A 24 (1.7) 5 (0.7) 2.40 (0.92, 6.26) 0.06 -1.0 (-1.9, -0.1) 
Influenza type A with RSV 1 (0.1) 1 (0.1) 0.50 (0.03, 7.98) 1.00 0.1 (-0.2, 0.4) 
Influenza type A without RSV 23 (1.7) 4 (0.6) 2.88 (0.99, 8.28) 0.04 -1.1 (-0.2, -2.0) 
      
Influenza type B 9 (0.7) 5 (0.7) 0.90 (0.30, 2.68) 1.00 0.1 (-0.7, 0.8) 
Influenza type B with RSV 2 (0.1) 0 (0.0) - 0.55 -0.1 (-0.3, 0.1) 
Influenza type B without RSV 7 (0.5) 5 (0.7) 0.70 (0.22, 2.20) 0.55 0.2 (-0.5, 0.9) 
      
Enterovirus 3 (0.2) 0 (0.0) - 0.55 -0.2 (0.5, 0.0) 
Enterovirus with RSV 1 (0.1) 0 (0.0) - 1.00 -0.1 (-0.2, 0.1) 
Enterovirus without RSV 2 (0.1) 0 (0.0) - 0.55 -0.1 (-0.3, 0.1) 
      
Coronavirus4 47 (3.4) 13 (1.9) 1.81 (0.98, 3.32) 0.05 -1.5 (-2.9, -1.3) 
Coronavirus with RSV 8 (0.6) 3 (0.4) 1.33 (0.35, 5.01) 0.76 -0.1 (-0.8, 0.5) 
Coronavirus without RSV 39 (2.8) 10 (1.4) 1.95 (0.98, 3.88) 0.07 -1.4 (-2.6, -1.3) 
      
Bocavirus 26 (1.2) 9 (1.3) 0.89 (0.39, 2.00) 0.83 0.1 (-0.9, 1.2) 
Bocavirus with RSV 4 (0.3) 6 (0.9) 0.33 (0.09, 1.78) 0.09 0.6 (-0.2, 1.3) 
Bocavirus without RSV 12 (0.9) 3 (0.4) 2.00 (0.57, 7.06) 0.41 -0.4 (-1.1, 0.3) 
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1Fishers exact test, alpha =0.05 
2Excludes n=2 placebo participants positive for RSV in the motavizumab trial but without a specimen available for testing for additional viruses. Only samples 
tested for RSV and other viruses could be categorized as ‘RSV only’ or ‘RSV with other viruses’. Denominators for calculation of relative risk and absolute rate 
reduction include the entire intention to treat population for each treatment arm. 
3Some Rhinovirus positive secretions were positive for more than one subtype, in which case they were counted as both; therefore the sum of participants with 
HRV-A + HRV-B + HRV-C  > total participants HRV. 
4Includes coronavirus types 229E, NL63, OC43, and HKU1
Figure 6.3.A Proportion of inpatient medically attended lower respiratory illness 
events in first 150 days of follow up with pathogen detected, with 95% confidence 
intervals 
Denominators include only samples tested for the pathogen in question (Motavizumab group: n=134 for 
RSV testing; n=112 for other viruses; n=105 for S. pneumoniae. Placebo group: n=127 for RSV testing; 
n=120 for other viruses; n=118 for S. pneumoniae.) 
Any HRV: any of human rhinovirus subtypes A, B, or C; HMPV: human metapneumovirus; PIV: any of 
parainfluzenza viruses 1-4; Flu A: influenza type A; Flu B: influenza type B; S. pneumoniae: Streptococcus 
pneumoniae carriage in the nasopharynx. 
*p<0.0
Figure 6.3.B Proportion of outpatient medically attended lower respiratory illness 
events in first 150 days of follow up with pathogen detected, with 95% confidence 
intervals 
 
Denominators include only samples tested for the pathogen in question (Motavizumab group: n=320 for 
RSV testing; n=280 for other viruses; n=269 for S. pneumoniae. Placebo group: n=213 for RSV testing; 
n=193 for other viruses; n=175 for S. pneumoniae.) 
Any HRV: any of human rhinovirus subtypes A, B, or C; HMPV: human metapneumovirus; PIV: any of 
parainfluzenza viruses 1-4; Flu A: influenza type A; Flu B: influenza type B; S. pneumoniae: Streptococcus 
pneumoniae carriage in the nasopharynx. 
*p<0.05
Figure 6.4.A Detection of pathogens at inpatient medically attended respiratory 
illness events occurring in the first 150 days of follow up in the motavizumab group 
by RSV- status, with 95% confidence intervals 
 
Denominators include only samples tested for the pathogen in question (RSV positive samples: n=19 for 
other viruses; n=19 for S. pneumoniae. RSV negative samples: n=93 for other viruses; n=86 for S. 
pneumoniae). 
Any HRV: any of human rhinovirus subtypes A, B, or C; HMPV: human metapneumovirus; PIV: any of 
parainfluzenza viruses 1-4; Flu A: influenza type A; Flu B: influenza type B; S. pneumoniae: Streptococcus 
pneumoniae carriage in the nasopharynx. 
*p<0.05 
Figure 6.4.B Detection of pathogens at inpatient medically attended respiratory 
illness events occurring in the first 150 days of follow up in the placebo group by 
RSV- status, with 95% confidence intervals 
 
Denominators include only samples tested for the pathogen in question (RSV positive samples: n=80 for 
other viruses; n=79 for S. pneumoniae. RSV negative samples: n=40 for other viruses; n=39 for S. 
pneumoniae). 
Any HRV: any of human rhinovirus subtypes A, B, or C; HMPV: human metapneumovirus; PIV: any of 
parainfluenza viruses 1-4; Flu A: influenza type A; Flu B: influenza type B; S. pneumoniae: Streptococcus 
pneumoniae carriage in the nasopharynx. 
*p<0.05 
Figure 6.4.C Detection of pathogens at outpatient medically attended respiratory 
illness events occurring in the first 150 days of follow up in the motavizumab group 
by RSV- status, with 95% confidence intervals 
 
Denominators include only samples tested for the pathogen in question (RSV positive samples: n=41 for 
other viruses; n=33 for S. pneumoniae. RSV negative samples: n=239 for other viruses; n=235 for S. 
pneumoniae). 
Any HRV: any of human rhinovirus subtypes A, B, or C; HMPV: human metapneumovirus; PIV: any of 
parainfluenza viruses 1-4; Flu A: influenza type A; Flu B: influenza type B; S. pneumoniae: Streptococcus 
pneumoniae carriage in the nasopharynx. 
*p<0.05 
Figure 6.4.D Detection of pathogens at outpatient medically attended respiratory 
illness events occurring in the first 150 days of follow up in the placebo group by 
RSV- status, with 95% confidence intervals 
 
Denominators include only samples tested for the pathogen in question (RSV positive samples: n=67 for 
other viruses; n=58 for S. pneumoniae. RSV negative samples: n=126 for other viruses; n=116 for S. 
pneumoniae). 
Any HRV: any of human rhinovirus subtypes A, B, or C; HMPV: human metapneumovirus; PIV: any of 
parainfluenza viruses 1-4; Flu A: influenza type A; Flu B: influenza type B; S. pneumoniae: Streptococcus 
pneumoniae carriage in the nasopharynx. 
*p<0.05 
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Table 6.3.A Baseline risk factors for subsequent medically attended wheeze outcomes in the motavizumab group 
1Family history of asthma, wheeze, eczema or hay fever defined as mother, father or sibling having a history of asthma, wheeze, eczema or hay fever. 
	
 ≥1 medically attended 
wheeze event 
N (%) 
RR (95%CI) Serious early childhood 
wheeze 
N (%) 
RR (95%CI) Recurrent wheeze 
N (%) 
RR (95%CI) 
Male       
Yes (n=696) 157 (22.6) 0.02 (0.76, 1.11) 81 (11.6) 0.81 (0.62, 1.06) 14 (2.0) 0.7 (0.36, 1.37) 
No (n=696) 171 (24.6)  100 (14.4)  20 (2.9)  
Attends day care       
Yes (n=43) 11 (25.6) 1.09 (0.65, 1.83) 9 (20.9) 1.64 (0.90, 2.98) 3 (7.0) 3.03 (0.96, 9.54) 
No (n=1348) 317 (23.5)  172 (12.8)  31 (23.0)  
Family history of asthma1       
Yes (n=292) 100 (34.2) 1.65 (1.36, 2.01) 56 (19.2) 1.69 (1.26, 2.25) 15 (5.1) 2.97 (1.53, 5.78) 
No (n=1099) 228 (20.7)  125 (11.4)  19 (0.2)  
Family history of wheeze       
Yes (n= 200) 66 (33.0) 1.50 (1.20, 1.88) 35 (17.5) 1.42 (1.02, 2.00) 6 (3.0) 1.28 (0.54, 3.05) 
No (n= 1192) 262 (22.0)  146 (12.2)  28 (2.3)  
Family history of hay fever       
Yes (n= 139) 43 (30.1) 1.36 (1.04, 1.78) 24 (17.3) 1.38 (0.93, 2.04) 6 (4.3) 1.93 (0.81, 4.58) 
No (n= 1251) 285 (22.8)  157 (12.5)  28 (2.2)  
Family history of eczema       
Yes (n=134) 39 (29.1) 1.26 (0.95, 1.68) 19 (14.2) 1.10 (0.71, 1.71) 5 (3.7) 1.62 (0.64, 4.11) 
No (n=1256) 289 (23.0)  162 (12.9)  29 (2.3)  
Smoke exposure       
Yes (n= 957) 221 (23.1) 0.94 (0.77, 1.15) 122 (12.7) 0.94 (0.70, 1.25) 24 (2.5) 1.09 (0.53, 2.26) 
No (n=434) 107 (24.7)  59 (13.6)  10 (2.3)  
Household crowding       
Yes (n=1088) 254 (23.3) 0.96 (0.76, 1.20) 130 (11.9) 0.71 (0.53, 0.96) 28 (2.6) 1.30 (0.54, 3.11) 
No (n=303) 74 (24.4)  51 (16.8)  6 (2.0)  
Other child <18 yrs in household       
Yes (n=1212) 288 (23.8) 0.69 (0.49, 0.97) 31 (2.6) 0.69 (0.49, 0.97) 31 (2.6) 1.53 (0.47, 4.94) 
No (n=179) 40 (22.3)  3 (1.7)  3 (1.7)  
Other child <6 yrs in household       
Yes (n=899) 221 (24.6) 1.13 (0.92, 1.39) 115 (12.8) 0.96 (0.72, 1.27) 20 (2.2) 0.78 (0.40, 1.54) 
No (n=493) 107 (21.7)  66 (13.4)  14 (2.8)  
Other child  <6 yrs in household, in day care       
Yes (n=144) 41 (28.5) 1.24 (0.94, 1.64) 28 (19.4) 1.59 (1.10, 2.28) 8 (5.6) 2.67 (1.23, 5.78) 
No (n=1248) 287 (23.0)  153 (12.2)  26 (2.1)  
	
	 200	
Table 6.3.B Baseline risk factors for subsequent medically attended wheeze outcomes in the placebo group 
aFamily history of asthma, wheeze, eczema or hay fever defined as mother, father or sibling having a history of asthma, wheeze, eczema or hay fever. 
 ≥1 medically attended 
wheeze event 
N (%) 
RR (95%CI) Serious early childhood 
wheeze 
N (%) 
RR (95%CI) Recurrent wheeze 
N (%) 
RR (95%CI) 
Male       
Yes (n=360) 83 (24.7) 0.99 (0.76, 1.28) 45 (13.3) 1.21 (0.81, 1.80) 8 (2.4) 1.07 (0.41, 2.82) 
No (n=336) 90 (25.0)  40 (11.1)  8 (2.2)  
Attends day care       
Yes (n=21) 2 (9.5) 0.38 (0.09, 1.41) 1 (4.8) 0.38 (0.06, 2.62) 0 (0.0) - 
No (n=675) 171 (25.3)  84 (12.4)  16 (2.4)  
Family history of asthmaa       
Yes (n= 135) 46 (34.1) 1.50 (1.14, 1.99) 26 (19.3) 1.83 (1.20, 2.79) 3 (2.2) 0.96 (0.28, 3.31) 
No (n=560) 127 (22.7)  59 (10.5)  13 (2.3)  
Family history of wheeze       
Yes (n= 103) 38 (36.9) 1.62 (1.21, 2.17) 23 (22.3) 2.14 (1.39, 3.28) 3 (2.9) 1.33 (0.39, 4.58) 
No (n=593 ) 135 (22.8)  62 (10.5)  13 (2.2)  
Family history of hay fever       
Yes (n= 72) 18 (25.0) 1.00 (0.66, 1.53) 11 (15.3) 1.29 (0.72, 2.31) 2 (2.8) 1.24 (0.29, 5.33) 
No (n= 623) 155 (24.9)  74 (11.9)  14 (2.2)  
Family history of Eczema       
Yes (n=76) 25 (32.9) 1.38 (0.97, 1.95) 15 (19.7) 1.75 (1.05, 2.89) 3 (3.9) 1.88 (0.55, 6.45) 
No (n=619) 148 (23.9)  70 (11.3)  13 (2.1)  
Smoke exposure       
Yes (n=471) 117 (24.8) 1.00 (0.76, 1.32) 58 (12.3) 1.03 (0.67, 1.57) 11 (2.3) 1.05 (0.37, 2.99) 
No (n=225) 56 (24.9)  27 (12.0)  5 (2.2)  
Household crowding       
Yes (n=537) 140 (26.1) 1.26 (0.90, 1.76) 71 (0.13) 1.50 (0.87, 2.59) 14 (2.6) 2.07 (0.48, 9.02) 
No (n=159) 33 (20.8)  14 (8.8)  2 (1.3)  
Other children <18 yrs in household       
Yes (n=601) 159 (26.5) 1.80 (1.09, 2.96) 78 (13.0) 1.76 (0.84, 3.70) 14 (2.3) 1.11 (0.25, 4.79) 
No (n=95) 14 (14.7)  7 (7.4)  2 (2.1)  
Other children <6 yrs in household       
Yes (n=447) 121 (27.1) 1.30 (0.97, 1.72) 61 (13.6) 1.42 (0.91, 2.21) 11 (2.5) 1.23 (0.43, 3.49) 
No (n=249) 52 (20.9)  24 (9.6)  5 (2.0)  
Other children <6 yrs in household, in day care       
Yes (n=68) 18 (26.5) 1.07 (0.71, 1.63) 10 (14.7) 1.23 (0.67, 2.27) 4 (5.9) 3.07 (1.02, 9.28) 
No (n=628) 155 (24.7)  75 (11.9)  12 (1.9)  
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Figure 6.5 Adjusted odds ratios for risk factors associated with sunsequent wheeze1 
 
1Multiple logistic regression models included the following: baseline characteristics associated with subsequent wheeze in the univariate analyses (Table 6.2.A 
and Table 6.2.B), pathogens detected at medically attended lower respiratory illness in the first 150 days of follow up associated with subsequent wheeze in the 
univariate analyses (Supplemental Tables 6.4-6.6), and an interaction term for inpatient RSV MALRI and treatment group. 
Figure 6.6 Increased risk of subsequent medically attended wheeze in motavizumab participants who had inpatient RSV 




Table 6.4 Characteristics associated with treatment failure (inpatient RSV medically attended respiratory illness in the first 150 days of 
follow up) in the motavizumab group compared to participants in the motavizumab group without treatment failure, and to placebo 
recipients with inpatient RSV medically attended respiratory illness in the first 150 days of follow up 
 










A vs. B 





A vs. C 
 n (%) n (%) Relative Risk (95%CI) n (%) Relative Risk (95%CI) 
Male 11 (52.4) 685 (50.0) 1.05 (0.69, 1.58) 33 (41.3) 1.27 (0.78, 2.06) 
Attends daycare 2 (9.5) 19 (3.0) 3.30 (0.79, 13.72) 3 (3.8) 2.54 (0.45, 14.29) 
Other child <18 in house 21 (100.0) 1191 (86.9) 1.15 (1.13, 1.17) 71 (88.8) 1.13 (1.04, 1.22) 
Other child <6 in house 21 (100.0) 877 (64.0) 1.56 (1.50, 1.63) 55 (68.8) 1.45 (1.25, 1.69) 
Other child <6 in house who 
attends daycare 
6 (28.6) 137 (10.0) 2.86 (1.43, 5.72) 8 (10.0) 2.86 (1.11, 7.34) 
Crowding 20 (95.2) 1068 (78.0) 1.22 (1.11, 1.35) 60 (75.0) 1.27 (1.08, 1.49) 
Smoke exposure 15 (71.4) 942 (68.8) 1.04 (0.79, 1.36) 22 (72.5) 0.99 (0.73, 1.33) 
Family history of atopy 10 (47.6) 421 (30.7) 1.55 (0.98, 2.44) 27 (33.6) 1.41 (0.82, 2.43) 
Family history of asthma1 6 (28.6) 286 (20.9) 1.37 (0.69, 2.71) 14 (17.5) 1.63 (0.71, 3.73) 
Family history of wheeze 6 (28.6) 194 (14.2) 2.02 (1.01, 4.02) 13 (16.3) 1.75 (0.76, 4.07) 
Family history of eczema 3 (14.3) 131 (9.6) 1.49 (0.52, 4.31) 13 (16.3) 0.88 (0.28, 2.80) 
Family history of hay fever 3 (14.3) 136 (9.9) 1.44 (0.50, 4.15) 7 (8.8) 1.63 (0.46, 5.78) 
Any late or missing study drug 17 (81.0) 633 (46.2) 1.75 (1.41, 2.17) 43 (53.8) 1.51 (1.13, 2.01) 
>1 inpatient MALRI 8 (38.1) - - 13 (16.3) 2.34 (1.12, 4.90) 
Had outpatient MALRI 9 (42.9) 305 (22.2) 1.93 (1.16, 3.19) 23 (28.8) 1.49 (0.82, 2.72) 
RSV detected alone at inpatient 
RSV MALRI 
11 (52.4) n/a n/a 44 (55.0) 0.95 (0.61, 1.50) 
 Mean (SD)  p-value2 Mean (SD) p-value2 
Mean number of inpatient MALRI 
events 
1.5 (0.7) 0.1 (0.03) <0.01 1.2 (0.5) 0.02 
Mean number outpatient MALRI 
events 
0.4 (0.5) 0.3 (0.6) 0.25 0.4 (0.7) 0.59 
Age at inpatient RSV MALRI 3.8 (2.3) n/a n/a 3.9 (2.1) 0.82 
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Figure 6.7 Motavizumab acts as a probe, revealing sub-group of infants at high risk for both severe RSV-MALRI in infancy 






Supplemental Tables and Figures 
 
Supplemental Table 6.1 Association between inpatient and outpatient medically attended lower respiratory events in the first 
150 days of follow up and subsequent medically attended wheeze outcomes 
 
 ≥1 medically attended wheeze event 
 
 Serious early childhood wheeze Recurrent wheeze 
Inpatient MALRI N (%) OR (95% CI) aOR1 (95% CI) N (%) OR (95% CI) aOR (95% CI) N (%) OR (95% CI) aOR (95% CI) 
Yes (n=231) 87 (37.7) 2.11 (1.58, 2.81) 2.04 (1.55, 2.74) 49 (21.2) 2.07 (1.58, 2.71) 2.00 (1.41, 2.84) 16 (6.9) 3.78 (2.12, 6.74) 4.15 (2.22, 7.74) 
No (n=1857) 414 (22.3)   217 (11.7)   34 (1.8)   
Outpatient MALRI          
Yes (n=511) 177 (34.6) 2.05 (1.65, 2.55) 1.96 (1.57, 2.44) 100 (19.6) 2.03 (1.44, 2.88) 2.00 (1.51 2.63) 20 (3.9) 2.06 (1.18, 3.59) 1.92 (1.07, 3.43) 
No (n=1577) 324 (24.0)   166 (10.5)   30 (1.9)   
1Adjusted for baseline risk factors for wheeze: family history of asthma, wheeze eczema, hay fever, household crowding, presence of another child <18 yrs, and 





Supplemental Table 6.2.A Association between virus detected at inpatient medically attended lower respiratory illness in the 
first 150 days of follow up and ≥1 subsequent medically attended wheeze event 
 
Placebo (n=696) Motavizumab (n=1,392) Combined (n=2,088) 
 N(%) RR (95%CI)  N(%) RR (95%CI)  N(%) RR (95%CI) 
RSV 1   RSV    RSV    
Yes (n=80) 51 (36.3) 1.55 (1.12, 2.14) Yes (n=21) 13 (61.9) 2.69 (1.90, 3.82) Yes (n=101) 42 (41.5) 1.80 (1.41, 2.30) 
No (n=616) 472 (23.3)  No (n=1,371) 315 (23.0)  No (n=1,986) 459 (13.1)  
HRV A    HRV A    HRV A   
Yes (n=14) 7 (50.0) 2.05 (1.20, 3.52) Yes (n=18) 7 (38.9) 1.66 (0.93, 2.99) Yes (n=32) 14 (43.8) 1.85 (1.24, 2.76) 
No (n=682) 516 (24.3)  No (n=1,374) 321 (23.3)  No (n=2,056) 487 (23.7)  
HRV B   HRV B    HRV B   
Yes (n=2) 1 (50.0) 2.02 (0.50, 8.12) Yes (n=2) 0 (0.0) - Yes (n=4) 1 (25.0) 1.04 (0.19, 5.70) 
No (n=694) 522 (24.8)  No (n=1,390) 328 (23.6)  No (n=2,084) 500 (24.0)  
HRV C   HRV C    HRV C   
Yes (n=19) 6 (31.6) 1.28 (0.65, 2.51) Yes (n=15) 6 (40.0) 1.71 (0.91, 3.20) Yes (n=34) 12 (35.3) 1.48 (0.93, 2.35) 
No (n=677) 167 (24.7)  No (n=1,377) 322 (23.4)  No (n=2054) 489 (23.8)  
PIV    PIV    PIV   
Yes (n=16) 9 (56.3) 2.33 (1.48, 3.67) Yes (n=14) 6 (57.1) 2.46 (1.55, 3.91) Yes (n=30) 17 (56.7) 2.41 (1.74, 3.33) 
No (n=680) 164 (24.1)  No (n=1,378) 320 (23.2)  No (n=2,058) 484 (23.5)  
HMPV    HMPV    HMPV   
Yes (n=12) 4 (33.3) 1.35 (0.60, 3.04) Yes (n=12) 5 (41.7) 1.78 (0.91, 3.50) Yes (n=24) 9 (37.5) 1.57 (0.93, 2.65) 
No (n=684) 169 (24.0)  No (n=1,380) 323 (23.4)  No (n=2064) 492 (23.8)  
Adeno    Adeno    Adeno   
Yes (n=10) 3 (30.0) 1.21 (0.47, 3.15) Yes (n=18) 5 (27.8) 1.18 (0.56, 2.50) Yes (n=28) 8 (28.6) 1.19 (0.66, 2.16) 
No (n=686) 170 (24.8)  No (n=1,374) 323 (23.5)  No (n=2060) 493 (23.9)  
Flu A    Flu A    Flu A    
Yes (n=7) 2 (28.6) 1.15 (0.35, 3.74) Yes (n=12) 1 (0.08) 0.35 (0.05, 2.30) Yes (n=19) 3 (15.8) 0.67 (0.23, 1.86) 
No (n=689) 171 (24.8)  No (n=1,380) 327 (23.7)  No (n=2069) 498 (24.1)  
Flu B    Flu B    Flu B    
Yes (n=1) 1 (100.0) 4.04 (3.55, 4.60) Yes (n=5) 1 (20.0) 0.84 (0.15, 4.91) Yes (n=6) 2 (33.3) 1.39 (0.45, 4.32) 
No (n=695) 172 (24.7)  No (n=1387) 327 (23.8)  No (n=2082) 499 (24.0)  
Boca    Boca    Boca    
Yes (n=2) 2 (100.0) 4.05 (3.56, 4.62) Yes (n=4) 2 (50.0) 2.13 (0.80, 5.70) Yes (n=6) 4 (66.7) 2.79 (1.58, 4.94) 
No (n=694) 171 (24.6)  No (n=1388) 326 (23.5)  No (n=2082) 497 (23.9)  
Coronavirus    Coronavirus    Coronavirus    
Yes (n=15) 5 (33.3) 1.35 (0.65, 2.80) Yes (n=13) 5 (38.5) 1.64 (0.82, 3.29) Yes (n=28) 10 (35.7) 1.50 (0.91, 2.48) 
No (n=681) 168 (24.7)  No (n=1379) 323 (23.4)  No (n=2060) 491 (23.8)  
S. pneumoniae    S. pneumoniae    S. pneumoniae    
Yes (n=71) 25 (35.2) 1.49 (1.05, 2.10) Yes (n=56) 20 (35.7) 1.55 (1.08, 2.23) Yes (n=127) 45 (35.4) 1.52 (1.19, 1.95) 
No (n=625) 148 (23.7)  No (n=1336) 308 (23.1)  No (n=1961) 456 (23.2)  
1Interaction by treatment group for risk of wheeze following inpatient RSV MALRI. No interaction by treatment group was found for any other pathogen. 
HRV A-C: human rhinovirus subtypes A-C; PIV: any of parainfluenza viruses 1-4; HMPV: human metapneumovirus; Adeno: adenovirus; Flu A: influenza type 
A; Flu B: influenza type B; Boca: bocavirus; S. pneumoniae: Streptococcus pneumoniae carriage in the nasopharynx 
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Supplemental Table 6.2.B Association between virus detected at outpatient medically attended lower respiratory illness in the 
first 150 days of follow up and ≥1 subsequent medically attended wheeze event 
 
Placebo (n=696) Motavizumab (n=1,392) Combined (n=2,088) 
 N(%) RR (95%CI)  N(%) RR (95%CI)  N(%) RR (95%CI) 
RSV    RSV    RSV    
Yes (n=69) 24 (35.8) 1.46 (1.03, 2.08) Yes (n=40) 13 (32.5) 1.39 (0.88, 2.20) Yes (n=109) 37 (33.9) 1.45 (1.10, 1.90) 
No (n=627) 149 (23.8)  No (n=1351) 315 (23.3)  No (n=1978) 464 (23.5)  
HRV A    HRV A    HRV A    
Yes (n=45) 16 (35.6) 1.47 (0.97, 2.24) Yes (n=57) 28 (49.1) 2.19 (1.65, 2.90) Yes (n=102) 44 (43.1) 1.87 (1.48, 2.38) 
No (n=651) 157 (24.1)  No (n=1335) 300 (22.5)  No (n=1986) 457 (23.0)  
HRV B    HRV B    HRV B    
Yes (n=2)  1 (50.0)  Yes (n=6) 2 (33.3) 1.42 (0.46, 4.41) Yes (n=8) 3 (37.5) 1.57 (0.64, 3.84) 
No (n=694) 172 (24.8) 2.02 (0.50, 8.12) No (n=1386) 326 (23.5)  No (n=2080) 498 (23.9)  
HRV C    HRV C    HRV C    
Yes (n=37) 23 (62.1) 2.73 (2.04, 3.64) Yes (n=48) 17 (35.4) 1.53 (1.03, 2.27) Yes (n=85) 40 (47.1) 2.04 (1.61, 2.60) 
No (n=659) 150 (22.8)  No (n=1344) 311 (23.1)  No (n=2003) 461 (23.0)  
PIV    PIV   PIV    
Yes (n=15) 6 (40.0) 1.63 (0.87, 3.07) Yes (n=40) 16 (40.0) 1.73 (1.17, 2.56) Yes (n=55) 22 (40.0) 1.70 (1.22, 2.37) 
No (n=681) 167 (24.5)  No (n=1352) 312 (23.1)  No (n=2033) 479 (23.6)  
HMPV    HMPV    HMPV    
Yes (n=11) 3 (27.2) 1.10 (0.42, 2.91) Yes (n=34) 20 (41.2) 1.78 (1.18, 2.69) Yes (n=45) 17 (37.8) 1.59 (1.09, 2.34) 
No (n=685) 170 (24.8)  No (n=1358) 314 (23.1)  No (n=2043) 484 (23.7)  
Adeno    Adeno    Adeno    
Yes (n=15) 5 (33.3) 1.35 (0.65, 2.80) Yes (n=27) 13 (48.1) 2.09 (1.39, 3.12) Yes (n=42) 18 (42.9) 1.82 (1.27, 2.60) 
No (n=681) 168 (24.7)  No (n=1365) 315 (23.1)  No (n=2046) 483 (23.6)  
Flu A    Flu A   Flu A    
Yes (n=5) 3 (60.0) 2.44 (1.18, 5.05) Yes (n=24) 7 (29.2) 1.24 (0.66, 2.34) Yes (n=29) 10 (34.5) 1.45 (0.87, 2.40) 
No (n=691) 170 (24.6)  No (n=1368) 321 (23.5)  No (n=2059) 491 (23.8)  
Flu B    Flu B   Flu B    
Yes (n=5) 2 (40.0) 1.62 (0.55, 4.77) Yes (n=9) 4 (44.4) 1.90 (0.91, 3.96) Yes (n=14) 6 (42.9) 1.80 (0.98, 3.30) 
No (n=691) 171 (24.7)  No (n=1383) 324 (23.4)  No (n=2074) 495 (23.9)  
Boca    Boca    Boca    
Yes (n=9) 3 (33.3) 1.35 (0.53, 3.42) Yes (n=16) 8 (50.0) 2.15 (1.30, 3.54) Yes (n=25) 11 (44.0) 1.85 (1.18, 2.90) 
No (n=687) 170 (24.7)  No (n=1376) 320 (23.3)  No (n=2063) 490 (23.8)  
Coronavirus    Coronavirus    Coronavirus    
Yes (n=13) 4 (30.7) 1.24 (0.54, 2.84) Yes (n=47) 17 (36.2) 1.56 (1.06, 2.32) Yes (n=60) 21 (35.0) 1.48 (1.04, 2.11) 
No (n=683) 169 (24.7)  No (n=1345) 311 (23.1)  No (n=2028) 480 (23.7)  
	
	 209	
S. pneumoniae    S. pneumoniae   S. pneumoniae   
Yes (n=98) 33 (33.7) 1.44 (1.05, 1.97) Yes (n=153) 61 (39.9) 1.85 (1.48, 2.31) Yes (n=251) 94 (37.5) 1.69 (1.41, 2.03) 
No (n=598) 140 (23.4)  No (n=1239) 267 (21.5)  No (n=1837) 407 (22.2)  
HRV A-C: human rhinovirus subtypes A-C; PIV: any of parainfluenza viruses 1-4; HMPV: human metapneumovirus; Adeno: adenovirus; Flu A: influenza type 
A; Flu B: influenza type B; Boca: bocavirus; S. pneumoniae: Streptococcus pneumoniae carriage in the nasopharynx. 
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Supplemental Table 6.3.A Association between virus detected at inpatient medically attended lower respiratory illness in the 
first 150 days of follow up and subsequent medically attended serious early childhood wheeze 
 
Placebo (n=696) Motavizumab (n=1,392) Combined (n=2,088) 
 N(%) RR (95%CI)  N(%) RR (95%CI)  N(%) RR (95%CI) 
RSV (+)1   RSV (+)   RSV (+)   
Yes (n=80) 14 (17.5) 1.52 (0.90, 2.56) Yes (n=21) 9 (0.43) 3.41 (2.04, 5.70) Yes (n=101) 23 (22.8) 1.86 (1.28, 2.72) 
No (n=616) 71 (11.5)  No (n=1370) 172 (12.6)  No (n=1986) 243 (12.2)  
HRV (+)   HRV (+)   HRV (+)   
Yes (n=32) 6 (18.8) 1.58 (0.74, 3.34) Yes (n=32) 7 (2.19) 1.71 (0.88, 3.34) Yes (n=64) 13 (20.2) 1.63 (0.99, 2.68) 
No (n=664) 79 (11.9)  No (n=1360) 174 (12.8)  No (n=2024) 253 (12.5)  
HRV A (+)   HRV A (+)   HRV A (+)   
Yes (n=14) 4 (28.6) 2.41 (1.03, 5.65) Yes (n=18) 3 (16.7) 1.29 (0.45, 3.65) Yes (n=32) 7 (21.9) 1.74 (0.89, 3.38) 
No (n=682) 81 (11.9)  No (n=1374) 178 (13.0)  No (n=2056) 259 (12.6)  
HRV B (+)   HRV B (+)   HRV B (+)   
Yes (n=2)  0 (0.0) - Yes (n=2) 0 (0.0) - Yes (n=4) 0 (0.0) - 
No (n=694) 85 (12.2)  No (n=1390) 181 (13.0)  No (n=2084) 266 (12.8)  
HRV C (+)   HRV C (+)   HRV C (+)   
Yes (n=19) 3 (15.8) 1.30 (0.45, 3.76) Yes (n=15) 4 (26.7) 2.07 (0.89, 4.86) Yes (n=34) 7 (20.6) 1.63 (0.84, 3.19) 
No (n=677) 82 (12.1)  No (n=1377) 177 (12.9)  No (n=2054) 259 (12.6)  
PIV (+)   PIV (+)   PIV (+)   
Yes (n=16) 6 (37.5) 3.23 (1.66, 6.28) Yes (n=14) 4 (28.6) 2.22 (0.96, 5.15) Yes (n=30) 10 (33.3) 2.68 (1.59, 4.50) 
No (n=680) 79 (11.6)  No (n=1378) 177 (12.8)  No (n=2058) 256 (12.4)  
HMPV (+)   HMPV (+)   HMPV (+)   
Yes (n=12) 1 (0.08) 0.68 (0.10, 4.48) Yes (n=12) 1 (0.08) 0.64 (0.10, 4.19) Yes (n=24) 2 (0.08) 0.65 (0.17, 2.47) 
No (n=684) 84 (12.3)  No (n=1380) 180 (13.0)  No (n=2064) 264 (12.7)  
Adeno (+)   Adeno (+)   Adeno (+)   
Yes (n=10) 2 (20.0) 1.65 (0.47, 5.80) Yes (n=18) 5 (27.8) 2.17 (1.02, 4.63) Yes (n=28) 7 (25.0) 1.99 (1.04, 3.81) 
No (n=686) 83 (12.1)  No (n=1374) 176 (12.8)  No (n=2060) 259 (12.6)  
Flu A (+)   Flu A (+)   Flu A (+)   
Yes (n=7) 2 (28.6) 2.37 (0.72, 7.78) Yes (n=12) 1 (0.08) 0.64, (0.10, 4.19) Yes (n=19) 3 (15.8) 1.24 (0.44, 3.53) 
No (n=689) 83 (12.0)  No (n=1380) 180 (13.0)  No (n=2069) 263 (12.7)  
Flu B (+)   Flu B (+)   Flu B (+)   
Yes (n=1) 0 (0.0) - Yes (n=5) 1 (20.0) 1.54 (0.27, 8.84) Yes (n=6) 1 (16.7) 1.31 (0.22, 7.86) 
No (n=695) 85 (12.2)  No (n=1387) 180 (13.0)  No (n=2082) 256 (12.7)  
Boca (+)   Boca (+)   Boca (+)   
Yes (n=2) 0 (0.0) - Yes (n=4) 1 (25.0) 1.93 (0.35, 10.58) Yes (n=6) 1 (16.7) 1.31 (0.22, 7.86) 
No (n=694) 85 (12.2)  No (n=1388) 180 (13.0)  No (n=2082) 265 (12.7)  
Coronavirus    Coronavirus   Coronavirus   
Yes (n=15) 3 (20.0) 1.66 (0.59, 4.66) Yes (n=13) 3 (23.0) 1.79 (0.66, 4.87) Yes (n=28) 6 (21.4) 1.70 (0.82, 3.48) 
No (n=681) 82 (12.0)  No (n=1379) 178 (12.9)  No (n=2060) 260 (12.6)  
S. pneumoniae    S. pneumoniae   S. pneumoniae   
Yes (n=71) 11 (15.5) 1.31 (0.73, 2.35) Yes (n=56) 13 (23.2) 1.85 (1.12, 3.30) Yes (n=127) 24 (18.9) 1.53 (1.05, 2.24) 
No (n=625) 74 (11.8)  No (n=1336) 168 (12.6)  No (n=1961) 242 (12.3)  
1Interaction by treatment group for risk of wheeze following inpatient RSV MALRI. No interaction by treatment group was found for any other pathogen. 
HRV A-C: human rhinovirus subtypes A-C; PIV: any of parainfluenza viruses 1-4; HMPV: human metapneumovirus; Adeno: adenovirus; Flu A: influenza type 
A; Flu B: influenza type B; Boca: bocavirus; S. pneumoniae: Streptococcus pneumoniae carriage in the nasopharynx. 
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Supplemental Table 6.3.B Association between virus detected at outpatient medically attended lower respiratory illness in the 
first 150 days of follow up and subsequent medically attended serious early childhood wheeze 
 
Placebo (n=696) Motavizumab (n=1,392) Combined (n=2,088) 
 N(%) RR (95%CI)  N(%) RR (95%CI)  N(%) RR (95%CI) 
RSV (+)   RSV (+)   RSV (+)   
Yes (n=69) 12 (17.4) 1.49 (0.86, 2.61) Yes (n=40) 8 (20.0) 1.56 (0.83, 2.95) Yes (n=109) 20 (18.3) 1.48 (0.98, 2.23) 
No (n=627) 73 (11.6)  No (n=1351) 173 (12.8)   No (n=1978) 246 (12.4)  
HRV A (+)   HRV A (+)   HRV A (+)   
Yes (n=45) 11 (24.4) 2.15 (1.23, 3.75) Yes (n=57) 17 (29.8) 2.43 (1.59, 3.71) Yes (n=102) 28 (27.5) 2.29 (1.63, 3.21) 
No (n=651) 74 (11.4)  No (n=1335) 164 (12.3)  No (n=1986) 238 (12.0)  
HRV B (+)   HRV B (+)   HRV B (+)   
Yes (n=2)  1 (50.0) 4.13 (1.02, 16.76) Yes (n=6) 2 (33.3) 2.58 (0.83, 8.07) Yes (n=8) 3 (37.5) 2.97 (1.20, 7.31) 
No (n=694) 84 (12.1)  No (n=1386) 179 (12.9)  No (n=2080) 263 (12.6)  
HRV C (+)   HRV C (+)   HRV C (+)   
Yes (n=37) 15 (40.5) 3.82 (2.44, 5.98) Yes (n=48) 10 (20.8) 1.64 (0.93, 2.89) Yes (n=85) 25 (29.4) 2.44 (1.72, 3.47) 
No (n=659) 70 (10.6)  No (n=1344) 171 (12.7)  No (n=2003) 241 (12.0)  
PIV (+)   PIV (+)   PIV (+)   
Yes (n=15) 2 (13.3) 1.09 (0.30, 4.04) Yes (n=40) 70 (25.0) 1.98 (1.14, 3.44) Yes (n=55) 12 (21.8) 1.75 (1.05, 2.92) 
No (n=681) 83 (12.2)  No (n=1352) 171 (12.6)  No (n=2033) 254 (12.5)  
HMPV (+)   HMPV (+)   HMPV (+)   
Yes (n=11) 2 (18.2) 1.50 (0.42, 5.34) Yes (n=34) 7 (20.6) 1.61 (0.82, 3.15) Yes (n=45) 9 (20.0) 1.59 (0.88, 2.88) 
No (n=685) 83 (12.1)  No (n=1358) 174 (12.8)  No (n=2043) 257 (12.6)  
Adeno (+)   Adeno (+)   Adeno (+)   
Yes (n=15) 4 (26.7) 2.24 (0.95, 5.32) Yes (n=27) 8 (29.6) 2.34 (1.29, 4.25) Yes (n=42) 12 (16.2) 2.30 (1.41, 3.76) 
No (n=681) 81 (11.9)  No (n=1365) 173 (12.7)  No (n=2046) 254 (12.4)  
Flu A (+)   Flu A (+)   Flu A (+)   
Yes (n=5) 1 (20.0) 1.65 (0.28, 9.61) Yes (n=24) 5 (20.8) 1.62 (0.73, 3.58) Yes (n=29) 6 (20.7) 1.64 (0.80, 3.37) 
No (n=691) 84 (12.1)  No (n=1368) 176 (12.9)  No (n=2059) 260 (12.6)  
Flu B (+)   Flu B (+)   Flu B (+)   
Yes (n=5) 1 (20.0) 1.65 (0.28, 9.61) Yes (n=9) 1 (11.1) 2.95 (1.54, 5.63) Yes (n=14) 2 (14.3) 1.12, (0.31, 4.07) 
No (n=691) 84 (12.2)  No (n=1383) 180 (13.0)  No (n=2074) 264 (12.7)  
Boca (+)   Boca (+)   Boca (+)   
Yes (n=9) 1 (11.1) 0.91 (0.14, 5.83) Yes (n=16) 6 (37.5) 2.94 (1.54, 5.63) Yes (n=25) 7 (28.0) 2.23 (1.18, 4.22) 
No (n=687) 84 (12.2)  No (n=1376) 175 (12.7)  No (n=2063) 259 (12.6)  
Coronavirus   Coronavirus   Coronavirus   
Yes (n=13) 1 (15.3) 1.27 (0.35, 4.60) Yes (n=47) 11 (23.4) 1.85 (1.08, 3.16) Yes (n=60) 13 (21.7) 1.73 (1.06, 2.85) 
No (n=683) 83 (12.2)  No (n=1345) 170 (12.6)  No (n=2028) 253 (12.5)  
S. pneumoniae    S. pneumoniae   S. pneumoniae   
Yes (n=98) 19 (19.4) 1.76 (1.11, 2.79) Yes (n=153) 37 (24.2) 2.08 (1.51, 2.86) Yes (n=251) 56 (22.3) 1.95 (1.50, 2.54) 
No (n=598) 66  (11.0)  No (n=1239) 144 (11.6)  No (n=1837) 210 (11.4)  
HRV A-C: human rhinovirus subtypes A-C; PIV: any of parainfluenza viruses 1-4; HMPV: human metapneumovirus; Adeno: adenovirus; Flu A: influenza type 
A; Flu B: influenza type B; Boca: bocavirus; S. pneumoniae: Streptococcus pneumoniae carriage in the nasopharynx.
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Supplemental Table 6.4.A Association between virus detected at inpatient medically attended lower respiratory illness in the 
first 150 days of follow up and subsequent medically attended recurrent wheeze 
 
Placebo (n=696) Motavizumab (n=1,392) Combined (n=2,088 
 N(%) RR (95%CI)  N(%) RR (95%CI)  N(%) RR (95%CI) 
RSV (+)1   RSV (+)   RSV (+)   
Yes (n=80) 3 (3.8) 1.78 (0.52, 6.10) Yes (n=21) 5 (23.8) 11.25 (4.83, 26.20) Yes (n=101) 8 (7.9) 3.75 (1.81, 7.77) 
No (n=616) 13 (2.1)  No (n=1370) 29 (2.1)  No (n=1986) 42 (2.1)  
HRV A (+)   HRV A (+)   HRV A (+)   
Yes (n=14) 3 (21.4) 11.24 (3.60, 35.09) Yes (n=18) 1 (5.6) 2.31 (0.33, 16.01) Yes (n=32) 4 (12.5) 6.24 (2.10, 18.52) 
No (n=682) 13 (1.9)  No (n=1374) 33 (2.4)  No (n=2056) 46 (2.2)  
HRV B (+)   HRV B (+)   HRV B (+)   
Yes (n=2)  0 (0.0) - Yes (n=2) 0 (0.0) - Yes (n=4) 0 (0.0) - 
No (n=694) 16 (2.3)  No (n=1390) 34 (2.4)  No (n=2084) 50 (2.4)  
HRV C (+)   HRV C (+)   HRV C (+)   
Yes (n=19) 1 (5.3) 2.40 (0.33, 17.07) Yes (n=15) 1 (6.7) 2.78 (0.41, 19.04) Yes (n=34) 2 (5.9) 2.61 (0.61, 11.21) 
No (n=677) 15 (2.2)  No (n=1377) 33 (2.4)  No (n=2054) 48 (2.3)  
PIV (+)   PIV (+)   PIV (+)   
Yes (n=16) 2 (12.5) 6.07 (1.50, 24.53) Yes (n=14) 1 (7.1) 2.98 (0.44, 20.31) Yes (n=30) 3 (10.0) 4.38 (1.44, 13.29) 
No (n=680) 14 (2.1)  No (n=1378) 33 (2.4)  No (n=2058) 47 (2.3)  
HMPV (+)   HMPV (+)   HMPV (+)   
Yes (n=12) 1 (8.3) 3.80 (0.54, 26.50) Yes (n=12) 0 (0.0) - Yes (n=24) 1 (4.2) 1.76 (0.25, 12.20) 
No (n=684) 15 (2.2)  No (n=1380) 34 (2.5)  No (n=2064) 49 (2.4)  
Adeno (+)   Adeno (+)   Adeno (+)   
Yes (n=10) 0 (0.0) - Yes (n=18) 0 (0.0) - Yes (n=28) 0 (0.0) - 
No (n=686) 16 (2.3)  No (n=1374) 34 (2.5)  No (n=2060) 50 (2.4)  
Flu A (+)   Flu A (+)   Flu A (+)   
Yes (n=7) 0 (0.0) - Yes (n=12) 0 (0.0)  Yes (n=19) 0 (0.0) - 
No (n=689) 16 (2.3)  No (n=1380) 34 (2.5)  No (n=2069) 50 (2.4)  
Flu B (+)   Flu B (+)   Flu B (+)   
Yes (n=1) 0 (0.0) - Yes (n=5) 1 (20.0) 8.41 (1.41, 50.10) Yes (n=6) 1 (16.7) 7.08 (1.16, 43.29) 
No (n=695) 16 (2.3)  No (n=1387) 33 (2.4)  No (n=2082) 49 (2.4)  
Boca (+)   Boca (+)   Boca (+)   
Yes (n=2) 0 (0.0) - Yes (n=4) 0 (0.0) - Yes (n=6) 0 (0.0) - 
No (n=694) 16 (2.3)  No (n=1388) 34 (2.4)  No (n=2082) 50 (2.4)  
Coronavirus    Coronavirus    Coronavirus   
Yes (n=15) 1 (6.3) 3.03 ( 0.43, 21.71) Yes (n=13) 1 (7.7) 3.21 (0.47, 21.77) Yes (n=6) 2 (7.1) 3.07 (0.78, 12.00) 
No (n=681) 14 (2.1)  No (n=1379) 33 (2.4)  No (n=2082) 48 (2.3)  
S. pneumoniae    S. pneumoniae   S. pneumoniae   
Yes (n=71) 3 (4.2) 2.03 (0.59, 6.96) Yes (n=56) 4 (7.1) 3.18 (1.16, 8.72) Yes (n=127) 7 (5.5) 2.51 (1.15, 5.47) 
No (n=625) 13 (2.1)  No (n=1336) 30 (2.2)  No (n=1961) 43 (2.2)  
1Interaction by treatment group for risk of wheeze following inpatient RSV MALRI. No interaction by treatment group was found for any other pathogen. 
HRV A-C: human rhinovirus subtypes A-C; PIV: any of parainfluenza viruses 1-4; HMPV: human metapneumovirus; Adeno: adenovirus; Flu A: influenza type 
A; Flu B: influenza type B; Boca: bocavirus; S. pneumoniae: Streptococcus pneumoniae carriage in the nasopharynx.
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Supplemental Table 6.4.B Association between virus detected at outpatient medically attended lower respiratory illness in the 
first 150 days of follow up and subsequent medically attended recurrent wheeze 
 
Placebo (n=696) Motavizumab (n=1,392) Combined (n=2,088) 
 N(%) RR (95%CI)  N(%) RR (95%CI)  N(%) RR (95%CI) 
RSV (+)   RSV (+)   RSV (+)   
Yes (n=69) 1 (6.3) 0.61 (0.08, 4.52) Yes (n=40) 1 (2.5) 1.02 (0.14, 7.30) Yes (n=109) 2 (1.8) 0.76 (0.19, 3.07) 
No (n=627) 15 (2.4)  No (n=1351) 33 (2.4)  No (n=1978) 48 (2.4)  
HRV A (+)   HRV A (+)   HRV A (+)   
Yes (n=45) 3 (6.7) 3.34 (0.99, 11.29) Yes (n=57) 3 (5.3) 2.27 (0.71, 7.19) Yes (n=102) 6 (5.9) 2.66 (1.16, 6.09) 
No (n=651) 13 (2.0)  No (n=1335) 31 (2.3)  No (n=1986) 44 (2.2)  
HRV B (+)   HRV B (+)   HRV B (+)   
Yes (n=2) 0 (0.0) - Yes (n=6) 0 (0.0) - Yes (n=8) 0 (0.0) - 
No (n=694) 16 (2.3)  No (n=1386) 34 (2.5)  No (n=2080) 50 (2.4)  
HRV C (+)   HRV C (+)   HRV C (+)   
Yes (n=37) 3 (8.1) 4.11 (1.22, 13. 80) Yes (n=48) 1 (2.1) 0.85 (0.12, 6.08) Yes (n=85) 4 (4.7) 2.05 (0.76, 5.56) 
No (n=659) 13 (2.0)  No (n=1344) 33 (2.5)  No (n=2003) 46 (2.3)  
PIV (+)   PIV (+)   PIV (+)   
Yes (n=15) 0 (0.0) - Yes (n=40) 3 (7.5) 3.27 (1.04, 10.25) Yes (n=55) 3 (5.5) 2.36 (0.76, 7.35) 
No (n=681) 16 (2.3)  No (n=1352) 31 (2.3)  No (n=2033) 47 (2.3)  
HMPV (+)   HMPV (+)   HMPV (+)   
Yes (n=11) 0 (0.0) - Yes (n=34) 2 (5.9) 2.50 (0.62, 10.00) Yes (n=45) 2 (4.4) 1.89 (0.47, 7.54) 
No (n=685) 16 (2.3)  No (n=1358) 32 (2.4)  No (n=2043) 48 (2.3)  
Adeno (+)   Adeno (+)   Adeno (+)   
Yes (n=15) 2 (13.3) 6.49 (1.61, 26.05) Yes (n=27) 1 (3.7) 1.53 (0.22, 10.80) Yes (n=42) 3 (7.1) 3.11 (1.01, 9.59) 
No (n=681) 14 (2.1)  No (n=1365) 33 (2.4)  No (n=2046) 47 (2.3)  
Flu A (+)   Flu A (+)   Flu A (+)   
Yes (n=5) 0 (0.0) - Yes (n=24) 1 (4.2) 1.73 (0.25, 12.12) Yes (n=29) 1 (3.4) 1.45 (0.21, 10.14) 
No (n=691) 16 (2.3)  No (n=1368) 33 (2.4)  No (n=2059) 49 (2.4)  
Flu B (+)   Flu B (+)   Flu B (+)   
Yes (n=5) 0 (0.0) - Yes (n=9) 0 (0.0) - Yes (n=14) 0 (0.0) - 
No (n=691) 16 (2.3)  No (n=1383) 34 (2.5)  No (n=2074) 50 (2.4)  
Boca (+)   Boca (+)   Boca (+)   
Yes (n=9) 0 (0.0) - Yes (n=16) 1 (6.3) 2.61 (0.38, 17.91) Yes (n=25) 1 (4.0)  
No (n=687) 16 (2.3)  No (n=1376) 33 (2.4)  No (n=2063) 49 (2.4)  
Coronavirus   Coronavirus    Coronavirus   1.68 (0.24, 11.72) 
Yes (n=13) 0 (0.0) - Yes (n=47) 5 (10.6) 4.93 (2.00, 12.18) Yes (n=60) 5 (8.3) 3.76 (1.55, 9.12) 
No (n=683) 16 (2.3)  No (n=1345) 29 (2.2)  No (n=2028) 45 (2.2)  
S. pneumoniae    S. pneumoniae   S. pneumoniae   
Yes (n=98) 3 (3.1) 1.41 (0.41, 4.85) Yes (n=153) 10 (6.5) 3.37 (1.65, 6.92) Yes (n=251) 13 (5.2) 2.57 (1.39, 4.77) 
No (n=598) 13 (2.2)  No (n=1239) 24 (1.9)  No (n=1837) 37 (2.0)  
*Interaction by treatment group for risk of wheeze following inpatient RSV MALRI. No interaction by treatment group was found for any other pathogen. 
HRV A-C: human rhinovirus subtypes A-C; PIV: any of parainfluenza viruses 1-4; HMPV: human metapneumovirus; Adeno: adenovirus; Flu A: influenza type 
A; Flu B: influenza type B; Boca: bocavirus; S. pneumoniae: Streptococcus pneumoniae carriage in the nasopharynx. 
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Supplemental Table 6.5 Medically attended acute lower respiratory illness events in 
the first 150 days of follow up in participants with motavizumab treatment failure1 
 
  Inpatient MALRI2 Outpatient MALRI 







































1* 1 1.5 RSV A 29 29 - - - - 0 - 
2* 1 1.7 RSV A 36 10 - - - - 0 - 
3* 1 1.2 RSV A 36 36 - - - - 0 - 
4* 1 1.4 RSV A 41 16 - -  - 0 - 




6* 1 5.8 RSV A 41 19 - - - - 1 PIV-3 
7* 1 9.9 RSV B3 118 10 - - - - 0 - 
8* 1 5.1 RSV B 103 33 - - - - 1 HRV C, CoV NL63 









60 34 - - - - 0 - 
11* 1 3.1 RSV A, Boca 92 28 - -  - 0 - 
12* 1 5.9 RSV B, Flu A 51 51
d - - - - 0 - 
13* 1 2.5 RSV A, Adeno 60 4 - - - - 0 - 






36 - 2.0 RSVA 58 28 1 RSV B, HRV A 
15* 2 2.2 RSV B 49 49 5.3 PIV 4 141 1264 1 PIV-4 




34 34 5.5 RSV B, HRV C 69 69
4 0 - 
















69 16 0 - 
19 2 1.9 RSV A 49 - 3.7 HRV C 101 - 1 HRV A 








 6.4 HMPV 126 3 - - - - - - 
21 3 1.0 RSV-negative3 113 - 4.2 RSV A
3 - - 0 - 
21 – 3rd 
inpatient 
MALRI 
 4.4 RSV A3 - - - - - - - - 
*Participant had at least one late or missed dose of study drug during the trial 
1Treatment failure defined as one or more inpatient RSV medically attended lower respiratory illness 
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2Medically attended lower respiratory illness 
3Sample not available for additional viral testing 
4Plus at least one missed dose before this medically attended lower respiratory illness 
HRV A-C: human rhinovirus subtypes A-C; Cov: coronavirus; PIV: any of parainfluenza viruses 1-4; 
HMPV: human metapneumovirus; Adeno: adenovirus; Flu A: influenza type A; Flu B: influenza type B; 




Chapter 7: Evaluating the risk of respiratory syncytial virus lower respiratory 
illness in the second RSV season after disease prevention with immunoprophylaxis 





Respiratory syncytial virus (RSV) associated lower respiratory illness is a leading cause 
of child morbidity and is most severe in early infancy. To what extent this is attributable 
to young age and to what extent it is due to the experience of a primary infection is not 
fully understood. Recently, a phase three randomized trial of a next-generation RSV 
monoclonal antibody, motavizumab, was shown to have high efficacy for the prevention 
of inpatient and outpatient RSV-associated medically attended lower respiratory illness 
(MALRI) in a population of healthy full term infants during their first winter RSV 
season. We assessed whether there was increased risk of RSV MALRI in this population 
in the second RSV season following RSV MALRI prevention in the first season.	
	
Methods: 	
Infants less than six months of age by December 31st of any of the four years of 
enrollment in the motavizumab trial were enrolled and prophylaxed with monthly doses 
of motavizumab or placebo for five total doses through the first winter RSV season (150 
days following randomization). Nasopharyngeal samples were collected at every MALRI 
for three years following enrollment in the motavizumab trial. We tested stored 
nasopharyngeal samples collected at MALRI events that occurred during the RSV season 





We observed no increased relative risk of RSV-MALRI events in the second season for 
the motavizumab group compared to the placebo group (RR 1.09 (95%CI 0.79, 1.50, 
equivalent to a <1% increase in absolute risk). Participants with RSV MALRI in the first 
RSV season were less likely to have an RSV MALRI, but more likely to have a non-RSV 




We found no statistical difference in rates of medically attended RSV illness, either 
inpatient or outpatient or both, by treatment group in the second RSV season. This 
reassures that there is not a substantial increased risk of medially attended respiratory 
events attributable to RSV in the second year of life among children who had protection 
against RSV disease as infants. We did observe a 9% relative increase in the rate of any 
RSV MALRI in the second RSV season for the motavizumab treatment group compared 
to the placebo treatment group that was not statistically significant, and which 
corresponded to a <1% absolute increase in the rate of any RSV MALRI. We also 
observed a trend of decreased severity of RSV MALRI in the second season compared to 
the first season for both treatment groups. The proportion of MALRI events in the second 
RSV season with samples collected within the analytic window that were available for 
RSV testing reduced our statistical power to detect true differences in rates of RSV 
MALRI between treatment groups in this time period. However, the small magnitude of 
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the increase in risk that we observed in the motavizumab group, combined with less 
severe RSV MALRI in the second compared to the first year of life, provides strong 
support for the benefit of delaying primary RSV lower respiratory illness beyond infancy. 
 
Conclusion:  
Young age and the experience of a primary infection are both thought to contribute to 
elevated risk of severe illness with RSV in infancy. We found no significant increase in 
RSV MALRI in the second RSV season after preventing RSV MALRI with 
motavizumab in the first RSV season.  Our results support the argument of a significant 
overall public health benefit to delaying the primary lower respiratory illness until the 






Respiratory syncytial virus (RSV) is a leading cause of child morbidity, with 
approximately 3.2 million annual hospital admissions and 59,600 – 118,200 deaths in 
children less than five years of age in 2015 [29]. The burden of severe RSV illness is 
disproportionately borne by infants less than six months of age, who are estimated to 
make up 45% of RSV-associated hospital admissions and deaths among children [29]. 
While RSV-ALRI incidence peaks at ages 3-5 months, it remains elevated during the 
second year of life before declining thereafter [29].  By two years of age, more than 80% 
of children have experienced an RSV infection, the majority of which are mild upper 
airway illnesses, with two thirds of primary infections occurring in the first year [12]. 
Protection against subsequent episodes of infection and disease following a primary RSV 
infection is limited and wanes over time [38], with a unique characteristic of the virus 
being its ability to cause re-infection throughout the lifetime [12, 38, 286, 287]. The 
precise timeframe of the protective period following natural infection is not completely 
understood, but has been estimated to be approximately 6 months in children [38].  
 
Young infants are at highest risk of developing severe disease with RSV-infection, but it 
is not fully understood to what extent this can be attributed to the immaturity of their 
immune system, anatomical factors, or to the experience of a primary infection [32]. 
Studies comparing the severity of primary versus subsequent RSV infections in children 
provide conflicting information and can be confounded by age. Some have found 
subsequent reinfections to be less severe than primary infections [12], while others have 
found no difference [38, 39]. If a substantial fraction of the risk of severe RSV illness is 
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attributed to the experience of the primary infection, regardless of age at which it occurs, 
we would expect to see an increased incidence of severe RSV-illness in children whose 
primary infection is delayed beyond infancy compared to those with a primary infection 
in infancy, controlling for all other factors. This has implications for future immunization 
strategies that prevent RSV-illness early in life but do not offer sustained protection 
through childhood. One method to assess the relative contribution of primary infection to 
the frequency and severity of RSV lower respiratory illness is to compare illness 
outcomes in a population where a subgroup has been randomized to receive an 
intervention that significantly reduces the incidence of primary RSV disease in infancy. 
Such an opportunity is provided by a randomized, double blinded, phase three clinical 
trial of a next generation RSV monoclonal antibody (motavizumab) that showed high 
efficacy for the prevention of RSV-associated medically attended lower respiratory 
illness (RSV-MALRI) events in a cohort of healthy, full term infants [140]. In this study, 
participants were followed through two subsequent winter RSV seasons following the 
first RSV season in which they were randomized to receive prophylaxis.  With each 
medically attended lower respiratory illness (MALRI) event, nasopharyngeal secretions 
were collected. Here we assess whether infants randomized to receive motavizumab in 
their first winter RSV season (thus delaying their primary RSV illness) experienced an 
increase in RSV-MALRI frequency or severity in their second winter RSV season, 







The full methods of the phase 3 double-blinded placebo controlled randomized trial of 
motavizumab (the parent study) have been published elsewhere [140]. Briefly, healthy 
Native American infants living on the Navajo Nation, White Mountain Apache and San 
Carlos Apache Indian reservations who were born at full-term (≥36 weeks gestation) and 
were less than 6 months of age at the time of enrollment, were randomized to receive 
either motavizumab or placebo during the winter RSV season (5 monthly doses, 2:1 
randomization). Four cohorts of infants were enrolled over four consecutive RSV seasons 
between 2004 and 2009, for a total of 2127 participants.  The current sub-study excluded 
the San Carlos Apache reservation participants, bringing the total number of participants 
to 2088 (1,392 participants randomized to motavizumab, 696 randomized to placebo). 
 
Evaluation of medically attended lower respiratory tract illness (MALRI) 
Study participants were followed from the time of study enrollment through three years 
of age and assessed for inpatient and outpatient medically attended lower respiratory tract 
illness. Lower respiratory tract illness events were reviewed for inclusion by study 
investigators and were defined as a medical diagnosis of bronchiolitis or pneumonia. In 
the absence of such a medical diagnosis, the occurrence of the lower respiratory illness 
was determined by the study investigator’s review of the medical records for the presence 
of lower respiratory signs and symptoms including cough, retractions, ronchi, wheezing, 





Nasopharyngeal secretions collected within five days of the MALRI event date (hospital 
admission for inpatient events; doctor visit date for outpatient events) were considered to 
be within the analytic window and were included in the analysis. A nasopharyngeal 
specimen was collected at every MALRI visit. The collection of nasal wash secretions 
involved instilling 15 – 20 cc of Ringer’s lactate solution into each nostril of a seated 
child with a bulb syringe and collecting it from the opposite nostril. In children who 
could not have a nasal wash specimen collected, a nasal aspirate was obtained by 
instilling 3 – 6 cc of sterile saline into the nose and withdrawing nasal mucus using a 
feeding tube with a suction device.  One milliliter of nasopharyngeal specimen was 
mixed with 6 ml viral transport medium and then divided into 4 – 8 aliquots which were 
snap frozen immediately using liquid nitrogen or an ethanol/dry ice bath, and stored at -
70°C. At facilities where snap freezing was not possible, aliquots were immediately 
stored at -80°C.  After freezing, aliquots were shipped to central laboratories for storage. 
Those collected within 150 days of randomization (the RSV season) were tested for RSV 
A and B by PCR assay for the primary efficacy analysis. Aliquots of untested specimen 
remained in storage at -80°C with continuous temperature monitoring.  
 
Definition of the second RSV season and selection of samples 
We defined the ‘RSV season’ as the continuous time period between the middle of 
October of one year through the end of May of the following year.  This definition is 
consistent with the enrollment and follow up periods for the motavizumab parent study, 
where children were enrolled between October 15th and December 31st, and were 
followed for medically attended RSV illness for 150 days following enrollment, with the 
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end of 150 day follow up falling between March 16th and May 30th, depending on the 
participant’s enrollment date. For all participants in this analysis, the second RSV season 
was defined as the period of time between October 15th and May 30th in the calendar 
year(s) following study enrollment (Table 7.1).  Specimens eligible for testing were those 
collected within five days of an inpatient or outpatient event that occurred during the 
second RSV season and which was determined to be a lower respiratory illness. 
 
Specimen testing for this sub-study 
For the present sub-study, stored nasopharyngeal secretions from events that occurred 
during the second RSV season were tested for RSV A and RSV B by a real-time PCR 
multiplex viral panel. For the multiplex panel, 350ul of nasal sample was extracted using 
the NucliSENS EasyMag kit (bioMerieux, Marcy l’Etoile, France) with an RNA eluate 
volume of 25ul. 10ul of eluate was used for the real-time NxTAG® Respiratory Pathogen 




Statistical analyses were performed using STATA13 (StataCorp. 2013. College Station, 
TX). 2,088 participants provided 81% power (assuming a two-sided alpha of 0.05) to 
show increased risk of RSV hospitalization in the motavizumab group assuming a 8% 
RSV hospitalization rate in the placebo group and a 12% RSV hospitalization rate in the 
motavizumab group (a 50% increase). The intention to treat analysis included all 
participants who were enrolled in the parent study, with the exception of participants at 
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one study site for whom IRB approval for this sub-study was not sought. The per-
protocol analysis included all participants who received all five doses of the study drug in 
their first RSV season and who remained in the study at the beginning of the second RSV 
season. The proportion of study participants with the study endpoints were compared 
with the Fisher exact test, with exact CI calculated for the relative risk. Chi-square and 
Student’s t-tests were used for pairwise comparisons. P-values <0.05 were considered 
significant.  A sensitivity analysis was conducted to take into account participants who 
had a respiratory event with no RSV test result available, as well as those who were lost 
to follow up.  
 
Ethical Approval 
Informed consent for participation in this study was obtained from a parent or guardian of 
participants. Approval for this study was obtained from the Johns Hopkins Bloomberg 
School of Health IRB, the Phoenix Area Indian Health Service IRB, and the Navajo 




Out of the 2,088 participants enrolled in the motavizumab trial, 1,876 (89.8%) remained 
in the study at the start of the second RSV season, while the remaining 212 (10.2%) were 
lost to follow up. Loss to follow up did not differ by treatment group (motavizumab: 




The mean age of participants who remained in the study at the beginning of the second 
RSV season was 11.6 months (range 9.5 months – 15.5 months). Approximately one 
third of the participants (34.1% [640 / 1,876]) experienced at least one MALRI event 
during the second season period, with 7.7% (144/1,876) experiencing at least one 
inpatient MALRI and 30.0% (561/1,876) experiencing at least one outpatient MALRI. 
Some participants experienced multiple events (Figure 7.1). When calculating and 
comparing rates of illness between treatment groups, we considered only the first event. 
Rates of all-cause inpatient MALRI were lower for both treatment groups in the second 
compared to the first RSV seasons (Table 7.2). Rates of all-cause outpatient MALRI 
were the same in both seasons for the placebo group, but higher in the second compared 
to the first season for the motavizumab group (Table 7.2). For both the motavizumab and 
placebo treatment groups, the proportion of MALRI events that were inpatient events was 
lower in the second RSV season compared to the first RSV season (Table 7.2). The mean 
age at inpatient MALRI events during the second RSV season (16.4 months) was not 
different than the mean age at outpatient events (16.1 months, p=0.21).   
 
 
A total of 894 MALRI events occurred during the second season, with hospitalizations 
accounting for 17.2% (155/894) and outpatient events accounting for 82.7% (739/894). 
All of the stored nasopharyngeal specimens from MALRI events that were collected 
within the analytic window and could be located were tested for RSV, with 120/155 
(77.4%) of all inpatient MALRI events and 480/894 (54.0%) of all outpatient events 
having a specimen tested (Figure 7.2). There was no difference in mean age at event or in 
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treatment group assignment for samples that were located and tested compared to those 
that were not (Table 7.3). 
 
Of the 600 events with samples tested in the second RSV season, RSV was detected in 
162 (27%), and was more frequently detected in inpatient compared to outpatient events 
(43/120 (35.8%) vs. 119/480 (24.8%)) respectively, p=0.02).  RSV was detected 
November through May of the second season, with peak frequency occurring between 
January and March, when the mean age of participants was 14.6 months – 16.6 months 
(Figure 7.3).  There was no difference in mean age for participants with inpatient RSV 
MALRI (16.5 months) compared to outpatient RSV MALRI (16.6 months, p=0.73). 
There was also no difference in age for participants with inpatient RSV MALRI (16.5 
months) compared to those with inpatient non-RSV MALRI (16.2 months, p=0.61), but 
participants with outpatient RSV MALRI were older than those with outpatient non-RSV 
MALRI (16.6 months vs. 15.7 months, p<0.001). Participants with RSV MALRI in the 
first season had a (non-significant) reduction in rates of RSV MALRI in the second 
season, but an increase in rates of non-RSV MALRI in the second season, compared to 
those without RSV MALRI in the first season (Table 7.4). 
 
As previously reported, the efficacy for motavizumab in the first RSV season was 87% 
for the prevention of inpatient RSV MALRI and 71% for the prevention of outpatient 
RSV MALRI [140]. We observed no statistically significant difference by treatment 
group in the proportion of participants with at least one MALRI, RSV-MALRI, or non-
RSV-MALRI event in the second RSV season (Table 7.5). The results were consistent in 
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the per protocol analysis (Table 7.6).  In a sensitivity analysis of the ITT population, there 
remained no difference in RSV inpatient or outpatient event rates in the second RSV 
season by treatment group when assuming frequency of RSV detection was the same in 
tested as in untested specimens, or when assuming all untested specimens were RSV-
positive (Supplemental Tables 7.1 and 7.2). The same was true for a sensitivity analysis 
of participants lost to follow up (Supplemental Table 7.3).  Within the MALRI events 
with a specimen collected and tested for RSV, there was a trend of increased detection of 
RSV in the motavizumab treatment group compared to the placebo group for both 
inpatient and outpatient MALRI events, though this did not reach statistical significance 
(Table 7.7, Figure 7.4). In the motavizumab group 27.0% (30/111) of second season 






It has been reported previously that motavizumab was highly effective for preventing 
RSV-associated medically attended illness compared to placebo when administered to 
healthy term infants during the first RSV season of life [140]. In the current study, we 
observed no significant difference in rates of medically attended RSV-illness, either 
inpatient or outpatient or both, by treatment group in the second RSV season of life. 
Similarly, we observed no difference in RSV severity (measured as the proportion of 
RSV illness events that resulted in hospitalization) by treatment group.  These findings 
are consistent with an observational study of RSV transmission in early childhood, which 
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found age to be a greater predictor of severe illness with RSV infection than the primary 
nature of the infection [38].  
 
Interestingly, we observed that compared to those without RSV MALRI in the first 
season, participants who experienced RSV MALRI in the first RSV season were less 
likely to have an RSV MALRI illness in the second RSV season but more likely to have a 
non-RSV MALRI during that time period. It may be that children who experienced RSV 
MALRI in the first season had increased risk factors for respiratory illness in the form of 
environmental exposures or host characteristics that persisted through the second season. 
Their experience of an RSV illness in the first season may have offered some immune 
protection from severe illness upon secondary infection, while they remained at increased 
risk for respiratory illnesses from other pathogens. 
 
A limitation of this study is that we were only able to test samples from 77% of inpatient 
events and 54% of outpatient events that occurred in the second RSV season. The 
proportion of events without available samples did not differ by treatment group, so it is 
unlikely that missing data introduced bias into our analysis of risk of RSV MALRI by 
treatment group. However, only tested samples could contribute to the numerator events 
which were used to calculate MALRI rates in the second season, which could have 
exaggerated the relative reduction in second compared to first season events that we 
observed. The sample size for the parent study was calculated for children experiencing 
RSV MALRI events in the first year of life, when risk of respiratory hospitalizations is 
highest. A limitation of this study was the constrained statistical power to detect a 
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difference in RSV MALRI rates between the two treatment groups given the reduced rate 
of respiratory hospitalizations in the second year of life. Loss to follow up between 
enrollment and the start of the second RSV season, as well as incomplete specimen 
collection, further reduced statistical power. Awareness that the primary objective of the 
parent study was to assess motavizumab efficacy in the first RSV season may have 
reduced study staff prioritization to collect NP specimens from children in the second 
year of life, evidenced by specimen collection in 75-95% of MALRI events in the first 
season and in 71-83% of MALRI events in the second season. We assume that all 
MALRI events occurring in the second RSV season were captured, as all participants 
enrolled in the study use the Indian Health Service facilities that served as our study sites. 
It is possible that some events occurred while children were out of the area, but we do not 
expect that this would have differed by treatment group, and therefore should not have 
biased our inferences. 
 
Overall, our results provide reassurance of no significant increase in RSV disease in the 
second RSV season following immunoprophylaxis in the first. We did, however, observe 
a non-significant 9% increase in RSV MALRI rates in the second RSV season for the 
motavizumab treatment group compared to the placebo treatment group, which was 
consistent in both the ITT and PPP analyses. We also observed a non-significant increase 
in the proportion of specimens from motavizumab group participants with RSV detected, 
compared to placebo participants. It may be that the increased frequency of primary RSV 
infections in the second RSV season results in a greater number of lower respiratory 
illness episodes, which in turns results in more medically attended events among the 
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motavizumab recipients that are RSV associated. However, if such an effect exists, it is 
of a small enough magnitude that our study lacked the power to detect it conclusively. 
Furthermore, if the small relative increase in rates of RSV MALRI that we observed for 
the motavizumab group truly does exist, it would correspond to a very small (<1%) 
absolute increase in RSV MALRI in the second season. Overall, we have shown that 
delaying primary RSV-illness beyond the most vulnerable period of young infancy 
significantly decreased the burden of medically attended RSV lower respiratory illness in 
our study population from birth through two years of age. These findings support the case 
for the development of RSV vaccines and immunoprophylaxis products to prevent RSV-
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Tables and Figures 
	
Table 7.1 Timing of first and second RSV seasons for the four enrollment cohorts in 
the motavizumab trial 
 
  RSV Season 1 RSV Season 2 
  Start 
Study day 0 
End 







       
 Enrollment 
Start1  
11/15/04 4/14/05 10/15/05 334 5/30/06 561 
 Enrollment 
End2 
12/30/04 5/29/05 10/15/05 289 5/30/06 516 
        
Enrollment 
Cohort 2 
       
 Enrollment 
Start 
10/17/05 3/16/06 10/15/06 363 5/30/07 590 
 Enrollment 
End 
12/30/05 5/29/06 10/15/05 289 5/30/07 516 
        
Enrollment 
Cohort 3 
       
 Enrollment 
Start 
11/30/06 4/29/07 10/15/07 319 5/30/08 547 
 Enrollment 
End 
12/31/06 5/30/07 10/15/07 288 5/30/08 516 
        
Enrollment 
Cohort 4 
       
 Enrollment 
Start 
10/15/07 3/13/08 10/15/08 366 5/30/09 593 
 Enrollment 
End 
12/31/07 5/29/08 10/15/08 289 5/30/09 516 
1The first date of enrollment of a participant in this cohort 








Figure 7.1 Number of all-cause medically attended lower respiratory illness 
(MALRI) events during the second RSV season, among participants with at least 
one MALRI event 
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Table 7.2 Rates of medically attended lower respiratory illness events in the first 
and second RSV seasons, by treatment group 
 
 RSV Season 1 RSV Season 2 p-value 
    
Motavizumab Group n=1,392 n=1,2501  
Any MALRI 390 (28.0%) 423 (33.8%) <0.01 
Inpatient MALRI 115 (8.3%) 98 (7.8%) 
0.72 
Outpatient MALRI 314 (22.6%) 368 (29.4%) <0.001 
    
Placebo Group n=696 n=6261  
Any MALRI 278 (39.9%) 217 (34.7%) 0.05 
Inpatient MALRI 116 (16.7%) 46 (7.4%) <0.001 
Outpatient MALRI 197 (28.3%) 193 (30.8%) 0.32 
    
Proportion of all 
MALRI events that 
were inpatient 
   
Motavizumab 144/540 (26.7%) 104/592 (17.6%) <0.001 











Figure 7.2 Medically attended lower respiratory illness events in the second RSV 




Table 7.3 Medically attended lower respiratory illness events occurring during the second RSV season with nasopharyngeal 
samples collected and tested for RSV  
 
  Age Treatment Group 
  Mean age,  
mo (SD) 





Inpatient    n= 85 n= 44  
 Tested (n=120) 16.3 (2.7) 0.62 78 (91.8) 42 (95.5) 0.44 
 Not Tested (n=9) 16.8 (3.2)  7 (8.2) 2 (4.6)  
Outpatient    n=344 n=180  
 Tested (n=480) 15.9 (2.7) 0.06  313 (91.0) 167 (92.8) 0.48 
 Not Tested (n=44) 15.1 (3.1)  31 (9.0) 13 (7.2)  
All Events    n=429 n=224  
 Tested (n=600) 16.0 (2.7) 0.13  391 (91.1) 209 (93.3) 0.34 
 Not Tested (n=53) 15.4 (3.1)  38 (8.9) 15 (6.7)  
1Student’s t-test 










Table 7.4 Rates of RSV medically attended respiratory illness in the second RSV season, by RSV status in the first season1 
 
 Any MALRI 
in second 
season2 
Relative Risk  
(95% CI) 













event in first 
season (n=95) 
41 (43.2%) 1.28 (1.01, 1.63) 0.06 5 (3.1%) 0.62 (0.26, 1.50) 0.28 27 (26.7%) 1.31 (0.94, 1.83) 0.13 
No RSV inpatient 
event in first 
season (n=1,781) 
599 (33.6%)   96 (5.0%)   405 (20.4%)   
          
RSV outpatient 
event in first 
season (n=104) 
43 (41.3%) 1.23 (0.97, 1.56) 0.11 6 (5.5%) 0.70 (0.32, 1.54) 0.37 34 (31.2%) 1.55 (1.16, 2.08) <0.01 
No RSV 
outpatient event 
in first season 
(n=1,772) 
597 (33.7%)   156 (7.9%)   398 (20.1%)   
          
          




1.28 (1.07, 1.53) 
0.01 11 (5.6%) 
0.62 (0.34, 1.12) 0.10 
61 (30.8%) 1.39 (1.11, 1.75) <0.01 
          
No RSV MALRI 
in first season 
(n=1,876) 
556 (33.1%)   151 (9.0%)   371 (22.1%)   
          
1Restricted to participants not lost to follow up at the beginning of season 2 
2Includes participants for whom a specimen was not collected at MALRI event occurring in second season, or collected but not available for RSV testing  
3Numerators in this category are drawn only from the subgroup of 77% of inpatient events and 65% of outpatient events in the second season with samples 
collected and tested.  
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p-value Absolute rate 
reduction, cases per 
100 children 
(95%CI) 
      
All-cause      
Inpatient MALRI 98 (7.0) 46 (6.6) 1.06 (0.76, 1.49) 0.71 -0.4 (-2.7, 1.9) 
Outpatient MALRI 368 (26.4) 193 (27.7) 0.95 (0.82, 1.11) 0.53 1.3 (-2.8, 5.3) 
Any MALRI 423 (30.4) 217 (31.1) 0.97 (0.85, 1.11) 0.71 0.8 (-3.4, 5.0) 
RSV-associated1      
Inpatient RSV MALRI 30 (2.4) 13 (2.1) 1.16 (0.61, 2.20) 0.66 -0.3 (-1.7, 1.1) 
Outpatient RSV MALRI 81  (6.5) 38 (6.1) 1.07 (0.73, 1.55) 0.73 -0.4 (-2.7, 1.9) 
Any RSV MALRI 111 (8.9) 51 (8.1) 1.09  (0.79, 1.50) 0.59 -0.7 (-3.4, 1.9) 
Non RSV-associated1      
Non-RSV Inpatient MALRI 47 (3.8) 27 (4.3) 0.87 (0.55, 1.39) 0.72 0.5 (-1.2, 2.2) 
Non-RSV Outpatient RSV MALRI 255 (18.3) 132 (19.0) 0.95 (0.80, 1.13) 0.57 0.6 (-2.9, 4.2) 
Any RSV MALRI 283 (20.3) 149 (21.4) 0.95 (0.80, 1.13) 0.57  1.1 (-2.6, 4.8) 
1Numerators in this category are drawn only from the subgroup of 77% of inpatient events and 65% of outpatient events in the second season with samples 
collected and tested.  
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p-value Absolute rate 
reduction, cases per 
100 children 
(95%CI) 
      
All-cause      
Inpatient MALRI 92 (8.3) 42  (7.6) 1.09 (0.77, 1.55) 0.70 -0.7 (-3.5, 2.0) 
Outpatient MALRI 336 (30.5) 171 (31.1) 0.98 (0.84, 1.14) 0.82 0.6 (-4.1, 5.3) 
Any MALRI 388 (35.2) 193 (35.1) 1.00 (0.87, 1.15) 1.00 0.1 (-5.0, 4.8) 
RSV-associated1      
Inpatient RSV MALRI 28 (2.5) 13 (2.4) 1.07 (0.56, 2.06) 1.00 -0.1 (-1.8, 1.4) 
Outpatient RSV MALRI 77  (7.0) 32 (5.8) 1.20 (0.81, 1.79) 0.40 -1.1 (-3.6, 1.3) 
Any RSV MALRI 105 (9.5) 45 (8.2) 1.16  (0.83, 1.63) 0.41 -1.3 (-4.2, 1.5) 
Non RSV-associated1      
Non-RSV Inpatient MALRI 46 (4.2) 25 (4.5) 0.92 (0.57, 1.49) 0.70 0.4 (-1.7, 2.5) 
Non-RSV Outpatient RSV MALRI 234 (21.2) 121 (22.0) 0.97 (0.97, 1.17) 0.75 0.7 (-3.5, 5.0) 
Any RSV MALRI 261 (23.7) 136 (24.7) 0.96 (0.80, 1.15) 0.67 1.0 (-3.4, 5.4) 
1Numerators in this category are drawn only from the subgroup of 77% of inpatient events and 65% of outpatient events in the second season with samples 









Table 7.7 RSV prevalence by treatment group, among MALRI events with specimens tested1 
MALRI Event Type Treatment Group RSV positive 
N (%) 
p-value2 
Inpatient    
 Motavizumab (n=78)  30 (38.5) 0.41 
 Placebo (n=42)  13 (31.0)  
    
Outpatient    
 Motavizumab (n=313) 81 (25.9) 0.45 
 Placebo (n=167)  38 (22.8)  
    
Any Event    
 Motavizumab (n=391) 111 (28.4) 0.30 
 Placebo (n=209) 51 (24.4)  




Figure 7.4 Proportion of MALRI events testing positive for RSV1 by RSV season and treatment group 
 
1Out of events with NP samples collected and tested 
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Supplemental Tables and Figures 
 
Supplemental Table 7.1 Sensitivity analysis for events with missing RSV result for inpatient medically attended lower 











Number of participants with RSV inpatient 
event 
30 (2.2%) 13 (1.9%) 1.07 (0.56, 2.06) 1.00 
Number of participants with inpatient event, 
with sample tested 
74 37 - - 
Number of participants with inpatient event, 
with no sample tested 
24 9 - - 
Number of additional 
hospitalizations based on rate #13 
10 3 - - 
Number of participants with RSV 
inpatient event, based on rate #2 
40 (2.9%) 16 (2.3%) 1.25 (0.71, 2.22) 0.48 
Number of additional 
hospitalizations based on rate #24 
24 9 - - 
Number of participants with RSV 
inpatient event, based on rate #2 
54 (3.9%) 22 (3.2%) 1.23 (0.75, 2.00) 0.46 
1Exact 95% confidence interval of relative risk 
2p-value based on Fisher’s exact test 
3Rate 1:Assume proportion of RSV+ results is the same for tested as for untested specimens, within each treatment group (30/74 (40.5% positive) for 
motavizumab; 13/37 (35.1% positive) for placebo) and apply this proportion to untested specimens 






Supplemental Table 7.2 Sensitivity analysis for events with missing RSV result for outpatient medically attended lower 











Number of participants with RSV inpatient 
event 
81  (5.8%) 38 (5.5%) 1.07 (0.73, 1.55) 0.77 
Number of participants with inpatient event, 
with sample tested 
225 117 - - 
Number of participants with inpatient event, 
with no sample tested 
143 74 - - 
Number of additional 
hospitalizations based on rate #13 
51 24 - - 
Number of participants with RSV 
inpatient event, based on rate #2 
132 (9.5%) 62 (8.9%) 1.06 (0.80, 1.42) 0.69 
Number of additional 
hospitalizations based on rate #24 
143 74 - - 
Number of participants with RSV 
inpatient event, based on rate #2 
224 (16.0%) 100 (14.4%) 1.12 (0.90, 1.39) 0.34 
1Exact 95% Confidence interval of relative risk 
2p-value based on Fisher’s exact test 
3Rate 1:Assume proportion of RSV+ results is the same for tested as for untested specimens, within each treatment group (81/225 (36.0% positive) for 
motavizumab; 38/117 (32.5% positive) for placebo) and apply this proportion to untested specimens 
4Rate 2: Assume all participants with a missing test result had an RSV+ result
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Supplemental Table 7.3 Sensitivity analysis for participants lost to follow up before 










Participants with MALRI2 inpatient 
event in second season 
98/1,2503 (7.8%) 46/6263 (7.3%) 1.07 (0.76, 1.49) 0.71 
Participants with MALRI outpatient 
event in second season 
368/1,250 (29.4%) 193/626 
(30.8%) 
0.95 (0.83, 1.10) 0.54 
Number of participants lost to follow up 
before second RSV season 
142 70 - - 
Number of additional 
hospitalizations based on rate 
#14 
11 5 - - 
Participants with inpatient 
event, based on rate #1 
109/1,3925 (7.8%) 62/6965 (8.9%) 0.88 (0.65, 1.18) 0.40 
Number of additional 
outpatient events based on rate 
#1 
42 22 - - 
Participants with outpatient 
event, based on rate #1 
410/1,392 (29.5%) 215/696 
(30.9%) 
0.95 (0.83, 1.09) 0.50 
Number of additional 
hospitalizations based on rate 
#26 
142 70 - - 
Participants with inpatient 
event, based on rate #2 
240/1,392 (17.2%) 116/696 
(16.7%) 
1.03 (0.85, 1.27) 0.74 
Number of additional 
outpatient events based on rate 
#2 
142 70 - - 
Participants with outpatient 
event, based on rate #2 
510/1,392 (36.6%) 263/696 
(37.8%) 
0.98 (0.87, 1.11) 0.78 
Participants with inpatient RSV 
MALRI second season 
30/1,250 (2.4%) 13/696 (1.9%) 1.28 (0.67, 2.45) 0.44 
Participants with outpatient RSV 
MALRI second season 
81/1,250 (6.5%) 38/696 (5.5%) 1.17 (0.82, 1.73) 0.37 
Number of additional RSV 
hospitalizations based on rate 
#37 
3 1 - - 
Participants with RSV 
inpatient event, based on rate 
#3 
33/1,392 (2.4%) 14/696 (2.0%) 1.18 (0.63, 2.19) 0.60 
Number of additional RSV 
outpatient events based on rate 
#3 
9 4 - - 
Participants with RSV 
outpatient event, based on rate 
#3 
90/1,392 (6.5%) 42/696 (6.0%) 1.07 (0.75, 1.53) 0.70 
Number of RSV additional 
hospitalizations based on rate 
#48 
142 70 - - 
Participants with RSV 
inpatient event, based on rate 
#4 
172/1,392 (12.4%) 83/696 (11.9%) 1.04 (0.81, 1.32) 0.78 
Number of additional RSV 
outpatient events based on rate 
#4 
142 70 - - 
Participants with RSV 
outpatient event, based on rate 
#4 
223/1,392 (16.0%) 108/696 (15.%) 1.03 (0.84, 1.27) 0.77 
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1p-value based on Fisher’s exact test 
2Medically attended lower respiratory illness 
3Denominator for participants remaining in study at the start of the second RSV season 
4Rate 1: Assume proportion of participants lost to follow up (LTFU) with MALRI events is the same as for 
participants who remained in the study, and apply this proportion to those LTFU  
5Denominator for all participants, including those LTFU 
6Rate 2: Assume all participants lost to follow up had an inpatient and outpatient event 
7Rate 3: Assume proportion of participants lost to follow up (LTFU) with RSV MALRI events is the same 
as for participants who remained in the study, and apply this proportion to those LTFU. 






Chapter 8: Discussion 
Summary of Study Findings 
	
 
Interventions to prevent RSV disease in infancy, including vaccine candidates and an 
extended half-life monoclonal antibody, are rapidly advancing through clinical trials and 
may be considered for licensure within the next five to ten years [100]. Because the use 
of RSV immunoprophylaxis products has so far been restricted to high-risk infants, our 
understanding of how prevention of RSV disease in the general infant population may 
affect other acute respiratory illnesses and subsequent outcomes is limited. Drawing on 
the only clinical trial, to our knowledge, of an RSV immunoprophylaxis product in a 
healthy full term infant population, the findings from this thesis research will contribute 
to narrowing the gap in this evidence base. 
 
 
8.1.1 Objective 1: To evaluate the role of RSV MALRI prevention on the prevalence 
and density of Streptococcus pneumoniae carriage in the infant nasopharynx  
  
A growing evidence base supports the hypothesis that RSV and S. pneumoniae can 
interact synergistically to cause lower respiratory illness in children. Although S. 
pneumoniae carriage in the nasopharynx is common in childhood and does not usually 
result in lower respiratory illness, it is a required step for progression to pneumococcal 
disease. High nasopharyngeal colonization density is associated with pneumococcal 
pneumonia in children, which implies a role for the perturbation of pneumococcus in the 
nasopharynx on the progression to disease and the pathogenesis of pneumonia. The goal 
of this research objective was to assess whether preventing RSV lower respiratory illness 
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in infancy through prophylaxis with motavizumab was associated with reduced S. 
pneumoniae carriage in the nasopharynx, both in terms of overall prevalence and 
bacterial density. We hypothesized that the potential action of motavizumab against RSV 
in the upper respiratory tract could reduce interaction between these two pathogens in 
that space, thereby decreasing the presence and density of pneumococcus in the 
nasopharynx and reducing the risk of developing pneumococcal pneumonia in those with 
RSV MALRI compared to those without RSV MALRI. We also hypothesized that those 
prophylaxed with motavizumab could have reduced risk of pneumococcal pneumonia and 
that high pneumococcal density, which is a marker of pneumococcal pneumonia, would 
therefore be observed less frequently in the motavizumab treatment group. We found 
increased density, but not prevalence, of S. pneumoniae colonization of the nasopharynx 
in lower respiratory illnesses that were associated with RSV compared to those not 
associated with RSV. We observed a corresponding reduction in the density of 
pneumococcal carriage at medically attended lower respiratory illness events that 
occurred in the motavizumab treatment group compared to the placebo treatment group, 
although this did not reach statistical significance. We believe this provides further 
evidence that prevention of RSV lower respiratory tract disease may prevent LRI beyond 
RSV disease alone and provides a strong basis for the inclusion of pneumococcal 
outcomes in trials of RSV vaccines and additional monoclonal products. 
 
8.1.2 Objective 2: To evaluate the impact of RSV MALRI prevention in infancy on 
MALRI with other respiratory viruses, and on subsequent medically attended 
wheezing at ages one to three years 
 
Several observational studies have demonstrated an association between RSV illness in 
early infancy and an increased risk for subsequent wheeze or asthma. The motavizumab 
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trial, however, showed no difference by treatment group in rates of subsequent medically 
attended wheeze through 3 years of age, despite a significant reduction in RSV illness in 
infancy. The goal of this objective was to measure rates of medically attended lower 
respiratory illness associated with non-RSV viruses in children who were randomized to 
receive motavizumab or placebo throughout the RSV season, and to evaluate the 
independent contribution of RSV and other viruses to the risk of subsequent medically 
attended wheeze at ages one to three years. We hypothesized that some other, non-RSV, 
exposure was independently associated with risk of subsequent wheeze in this population, 
and that this might explain the lack of difference by treatment we observed in the 
subsequent wheezing outcomes. We detected viruses in approximately 90% of medically 
attended lower respiratory illnesses occurring during the winter season, with rhinovirus 
and RSV predominating. Motavizumab showed efficacy for preventing both lower 
respiratory illness with RSV alone and with RSV in combination with other viruses. For 
less severe illness (outpatient compared to inpatient events), however, motavizumab 
efficacy was reduced when other viruses were detected along with RSV compared to 
when RSV was detected alone. We believe this is evidence that some of the outpatient 
RSV associated events were attributable to other viruses with RSV either as a bystander 
or a co-infecting pathogen of the lower respiratory tract. The fact that the efficacy of 
motavizumab was equivalent for inpatient events with RSV alone or RSV in combination 
with other viruses supports a causal association of RSV for these more severe events. We 
did not find RSV illness in infancy to be independently associated with subsequent 
wheeze in this population, but did find that family history of asthma, exposure to other 
children who attend daycare, and medically attended respiratory illness with rhinovirus, 
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parainfluenza viruses, and coronaviruses in the first year of life were independently 
associated with subsequent medically attended wheeze between ages one and three. We 
also found that for the small group of infants who had an RSV hospitalization despite 
being prophylaxed with motavizumab, the risk of subsequent wheeze was significantly 
increased compared to placebo recipients who also had an RSV hospitalization, even 
after controlling for other risk factors. Our hypothesis is that there are a subset of children 
in the study population who have a host risk factor, or set of risk factors, that not only 
puts them at risk of serious illness when they have RSV infection, but that also increases 
their risk for subsequent wheeze in the future, independent of the RSV infection itself. 
Motavizumab is acting like a probe, revealing through prophylaxis failures a subgroup of 
children in the community who are inherently at high risk for wheezing.   
 
 
8.1.3 Objective 3: To evaluate the risk of RSV MALRI in the second year of life 
following the prevention of RSV MALRI with motavizumab immunoprophylaxis in 
infancy 
 
In the general population, infants less than five months of age are at highest risk for 
severe RSV disease, whereas older children tend to experience less severe illness with 
their RSV infections. The heightened risk of severe disease in young infants may be due 
to age-related factors including the immaturity of their immune systems and smaller 
bronchioles that are more easily obstructed. The increased risk of severe disease in this 
group may also be a consequence of the primary exposure to RSV, as re-infection has 
been shown in some studies to be less severe than the primary infection, though many of 
these studies are confounded by age. If a substantial fraction of the risk of severe RSV 
illness is attributed to the experience of the primary infection, regardless of age at which 
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it occurs, we would expect to see an increased incidence of severe RSV-illness in 
children whose primary infection is delayed beyond infancy, controlling for all other 
factors. The goal of this research objective was therefore to assess whether preventing 
RSV illness in infancy led to an increased risk of RSV associated medically attended 
lower respiratory illness in the second season of life in the motavizumab group compared 
to the placebo group. We found no statistical difference in rates of medically attended 
RSV illness, either inpatient or outpatient or both, by treatment group in the second RSV 
season, reassuring that there is not a substantial increased risk of medially attended 
respiratory events attributable to RSV in the second year of life among children who had 
protection against RSV disease as infants. We did observe a 9% relative increase in RSV 
MALRI in the second RSV season for the motavizumab compared to the placebo 
treatment group that was not statistically significant. This corresponded to an absolute 
rate increase of less than 1%. We also observed a trend of decreased severity of RSV 
MALRI in the second season compared to the first season for both treatment groups. The 
proportion of MALRI events with samples collected in the analytic window that were 
available for testing reduced our statistical power to detect true differences in rates of 
RSV MALRI between treatment groups in the second season. However, the small 
magnitude of the (non-statistically significant) increase in risk that we observed in the 
motavizumab group, in combination with less severe RSV MALRI in the second season 
provides strong support for the benefit of delaying primary RSV lower respiratory illness 
beyond infancy. 
 




Our findings have implications for (1) the design of RSV vaccine and 
immunoprophylaxis efficacy trials and (2) for the investment case for such products. 
 
An important finding from our research was the reduced efficacy we observed for 
outpatient RSV medically attended lower respiratory illness when other viruses are co-
detected, compared to outpatient medically attended lower respiratory illness with RSV 
detected alone. Our finding implies that as the severity of RSV related disease increases, 
there is an increased likelihood that these are truly RSV attributable and therefore 
preventable by vaccine or monoclonal antibodies. For events that are less severe the 
finding of RSV has a lower likelihood, albeit still high, of causal attribution.  This has 
particular implications for efficacy evaluations of vaccine and monoclonal antibody 
products that do not produce sterilizing immunity. While a substantial proportion of 
medically attended RSV disease burden occurs in outpatient settings, the fraction of 
lower respiratory illness in these settings that is causally associated with RSV is likely 
reduced compared to illness that warrants hospital admission. As the clinical severity 
threshold for RSV MALRI case definitions in efficacy trials is lowered, greater numbers 
of RSV-positive cases may be detected, but the product efficacy may be simultaneously 
driven down as the proportion of co-infections with respiratory viruses increases. This 
should be taken into consideration as case definitions for future trials are evaluated. It 
also provides a reason to evaluate respiratory secretions collected as part of RSV vaccine 




Our research has potential implications for the investment case for future RSV vaccines 
and immunoprophylaxis products. Our findings suggest that there may be a role for RSV 
prevention in the reduction of transmission of S. pneumoniae and, by extension, a role for 
RSV vaccination in reducing the incidence of pneumococcal pneumonia in vaccinated 
children and in their communities through indirect protection. This warrants additional 
research (as described in section 8.4 below) and could be particularly relevant to settings 
that continue to have a high burden of bacterial pneumonia.  
 
Our work also highlights the need for a better understanding of the role of RSV 
prevention on subsequent wheeze and childhood asthma so that the impact of vaccination 
on these outcomes can be more accurately predicted. Given the complexity of 
host/environment interactions in the development of asthma, it is possible that RSV-
illness prevention in infancy will have a differential impact on incidence of subsequent 
wheeze and childhood asthma depending on the characteristics of the settings and 
populations where it is used.  Finally, our work indicates no significant increase in risk of 
RSV associated lower respiratory illness in the second RSV season following 
immunoprophylaxis in the first, nor does it indicate significant viral replacement with 
motavizumab – an important consideration for vaccine introduction and one that has not 
been demonstrated previously in the context of RSV prevention in healthy infants.  
 
 
8.3 Strengths and Limitations 
	
	
A significant strength of this work was derived from it being embedded in a large, 
rigorously conducted double-blind randomized trial. We were fortunate to be able to 
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leverage the significant financial resources dedicated to generating the primary data and 
specimens, as well as the time required to conduct three years of follow up over four 
RSV seasons. From a methodological standpoint, the double-blinded randomized design 
of the motavizumab trial allowed us to evaluate associations within a study design that 
provides the strongest possible evidence of causation that can be achieved in 
epidemiologic studies. An additional advantage provided by the motavizumab trial was 
the opportunity to evaluate our research questions in a population of healthy full term 
infants. Given that this will be the likely target population for future licensed RSV 
vaccines, it is important to be able to generalize our findings to this group. 
 
This research was also limited by some aspects of being embedded as part of a larger 
study. The parent study was designed to evaluate the efficacy of motavizumab for the 
prevention of (primarily inpatient) medical attended lower respiratory illness attributable 
to RSV. It was not designed to answer the questions we posed as part of this thesis work, 
and if we were designing studies de novo to address these research objectives we would 
have structured some aspects of them differently. 
 
To better address the question of how RSV and S. pneumoniae interact synergistically in 
lower respiratory illness, we would have ideally included an outcome measure of 
pneumococcal pneumonia rather than nasopharyngeal colonization alone. Since this is a 
much rarer event than viral LRI, particularly in populations where PCV is used routinely, 
a significantly larger sample size would have been required to measure this association. 
Our study was also limited by only having access to nasopharyngeal samples. Serological 
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testing for RSV antibodies would also be beneficial to evaluate the presence of prior RSV 
infection in instances where the virus may have already been cleared from the 
nasopharynx. Pneumococcal colonization density can provide a useful proxy measure for 
risk of pneumococcal disease in children but a better study design to evaluate the 
association between colonization density and RSV infection would have included routine 
longitudinal sampling in order to assess whether preceding RSV infection predisposes to 
pneumococcal colonization, as hypothesized. In our investigation we also lacked 
pneumococcal serotype information, which could have provided additional insight into 
differences in colonization between those who were prophylaxed compared to those who 
were not. 
 
All of our investigations relied on available specimens from the parent trial. In the first 
RSV season, respiratory events were less likely to have an available stored sample for 
testing if they came from the motavizumab group, or if they were RSV-negative. Because 
we measured rates of other viral illnesses in the first RSV season and only events with a 
sample collected could contribute to the numerators used in the rate calculations, there 
could have been differential misclassification bias whereby participants in the placebo 
group were more likely to be assigned as having an RSV or other viral lower respiratory 
illness compared to the motavizumab group. This could have led to an overestimation of 
the true efficacy of motavizumab for the prevention of viral lower respiratory illness. 
However, the sensitivity analysis that we conducted indicated that this was not likely the 
case, and the fact that we did not observe overall efficacy of motavizumab for prevention 
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of illness with non-RSV viruses provides some assurance that misclassification did not 
occur in a substantial number of participants.  
 
The motavizumab trial design provided an ideal platform for the assessment of increased 
risk of RSV illness in the second RSV season, but because respiratory hospitalization 
rates significantly decrease in the second year of life, there was reduced statistical power 
to detect these second year events. This was compounded by a lower proportion of 
medically attended illnesses having nasopharyngeal samples collected, which further 
reduced our available sample size.  
 
 
8.4 Future Research and Next Steps 
	
	
Our findings highlight several areas where additional research would help to illuminate 
the questions we set out to address. 
 
We observed an association between RSV-illness and increased pneumococcal 
colonization density, a finding that is consistent with several other studies, and that is also 
consistent with experimental evidence that RSV infection can facilitate pneumococcal 
virulence and adherence to host epithelial cells. Our study was the first, to our 
knowledge, to assess this relationship in the context of a randomized trial with an RSV 
immunoprophylaxis product and although we did not see a statistically significant 
decrease in pneumococcal colonization density among those prophylaxed, we saw a 
consistent trend in that direction. An extension of the current study would be to evaluate 
the distribution of pneumococcal serotypes detected among RSV-associated compared to 
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non-RSV respiratory events. At least one previous study has shown RSV infection to be 
associated with non-invasive pneumococcal serotypes, but the finding was only 
marginally statistically significant and the study population was restricted to children 
with radiographically confirmed pneumonia [251].  S. pneumoniae density has also been 
shown to vary by serotype [279], and the difference in colonization densities we observed 
between RSV-associated and non-RSV-associated events could in part be driven by 
differential serotype distribution between these two groups. Future studies are also 
needed to further investigate the role of RSV prevention on pneumococcal disease itself, 
rather than its proxy, pneumococcal carriage. In trials of RSV monoclonal antibodies and 
vaccines, proxy and direct measures of pneumococcal pneumonia such as chest 
radiographs and blood culture results should be included, when possible, in the clinical 
data that is collected so that the impact of RSV prevention on pneumococcal pneumonia 
can be assessed.  
 
The finding of no difference in risk of wheeze by treatment group in the primary 
motavizumab trial analysis signaled that preventing RSV illness in early infancy may not 
result in reductions in subsequent wheeze at the population level. Our finding that 
medically attended respiratory illnesses with non-RSV viruses including rhinovirus, 
parainfluenza viruses and coronaviruses were independently associated with future 
medically attended wheeze, but RSV was not, suggest that in certain populations non-
RSV viruses may play a larger role, causally or as a non-causal association, than RSV in 
the development of subsequent wheezing, and potentially childhood asthma. Further 
investigations of these associations are needed within the context of clinical trials. As part 
	
	 258	
of this research it will be important to follow children through an age where asthma can 
be diagnosed. A follow up of this cohort is underway now that the children are between 
10 and 13 years of age.  
 
The conflicting results observed between our study and studies of preterm infants with 
respect to RSV prevention and subsequent wheeze suggest that the role of RSV in the 
causal pathway to asthma may be different in the lungs of preterm infants compared to 
full-term infants, a potential area for future research. They also highlight the need to 
standardize subsequent wheeze outcome definitions going forward in order to allow for 
comparisons between studies. 
 
Our findings support the notion that the development of childhood asthma is a complex 
phenomenon, involving a combination of genetic risk factors and environmental 
exposures, and that these may interact differently in the context of different phenotypes. 
In the subgroup of children who had RSV hospitalizations despite receiving 
motavizumab and who also had significantly increased risk of wheeze, we may have 
identified a particular high-risk phenotype for subsequent wheeze and potentially asthma. 
Future studies could be undertaken to better describe the host characteristics of such 
high-risk subgroups in the community.  
 
Finally, although our research provides some reassurance that there is not significant 
increase in RSV disease in the second RSV season following immunoprophylaxis in the 
first, this question would be better addressed by studies with sample sizes that provide 
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greater statistical power to assess it. In settings where the severity of respiratory illness is 
reduced significantly in the second year of life it is unlikely that a small increase in rates 
of RSV illness following prophylaxis would lead to a meaningful increase in severe 
disease, but in some developing country settings the risk of elevated severe RSV illness 
remains high in the second year of life [46], and the risk of RSV in the second year of life 
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